



# Guidelines for the diagnosis and treatment of pulmonary hypertension

## The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

**Authors/Task Force Members:** Nazzareno Galiè (Chairperson) (Italy)\*; Marius M. Hoeper (Germany); Marc Humbert (France); Adam Torbicki (Poland); Jean-Luc Vachiery (France); Joan Albert Barbera (Spain); Maurice Beghetti (Switzerland); Paul Corris (UK); Sean Gaine (Ireland); J. Simon Gibbs (UK); Miguel Angel Gomez-Sanchez (Spain); Guillaume Jondeau (France); Walter Klepetko (Austria); Christian Opitz (Germany); Andrew Peacock (UK); Lewis Rubin (USA); Michael Zellweger (Switzerland); Gerald Simonneau (France)

**ESC Committee for Practice Guidelines (CPG):** Alec Vahanian (Chairperson) (France); Angelo Auricchio (Switzerland); Jeroen Bax (The Netherlands); Claudio Ceconi (Italy); Veronica Dean (France); Gerasimos Filippatos (Greece); Christian Funck-Brentano (France); Richard Hobbs (UK); Peter Kearney (Ireland); Theresa McDonagh (UK); Keith McGregor (France); Bogdan A. Popescu (Romania); Zeljko Reiner (Croatia); Udo Sechtem (Germany); Per Anton Sirnes (Norway); Michal Tendera (Poland); Panos Vardas (Greece); Petr Widimsky (Czech Republic)

**Document Reviewers:** Udo Sechtem (CPG Review Coordinator) (Germany); Nawwar Al Attar (France); Felicita Andreotti (Italy); Michael Aschermann (Czech Republic); Riccardo Asteggiano (Italy); Ray Benza (USA); Rolf Berger (The Netherlands); Damien Bonnet (France); Marion Delcroix (Belgium); Luke Howard (UK); Anastasia N Kitsiou (Greece); Irene Lang (Austria); Aldo Maggioni (Italy); Jens Erik Nielsen-Kudsk (Denmark); Myung Park (USA); Pasquale Perrone-Filardi (Italy); Suzanna Price (UK); Maria Teresa Subirana Domenech (Spain); Anton Vonk-Noordegraaf (The Netherlands); Jose Luis Zamorano (Spain)

The disclosure forms of all the authors and reviewers are available on the ESC website [www.escardio.org/guidelines](http://www.escardio.org/guidelines)

**IMPORTANT NOTE:** Since the original publication of these Guidelines, the drug sitaxentan has been withdrawn from the market due to liver toxicity. Sitaxentan was withdrawn in December 2010 (for further information please see *Eur Heart J* 2011;32:386–387 and on the ESC website <http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/pulmonary-arterial-hypertension.aspx>). The instances where sitaxentan appears in this document have been highlighted in yellow.

## Table of Contents

Abbreviations and acronyms . . . . .	2494	6. Genetics, epidemiology, and risk factors of pulmonary hypertension . . . . .	2500
Preamble . . . . .	2495	7. Pulmonary arterial hypertension (group 1) . . . . .	2501
1. Introduction . . . . .	2496	7.1 Diagnosis . . . . .	2502
2. Definitions . . . . .	2497	7.1.1 Clinical presentation . . . . .	2502
3. Clinical classification of pulmonary hypertension . . . . .	2498	7.1.2 Electrocardiogram . . . . .	2502
4. Pathology of pulmonary hypertension . . . . .	2499	7.1.3 Chest radiograph . . . . .	2502
5. Pathobiology of pulmonary hypertension . . . . .	2499		

\* Corresponding author. Institute of Cardiology, Bologna University Hospital, Via Massarenti, 9, 40138 Bologna, Italy. Tel: +39 051 349 858, Fax: +39 051 344 859, Email: [nazzareno.galie@unibo.it](mailto:nazzareno.galie@unibo.it)

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the *European Heart Journal* and the party authorized to handle such permissions on behalf of the ESC.

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

© The European Society of Cardiology 2009. All rights reserved. For permissions please email: [journals.permissions@oxfordjournals.org](mailto:journals.permissions@oxfordjournals.org).

7.1.4 Pulmonary function tests and arterial blood gases .	2502	7.4.3 Pulmonary arterial hypertension associated with connective tissue disease . . . . .	2523
7.1.5 Echocardiography . . . . .	2502	Diagnosis . . . . .	2523
7.1.6 Ventilation/perfusion lung scan . . . . .	2504	Therapy . . . . .	2523
7.1.7 High-resolution computed tomography, contrast- enhanced computed tomography, and pulmonary angiography . . . . .	2504	7.4.4 Pulmonary arterial hypertension associated with portal hypertension . . . . .	2523
7.1.8 Cardiac magnetic resonance imaging . . . . .	2505	Diagnosis . . . . .	2524
7.1.9 Blood tests and immunology . . . . .	2505	Therapy . . . . .	2524
7.1.10 Abdominal ultrasound scan . . . . .	2505	7.4.5 Pulmonary arterial hypertension associated with human immunodeficiency virus infection . . . . .	2524
7.1.11 Right heart catheterization and vasoreactivity . .	2505	Diagnosis . . . . .	2525
7.1.12 Diagnostic algorithm . . . . .	2506	Therapy . . . . .	2525
<b>7.2 Evaluation of severity . . . . .</b>	<b>2507</b>	<b>8. Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis (group 1') . . . . .</b>	<b>2525</b>
7.2.1 Clinical, echocardiographic, and haemodynamic parameters . . . . .	2507	<b>8.1 Pulmonary veno-occlusive disease . . . . .</b>	<b>2525</b>
7.2.2 Exercise capacity . . . . .	2508	8.1.1 Diagnosis . . . . .	2525
7.2.3 Biochemical markers . . . . .	2508	8.2.2 Therapy . . . . .	2526
7.2.4 Comprehensive prognostic evaluation . . . . .	2509	<b>8.2 Pulmonary capillary haemangiomatosis . . . . .</b>	<b>2526</b>
7.2.5 Definition of patient status . . . . .	2509	<b>9. Pulmonary hypertension due to left heart disease (group 2)</b>	<b>2526</b>
7.2.6 Treatment goals and follow-up strategy (see also section 7.3.7 and Table 22) . . . . .	2510	9.1 Diagnosis . . . . .	2526
<b>7.3 Therapy . . . . .</b>	<b>2511</b>	9.2 Therapy . . . . .	2527
7.3.1 General measures . . . . .	2511	<b>10. Pulmonary hypertension due to lung diseases and/or hypoxia (group 3) . . . . .</b>	<b>2528</b>
Physical activity and supervised rehabilitation . . .	2511	10.1 Diagnosis . . . . .	2528
Pregnancy, birth control, and post-menopausal hormonal therapy . . . . .	2511	10.2 Therapy . . . . .	2528
Travel . . . . .	2511	<b>11. Chronic thromboembolic pulmonary hypertension (group 4) . . . . .</b>	<b>2528</b>
Psychosocial support . . . . .	2511	11.1 Diagnosis . . . . .	2529
Infection prevention . . . . .	2511	11.2 Therapy . . . . .	2529
Elective surgery . . . . .	2511	<b>12. Definition of a pulmonary arterial hypertension referral centre . . . . .</b>	<b>2530</b>
7.3.2 Supportive therapy . . . . .	2512	<b>References . . . . .</b>	<b>2531</b>
Oral anticoagulants . . . . .	2512		
Diuretics . . . . .	2512		
Oxygen . . . . .	2512		
Digoxin . . . . .	2512		
7.3.3 Specific drug therapy . . . . .	2512		
Calcium channel blockers . . . . .	2512		
Prostanoids . . . . .	2513		
Endothelin receptor antagonists . . . . .	2515		
Phosphodiesterase type-5 inhibitors . . . . .	2515		
Experimental compounds and alternative medical strategies . . . . .	2517		
Combination therapy . . . . .	2517		
Drug interactions . . . . .	2517		
7.3.4 Treatment of arrhythmias . . . . .	2518		
7.3.5 Balloon atrial septostomy . . . . .	2518		
7.3.6 Transplantation . . . . .	2518		
7.3.7 Treatment algorithm . . . . .	2519		
7.3.8 End of life care and ethical issues . . . . .	2520		
<b>7.4 Specific pulmonary arterial hypertension subsets . . . .</b>	<b>2521</b>		
7.4.1 Paediatric pulmonary arterial hypertension . . . .	2521		
Diagnosis . . . . .	2521		
Therapy . . . . .	2521		
7.4.2 Pulmonary arterial hypertension associated with congenital cardiac shunts . . . . .	2522		
Diagnosis . . . . .	2522		
Therapy . . . . .	2522		

## Abbreviations and acronyms

AIR	Aerosolized Iloprost Randomized study
ALPHABET	Arterial Pulmonary Hypertension And Beraprost European Trial
APAH	associated pulmonary arterial hypertension
ARIES	Ambrisentan in pulmonary arterial hypertension, Randomized, double-blind, placebo-controlled, multicentre, Efficacy Study
ASD	atrial septal defect
BENEFIT	Bosentan Effects in iNopEable Forms of chronic Thromboembolic pulmonary hypertension
BAS	balloon atrial septostomy
BNP	brain natriuretic peptide
BREATHE	Bosentan Randomised trial of Endothelin Antagonist THERapy
CCB	calcium channel blocker
CHD	congenital heart disease
CI	cardiac index
CO	cardiac output
COMBI	COMbination therapy of Bosentan and aerosolised Iloprost in idiopathic pulmonary arterial hypertension

COPD	chronic obstructive pulmonary disease
CTD	connective tissue disease
CT	computed tomography
CTEPH	chronic thromboembolic pulmonary hypertension
EARLY	Endothelin Antagonist tRial in mildLY symptomatic pulmonary arterial hypertension patients
ECG	electrocardiogram
ERA	endothelin receptor antagonist
HIV	human immunodeficiency virus
IPAH	idiopathic pulmonary arterial hypertension
INR	international normalized ratio
i.v.	intravenous
LV	left ventricle/ventricular
NO	nitric oxide
NT-proBNP	N-terminal fragment of pro- brain natriuretic peptide
PACES	Pulmonary Arterial hypertension Combination study of Epoprostenol and Sildenafil
PA	pulmonary artery
PAH	pulmonary arterial hypertension
PAP	pulmonary arterial pressure
PEA	pulmonary endarterectomy
PH	pulmonary hypertension
PHIRST	Pulmonary arterial Hypertension and ReSponse to Tadalafil
PVOD	pulmonary veno-occlusive disease
PVR	pulmonary vascular resistance
PWP	pulmonary wedge pressure
RAP	right atrial pressure
RCT	randomized controlled trial
RHC	right heart catheterization
RV	right ventricle/ventricular
6MWT	6-minute walking test
STEP	Safety and pilot efficacy Trial of inhaled iloprost in combination with bosentan for Evaluation in Pulmonary arterial hypertension
STRIDE	Sitaxsentan To Relieve Impaired Exercise
SUPER	Sildenafil Use in Pulmonary artERial hypertension
TAPSE	tricuspid annular plane systolic excursion
t.i.d.	three times a day
TPG	transpulmonary pressure gradient (mean PAP – mean PWP)
TRIUMPH	inhaled TReprostnil sodiUM in Patients with severe Pulmonary arterial Hypertension
WHO-FC	World Health Organization functional class

## Preamble

Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (<http://www.escardio.org/knowledge/guidelines>).

In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition.

Unpublished clinical trial results are not taken into account. A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in *Tables 1 and 2*.

The experts of the writing panels have provided disclosure statements of all relationships they may have which might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task force report was jointly and entirely supported financially by the ESC and the European Respiratory Society (ERS) and was developed without any involvement of the industry.

The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups, or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines and Expert Consensus Documents or statements. Once the document has been finalized and approved by all the experts involved in the Task Force, it is submitted to outside specialists for review. The document is revised, and finally approved by the CPG and subsequently published. The Guidelines on the diagnosis and treatment of pulmonary hypertension have been developed by a joint Task Force of the ESC and of the ERS and the document has been approved by the ESC CPG and the ERS Scientific Committee.

After publication, dissemination of the message is of paramount importance. Pocket-sized versions and personal digital assistant (PDA)-downloadable versions are useful at the point of care. Some surveys have shown that the intended end-users are sometimes not aware of the existence of guidelines, or simply do not translate them into practice. So this is why implementation programmes for new guidelines form an important component of the dissemination of knowledge. Meetings are organised by the ESC, and directed towards its member National Societies and key opinion leaders in Europe. Implementation meetings can also be undertaken at national levels, once the guidelines have been endorsed by the ESC member societies, and translated into the national language. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

**Table 1** Classes of recommendations

Classes of Recommendations	Definition
<b>Class I</b>	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
<b>Class II</b>	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.
<i>Class IIa</i>	Weight of evidence/opinion is in favour of usefulness/efficacy.
<i>Class IIb</i>	Usefulness/efficacy is less well established by evidence/opinion.
<b>Class III</b>	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.

**Table 2** Levels of evidence

<b>Level of Evidence A</b>	Data derived from multiple randomized clinical trials <sup>a</sup> or meta-analyses.
<b>Level of Evidence B</b>	Data derived from a single randomized clinical trial <sup>a</sup> or large non-randomized studies.
<b>Level of Evidence C</b>	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

<sup>a</sup>Or large accuracy or outcome trial(s) in the case of diagnostic tests or strategies.

Thus, the task of writing Guidelines or Expert Consensus documents covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. The loop between clinical research, writing of guidelines, and implementing them into clinical practice can then only be completed if surveys and registries are performed to verify that real-life daily practice is in keeping with what is recommended in the guidelines. Such surveys and registries also make it possible to evaluate the impact of implementation of the guidelines on patient outcomes. Guidelines and recommendations should help the physicians to make decisions in their daily practice; however, the ultimate judgement regarding the care of an individual patient must be made by the physician in charge of his/her care.

## 1. Introduction

The Guidelines on the diagnosis and treatment of pulmonary hypertension (PH) are intended to provide the medical community with updated theoretical and practical information on the management of patients with PH. As multiple medical specialties are

involved with this topic and different levels of insight may be needed by diverse physicians, these Guidelines should be considered as a compromise between heterogeneous requirements. The new features of this Guidelines document are:

- A joint Task Force of the ESC and of the ERS has developed these Guidelines. In addition, members of the International Society for Heart and Lung Transplantation and of the Association for European Paediatric Cardiology have been included.
- PH is a haemodynamic and pathophysiological state (Table 3) that can be found in multiple clinical conditions. These have been classified into six clinical groups with specific characteristics.<sup>1–6</sup> (Table 4). To highlight the remarkable differences between these clinical groups, a comparative description of pathology, pathobiology, genetics, epidemiology, and risk factors is detailed in the first part. More practical information related to clinical presentation, diagnostic features, and treatment are described in the second part for each individual group.
- As the diagnostic strategy in patients with suspected PH is of utmost importance, a new diagnostic algorithm has been provided in the section dedicated to pulmonary arterial



**Table 3** Haemodynamic definitions of pulmonary hypertension<sup>a</sup>

Definition	Characteristics	Clinical group(s) <sup>b</sup>
Pulmonary hypertension (PH)	Mean PAP $\geq 25$ mmHg	All
Pre-capillary PH	Mean PAP $\geq 25$ mmHg PWP $\leq 15$ mmHg CO normal or reduced <sup>c</sup>	1. Pulmonary arterial hypertension 3. PH due to lung diseases 4. Chronic thromboembolic PH 5. PH with unclear and/or multifactorial mechanisms
Post-capillary PH	Mean PAP $\geq 25$ mmHg PWP $> 15$ mmHg CO normal or reduced <sup>c</sup>	2. PH due to left heart disease
Passive	TPG $\leq 12$ mmHg	
Reactive (out of proportion)	TPG $> 12$ mmHg	

<sup>a</sup>All values measured at rest.<sup>b</sup>According to Table 4.<sup>c</sup>High CO can be present in cases of hyperkinetic conditions such as systemic-to-pulmonary shunts (only in the pulmonary circulation), anaemia, hyperthyroidism, etc.

CO = cardiac output; PAP = pulmonary arterial pressure; PH = pulmonary hypertension; PWP = pulmonary wedge pressure; TPG = transpulmonary pressure gradient (mean PAP – mean PWP).

hypertension (PAH, group 1). In this case the diagnosis requires the exclusion of all other groups of PH.

- PAH (Tables 4 and 5) represents the condition described more extensively due to the availability of specific treatments. Based on the publication of recent randomized controlled trials (RCTs) a new treatment algorithm with updated levels of evidence and grades of recommendation and the current approval status in different geographic areas have been provided. Definitions for the evaluation of a patient's severity, treatment goals, and follow-up strategy have been also included. The specific characteristics of the different types of PAH including paediatric PAH have been highlighted.
- The other four main clinical groups of PH, i.e. pulmonary veno-occlusive disease (PVOD, group 1'), PH due to left heart disease (group 2), PH due to lung diseases (group 3), and chronic thromboembolic pulmonary hypertension (CTEPH, group 4) have been discussed individually while the heterogeneity and rarity of the conditions included in group 5 (Table 4) prevent an appropriate description in these guidelines.

## 2. Definitions

PH has been defined as an increase in mean pulmonary arterial pressure (PAP)  $\geq 25$  mmHg at rest as assessed by right heart catheterization (RHC) (Tables 3 and 5).<sup>7,8</sup> This value has been used for selecting patients in all RCTs and registries of PAH.<sup>3,4,8</sup> Recent re-evaluation of available data has shown that the normal mean

**Table 4** Updated clinical classification of pulmonary hypertension (Dana Point, 2008<sup>1</sup>)

### 1 Pulmonary arterial hypertension (PAH)

- 1.1 Idiopathic
- 1.2 Heritable
  - 1.2.1 BMPR2
  - 1.2.2 ALK1, endoglin (with or without hereditary haemorrhagic telangiectasia)
  - 1.2.3 Unknown
- 1.3 Drugs and toxins induced
- 1.4 Associated with (APAH)
  - 1.4.1 Connective tissue diseases
  - 1.4.2 HIV infection
  - 1.4.3 Portal hypertension
  - 1.4.4 Congenital heart disease
  - 1.4.5 Schistosomiasis
  - 1.4.6 Chronic haemolytic anaemia
- 1.5 Persistent pulmonary hypertension of the newborn

### 1' Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis

### 2 Pulmonary hypertension due to left heart disease

- 2.1 Systolic dysfunction
- 2.2 Diastolic dysfunction
- 2.3 Valvular disease

### 3 Pulmonary hypertension due to lung diseases and/or hypoxia

- 3.1 Chronic obstructive pulmonary disease
- 3.2 Interstitial lung disease
- 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
- 3.4 Sleep-disordered breathing
- 3.5 Alveolar hypoventilation disorders
- 3.6 Chronic exposure to high altitude
- 3.7 Developmental abnormalities

### 4 Chronic thromboembolic pulmonary hypertension

### 5 PH with unclear and/or multifactorial mechanisms

- 5.1 Haematological disorders: myeloproliferative disorders, splenectomy.
- 5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
- 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
- 5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

ALK-1 = activin receptor-like kinase 1 gene; APAH = associated pulmonary arterial hypertension; BMPR2 = bone morphogenetic protein receptor, type 2; HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension.

PAP at rest is  $14 \pm 3$  mmHg, with an upper limit of normal of  $\sim 20$  mmHg.<sup>9,10</sup> The significance of a mean PAP between 21 and 24 mmHg is unclear. Patients presenting with PAP in this range need further evaluation in epidemiological studies.

The definition of PH on exercise as a mean PAP  $> 30$  mmHg as assessed by RHC is not supported by published data and healthy individuals can reach much higher values.<sup>9,11</sup> Thus no definition for PH on exercise as assessed by RHC can be provided at the present time.

According to various combinations of values of pulmonary wedge pressure (PWP), pulmonary vascular resistance (PVR), and cardiac

**Table 5** Important definitions

- Pulmonary hypertension (PH) is a *haemodynamic and pathophysiological condition* defined as an increase in mean pulmonary arterial pressure (PAP)  $\geq 25$  mmHg at rest as assessed by right heart catheterization (Table 3). PH can be found in multiple clinical conditions (Table 4).
- The definition of PH on exercise as a mean PAP  $>30$  mmHg as assessed by right heart catheterization is not supported by published data.
- Pulmonary arterial hypertension (PAH, group 1) is a *clinical condition* characterized by the presence of pre-capillary PH (Table 3) in the absence of other causes of pre-capillary PH such as PH due to lung diseases, chronic thromboembolic PH, or other rare diseases (Table 4). PAH includes different forms that share a similar clinical picture and virtually identical pathological changes of the lung microcirculation (Table 4).

output (CO), different haemodynamic definitions of PH are shown in Table 3. Pre-capillary PH includes the clinical groups 1, 3, 4, and 5 while post-capillary PH includes the clinical group 2 (Table 4).<sup>12</sup> The features of each group will be discussed in specific sections.

### 3. Clinical classification of pulmonary hypertension

The clinical classification of PH has gone through a series of changes since the first version was proposed in 1973 at the first international conference on primary pulmonary hypertension endorsed by the World Health Organization.<sup>7</sup> The previous version of the ESC-PAH guidelines adopted the Evian-Venice classification proposed at the second and third world meetings on PAH in 1998 and 2003, respectively.<sup>13</sup> In these classifications, clinical conditions with PH are classified into five groups according to pathological, pathophysiological, and therapeutic characteristics. Despite comparable elevations of PAP and PVR in the different clinical groups, the underlying mechanisms, the diagnostic approaches, and the prognostic and therapeutic implications are completely different. During the fourth World Symposium on PH held in Dana Point, California, the consensus agreement of experts worldwide was to maintain the general philosophy and organization of the Evian-Venice classifications while amending some specific points to improve clarity and to take into account new information.

The new clinical classification (derived from the Dana Point meeting) is shown in the Table 4.<sup>1</sup> To avoid possible confusion among the terms PH and PAH, the specific definitions have been included in Table 5. Compared with the previous version of the clinical classification the changes are as follows:

- Group 1, PAH (Tables 4, 6 and 7): the term familial PAH has been replaced by heritable PAH because specific gene mutations have been identified in sporadic cases with no family history. Heritable forms of PAH include clinically sporadic idiopathic PAH (IPAH) with germline mutations (mainly of the bone morphogenetic protein receptor 2 gene as well as the activin receptor-like kinase type-1 gene or the endoglin gene) and clinical familial cases with or without identified germline mutations.<sup>14,15</sup> This new category of heritable PAH does not mandate genetic testing

**Table 6** Clinical classification of congenital, systemic-to-pulmonary shunts associated with pulmonary arterial hypertension

**A. Eisenmenger's syndrome**

Eisenmenger's syndrome includes all systemic-to-pulmonary shunts due to large defects leading to a severe increase in PVR and resulting in a reversed (pulmonary-to-systemic) or bidirectional shunt. Cyanosis, erythrocytosis, and multiple organ involvement are present.

**B. Pulmonary arterial hypertension associated with systemic-to-pulmonary shunts**

In these patients with moderate to large defects, the increase in PVR is mild to moderate, systemic-to-pulmonary shunt is still largely present, and no cyanosis is present at rest.

**C. Pulmonary arterial hypertension with small<sup>a</sup> defects**

In cases with small defects (usually ventricular septal defects  $<1$  cm and atrial septal defects  $<2$  cm of effective diameter assessed by echocardiography) the clinical picture is very similar to idiopathic PAH.

**D. Pulmonary arterial hypertension after corrective cardiac surgery**

In these cases, congenital heart disease has been corrected but PAH is either still present immediately after surgery or has recurred several months or years after surgery in the absence of significant post-operative residual congenital lesions or defects that originate as a sequela to previous surgery.

<sup>a</sup>The size applies to adult patients.

PAH = pulmonary arterial hypertension; PVR = pulmonary vascular resistance.

in any patient with IPAH or in familial cases of PAH because this would not change the clinical management. The classification of congenital heart disease (CHD) causing PAH has been updated to include a clinical (Table 6) and an anatomical–pathophysiological version (Table 7) in order to better define each individual patient.<sup>16</sup> Associated PAH (APAH, Table 4) includes conditions which can have a similar clinical presentation to that seen in IPAH with identical histological findings including the development of plexiform lesions.<sup>13</sup> APAH accounts for approximately half of the PAH patients followed at specialized centres.<sup>3</sup> Schistosomiasis has been included among the APAH forms because recent publications show that patients with schistosomiasis and PAH can have the required specific clinical and pathological characteristics.<sup>17</sup> The mechanism of PAH in patients with schistosomiasis is probably multifactorial, and includes portal hypertension, a frequent complication of this disease, and local vascular inflammation caused by schistosome eggs. Chronic haemolytic anaemia such as sickle cell disease,<sup>18</sup> thalassaemia, hereditary spherocytosis, stomatocytosis, and microangiopathic haemolytic anaemia may result in PAH and are included in the APAH forms. The mechanism of PAH in chronic haemolysis is related to a high rate of nitric oxide (NO) consumption leading to a state of resistance to NO bioactivity. Smooth muscle cyclic guanosine monophosphate, a potent vasodilator/antiproliferative mediator and second messenger of NO, is not activated in chronic haemolytic anaemia.<sup>19</sup>

- Group 1' PVOD and pulmonary capillary haemangiomatosis remain difficult disorders to classify since they share some

**Table 7 Anatomical-pathophysiological classification of congenital systemic-to-pulmonary shunts associated with pulmonary arterial hypertension (modified from Venice 2003)**

<b>1. Type</b>
<b>1.1 Simple pre-tricuspid shunts</b>
1.1.1 Atrial septal defect (ASD)
1.1.1.1 Ostium secundum
1.1.1.2 Sinus venosus
1.1.1.3 Ostium primum
1.1.2 Total or partial unobstructed anomalous pulmonary venous return
<b>1.2 Simple post-tricuspid shunts</b>
1.2.1 Ventricular septal defect (VSD)
1.2.2 Patent ductus arteriosus
<b>1.3 Combined shunts</b>
Describe combination and define predominant defect
<b>1.4 Complex congenital heart disease</b>
1.4.1 Complete atrioventricular septal defect
1.4.2 Truncus arteriosus
1.4.3 Single ventricle physiology with unobstructed pulmonary blood flow
1.4.4 Transposition of the great arteries with VSD (without pulmonary stenosis) and/or patent ductus arteriosus
1.4.5 Other
<b>2. Dimension</b> (specify for each defect if more than one congenital heart defect exists)
<b>2.1 Haemodynamic (specify Qp/Qs)<sup>a</sup></b>
2.1.1 Restrictive (pressure gradient across the defect)
2.1.2 Non-restrictive
<b>2.2 Anatomic<sup>b</sup></b>
2.2.1 Small to moderate (ASD $\leq 2.0$ cm and VSD $\leq 1.0$ cm)
2.2.2 Large (ASD $> 2.0$ cm and VSD $> 1.0$ cm)
<b>3. Direction of shunt</b>
3.1 Predominantly systemic-to-pulmonary
3.2 Predominantly pulmonary-to-systemic
3.3 Bidirectional
<b>4. Associated cardiac and extracardiac abnormalities</b>
<b>5. Repair status</b>
5.1 Unoperated
5.2 Palliated [specify type of operation(s), age at surgery]
5.3 Repaired [specify type of operation(s), age at surgery]

<sup>a</sup>Ratio of pulmonary (Qp) to systemic (Qs) blood flow.

<sup>b</sup>The size applies to adult patients.

ASD = atrial septal defect; VSD = ventricular septal defect.

characteristics with IPAH but also demonstrate a number of differences. Given the current evidence, it was felt that these conditions should be a distinct category but not completely separated from PAH, and have been designated as clinical group 1'.

- Group 2, PH due to left heart disease, and group 3, PH due to lung diseases and hypoxia, are not substantially changed.
- Group 4, CTEPH: as there are no well-defined criteria to discriminate proximal from distal CTEPH obstructive lesions, it was decided to maintain only a single category of CTEPH without attempting to distinguish between proximal and distal forms.

- Group 5, PH with unclear and/or multifactorial mechanisms: this group comprises a heterogeneous collection of diseases with uncertain pathogenetic mechanisms leading to PH including haematological, systemic, metabolic, and other rare disorders.

## 4. Pathology of pulmonary hypertension

Different pathological<sup>20,21</sup> features characterize the diverse clinical PH groups.

- Group 1, PAH: pathological lesions affect the distal pulmonary arteries ( $< 500$   $\mu\text{m}$  of diameter) in particular. They are characterized by medial hypertrophy, intimal proliferative and fibrotic changes (concentric, eccentric), adventitial thickening with moderate perivascular inflammatory infiltrates, complex lesions (plexiform, dilated lesions), and thrombotic lesions. Pulmonary veins are classically unaffected.
- Group 1': includes mainly PVOD which involves septal veins and pre-septal venules (constant involvement) with occlusive fibrotic lesions, venous muscularization, frequent capillary proliferation (patchy), pulmonary oedema, occult alveolar haemorrhage, lymphatic dilatation and lymph node enlargement (vascular transformation of the sinus), and inflammatory infiltrates. Distal pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, and uncommon complex lesions.
- Group 2, PH due to left heart disease: pathological changes in this group are characterized by enlarged and thickened pulmonary veins, pulmonary capillary dilatation, interstitial oedema, alveolar haemorrhage, and lymphatic vessel and lymph node enlargement. Distal pulmonary arteries may be affected by medial hypertrophy and intimal fibrosis.
- Group 3, PH due to lung diseases and/or hypoxia: pathological changes in these cases include medial hypertrophy and intimal obstructive proliferation of the distal pulmonary arteries. A variable degree of destruction of the vascular bed in emphysematous or fibrotic areas may also be present.
- Group 4, CTEPH: pathological lesions are characterized by organized thrombi tightly attached to the pulmonary arterial medial layer in the elastic pulmonary arteries, replacing the normal intima. These may completely occlude the lumen or form different grades of stenosis, webs, and bands.<sup>22</sup> Interestingly, in the non-occluded areas, a pulmonary arteriopathy indistinguishable from that of PAH (including plexiform lesions) can develop.<sup>23</sup> Collateral vessels from the systemic circulation (from bronchial, costal, diaphragmatic and coronary arteries) can grow to reperfuse at least partially the areas distal to complete obstructions.
- Group 5, PH with unclear and/or multifactorial mechanisms: this group includes heterogeneous conditions with different pathological pictures for which the aetiology is unclear or multifactorial.

## 5. Pathobiology of pulmonary hypertension

Different pathobiological features<sup>24–26</sup> characterize the diverse clinical PH groups.

- Group 1, PAH: the exact processes that initiate the pathological changes seen in PAH are still unknown even if it is recognized that PAH has a multifactorial pathobiology that involves various biochemical pathways and cell types. The increase in PVR is related to different mechanisms, including vasoconstriction, proliferative and obstructive remodelling of the pulmonary vessel wall, inflammation, and thrombosis. Excessive vasoconstriction has been related to abnormal function or expression of potassium channels in the smooth muscle cells and to endothelial dysfunction. Endothelial dysfunction leads to chronically impaired production of vasodilator and antiproliferative agents such as NO and prostacyclin, along with overexpression of vasoconstrictor and proliferative substances such as thromboxane A<sub>2</sub> and endothelin-1. Reduced plasma levels of other vasodilator and antiproliferative substances such as vasoactive intestinal peptide have also been demonstrated in patients with PAH. Many of these abnormalities both elevate vascular tone and promote vascular remodelling by proliferative changes that involve several cell types, including endothelial and smooth muscle cells as well as fibroblasts. In addition, in the adventitia there is increased production of extracellular matrix including collagen, elastin, fibronectin, and tenascin. Inflammatory cells and platelets (through the serotonin pathway) may also play a significant role in PAH. Prothrombotic abnormalities have been demonstrated in PAH patients, and thrombi are present in both the small distal pulmonary arteries and the proximal elastic pulmonary arteries.
- Group 2, PH due to left heart disease: the mechanisms responsible for the increase in PAP are multiple and include the passive backward transmission of the pressure elevation (post-capillary passive PH, Table 3). In these cases the transpulmonary pressure gradient (TPG = mean PAP minus mean PWP) and PVR are within the normal range. In other circumstances the elevation of PAP is greater than that of PWP (increased TPG) and an increase in PVR is also observed (post-capillary reactive or 'out of proportion' PH, Table 3). The elevation of PVR is due to an increase in the vasomotor tone of the pulmonary arteries and/or to fixed structural obstructive remodelling of the pulmonary artery resistance vessels:<sup>27</sup> the former component of reactive PH is reversible under acute pharmacological testing while the latter, characterized by medial hypertrophy and intimal proliferation of the pulmonary arteriole, does not respond to the acute challenge.<sup>12</sup> Which factors lead to reactive (out of proportion) PH and why some patients develop the acutely reversible vasoconstrictive or the fixed obstructive components or both is poorly understood. Pathophysiological mechanisms may include vasoconstrictive reflexes arising from stretch receptors localized in the left atrium and pulmonary veins, and endothelial dysfunction of pulmonary arteries that may favour vasoconstriction and proliferation of vessel wall cells.
- Group 3, PH due to lung diseases and/or hypoxia: the pathobiological and pathophysiological mechanisms involved in this setting are multiple and include hypoxic vasoconstriction, mechanical stress of hyperinflated lungs, loss of capillaries, inflammation, and toxic effects of cigarette smoke. There are also

data supporting an endothelium-derived vasoconstrictor–vasodilator imbalance.

- Group 4, CTEPH: non-resolution of acute embolic masses which later undergo fibrosis leading to mechanical obstruction of pulmonary arteries is the most important pathobiological process in CTEPH. Pulmonary thromboembolism or *in situ* thrombosis may be initiated or aggravated by abnormalities in either the clotting cascade, endothelial cells, or platelets, all of which interact in the coagulation process.<sup>28</sup> Platelet abnormalities and biochemical features of a procoagulant environment within the pulmonary vasculature support a potential role for local thrombosis in initiating the disease in some patients. In most cases, it remains unclear whether thrombosis and platelet dysfunction are a cause or consequence of the disease. Inflammatory infiltrates are commonly detected in the pulmonary endarterectomy (PEA) specimens. Thrombophilia studies have shown that lupus anticoagulant may be found in ~10% of such patients, and 20% carry antiphospholipid antibodies, lupus anticoagulant, or both. A recent study has demonstrated that the plasma level of factor VIII, a protein associated with both primary and recurrent venous thromboembolism, is elevated in 39% of patients with CTEPH. No abnormalities of fibrinolysis have been identified. The obstructive lesions observed in the distal pulmonary arteries of non-obstructed areas (virtually identical to those observed in PAH) may be related to a variety of factors, such as shear stress, pressure, inflammation, and the release of cytokines and vasculotropic mediators.
- Group 5, PH with unclear and/or multifactorial mechanisms: the pathobiology in this group is unclear or multifactorial.

## 6. Genetics, epidemiology, and risk factors of pulmonary hypertension

Comparative epidemiological data on the prevalence of the different groups of PH are not available. In a survey performed in an echocardiography laboratory,<sup>29</sup> the prevalence of PH (defined as a PA systolic pressure >40 mmHg) among 4579 patients was 10.5%. Among the 483 cases with PH 78.7% had left heart disease (group 2), 9.7% had lung diseases and hypoxia (group 3), 4.2% had PAH (group 1), 0.6% had CTEPH (group 4), and in 6.8% it was not possible to define a diagnosis.

- Group 1, PAH: recent registries have described the epidemiology of PAH.<sup>3,4</sup> The lowest estimates of the prevalence of PAH and IPAH are 15 cases and 5.9 cases/million adult population, respectively. The lowest estimate of PAH incidence is 2.4 cases/million adult population/year. Recent data from Scotland and other countries have confirmed that PAH prevalence is in the range 15–50 subjects per million population in Europe.<sup>4</sup> In the French registry, 39.2% of patients had IPAH and 3.9% had family history of PAH. In the subgroup of APAH, 15.3% had connective tissue diseases (CTDs; mainly systemic sclerosis), 11.3% had CHD, 10.4% had portal hypertension, 9.5% had anorexigen-associated PAH and 6.2% had human immunodeficiency virus (HIV) infection.<sup>3</sup>



PAH may occur in different settings depending on associated clinical conditions.<sup>1</sup> IPAH corresponds to sporadic disease, without any familial history of PAH or known triggering factor. When PAH occurs in a familial context, germline mutations in the bone morphogenetic protein receptor 2 gene are detected in at least 70% of cases.<sup>14,15</sup> Mutations of this gene can also be detected in 11–40% of apparently sporadic cases, thus representing the major genetic predisposing factor for PAH.<sup>30</sup> The bone morphogenetic protein receptor 2 gene encodes a type 2 receptor for bone morphogenetic proteins, which belong to the transforming growth factor- $\beta$  superfamily. Among several biological functions, these polypeptides are involved in the control of vascular cell proliferation. Mutations of other receptors for these substances, such as activin receptor-like kinase 1 and endoglin, have been identified mostly in PAH patients with a personal or family history of hereditary haemorrhagic telangiectasia (Osler–Weber–Rendu syndrome).<sup>31</sup> A number of risk factors for the development of PAH have been identified and are defined as any factor or condition that is suspected to play a predisposing or facilitating role in the development of the disease. Risk factors were classified as definite, likely, possible, or unlikely based on the strength of their association with PH and their probable causal role.<sup>1</sup> A *definite* association is acknowledged in the case of an epidemic such as occurred with appetite suppressants in the 1960s or if large, multicentre epidemiological studies demonstrated an association between the clinical condition or drug and PAH. A *likely* association is acknowledged if a single centre case–control study or multiple case series demonstrated an association. A *possible* association can be suspected, for example, for drugs with similar mechanisms of action to those in the definite or likely category but which have not been studied yet, such as drugs used to treat attention deficit disorder. Lastly, an *unlikely* association is defined as one in which a suspected factor has been studied in epidemiological studies and an association with PAH has not been demonstrated. Definite clinical associations are listed among APAH conditions (Table 4) while the risk level of different drugs and toxins are listed in Table 8.

- Group 2, PH due to left heart disease: even if constitutional factors may play a role in the development of PH in this group, no specific genetic linkages have been identified.<sup>12</sup> The prevalence of PH in patients with chronic heart failure increases with the progression of functional class impairment. Up to 60% of patients with severe left ventricular (LV) systolic dysfunction and up to 70% of patients with isolated LV diastolic dysfunction may present with PH.<sup>32</sup> In left-sided valvular diseases, the prevalence of PH increases with the severity of the defect and of the symptoms. PH can be found in virtually all patients with severe symptomatic mitral valve disease and in up to 65% of those with symptomatic aortic stenosis.<sup>10,12,33</sup>
- Group 3, PH due to lung diseases and/or hypoxaemia: one study has shown that serotonin gene polymorphism appears to determine the severity of PH in hypoxaemic patients with chronic obstructive pulmonary disease (COPD).<sup>34</sup> Based on published series, the incidence of significant PH in COPD patients with at least one previous hospitalization for exacerbation of respiratory failure is 20%. In advanced COPD, PH is highly prevalent

**Table 8** Updated risk level of drugs and toxins known to induce PAH

<b>Definite</b> <ul style="list-style-type: none"> <li>• Aminorex</li> <li>• Fenfluramine</li> <li>• Dexfenfluramine</li> <li>• Toxic rapeseed oil</li> <li>• Benfluorex</li> </ul>	<b>Possible</b> <ul style="list-style-type: none"> <li>• Cocaine</li> <li>• Phenylpropanolamine</li> <li>• St John's Wort</li> <li>• Chemotherapeutic agents</li> <li>• Selective serotonin reuptake inhibitors</li> <li>• Pergolide</li> </ul>
<b>Likely</b> <ul style="list-style-type: none"> <li>• Amphetamines</li> <li>• L-tryptophan</li> <li>• Methamphetamines</li> </ul>	<b>Unlikely</b> <ul style="list-style-type: none"> <li>• Oral contraceptives</li> <li>• Oestrogen</li> <li>• Cigarette smoking</li> </ul>

PAH = pulmonary arterial hypertension.

(>50%),<sup>35,36</sup> although in general it is of only mild severity. In interstitial lung disease, the prevalence of PH is between 32 and 39%.<sup>37</sup> The combination of lung fibrosis with emphysema is associated with a higher prevalence of PH.<sup>38</sup>

- Group 4, CTEPH: no specific genetic mutations have been linked to the development of CTEPH. Even if more recent papers suggest that the prevalence of CTEPH is up to 3.8% in survivors of acute pulmonary embolism,<sup>39</sup> most experts believe that the true incidence of CTEPH after acute pulmonary embolism is 0.5–2%. CTEPH can be found in patients without any previous clinical episode of acute pulmonary embolism or deep venous thrombosis (up to 50% in different series).<sup>40</sup>
- Group 5, PH with unclear and/or multifactorial mechanisms: the heterogeneity of this group prevents an appropriate description of genetics, epidemiology and risk factors in these guidelines.

## 7. Pulmonary arterial hypertension (group 1)

PAH (see Table 5 for definition) represents the type of PH in which the most important advances in the understanding and treatment have been achieved in the past decade. It is also the group in which PH is the 'core' of the clinical problems and may be treated by specific drug therapy.

PAH comprises apparently heterogeneous conditions (Table 4) that share comparable clinical and haemodynamic pictures and virtually identical pathological changes of the lung microcirculation.

Even if many pathobiological mechanisms have been identified in the cells and tissues of patients with PAH, the exact interactions between them in the initiation and progression of the pathological processes are not well understood. The consequent increase in PVR leads to right ventricular (RV) overload, hypertrophy, and dilatation, and eventually to RV failure and death. The importance of the progression of RV failure on the outcome of IPAH patients is confirmed by the prognostic impact of right atrial pressure, cardiac index (CI), and PAP,<sup>8</sup> the three main parameters of RV pump function. The inadequate adaptation of myocardial

contractility seems to be one of the primary events in the progression of heart failure in a chronically overloaded RV. Changes in the adrenergic pathways of RV myocytes leading to reduced contractility have been shown in IPAH patients.<sup>41</sup> Afterload mismatch remains the leading determinant of heart failure in patients with PAH and CTEPH because its removal, as follows successful PEA or lung transplantation,<sup>42</sup> leads almost invariably to sustained recovery of RV function. The haemodynamic changes and the prognosis of patients with PAH are related to the complex pathophysiological interactions between the rate of progression (or regression) of the obstructive changes in the pulmonary microcirculation and the response of the overloaded RV, which may also be influenced by genetic determinants.<sup>43</sup>

## 7.1 Diagnosis

The evaluation process of a patient with suspected PH requires a series of investigations intended to confirm the diagnosis, clarify the clinical group of PH and the specific aetiology within the PAH group, and evaluate the functional and haemodynamic impairment. After the description of each examination, an integrated diagnostic algorithm is shown (Figure 1). Since PAH, and particularly IPAH, is a diagnosis of exclusion, this algorithm may be useful as a starting point in any case of suspected PH.

### 7.1.1 Clinical presentation

The symptoms of PAH are non-specific and include breathlessness, fatigue, weakness, angina, syncope, and abdominal distension.<sup>44</sup> Symptoms at rest are reported only in very advanced cases. The physical signs of PAH include left parasternal lift, an accentuated pulmonary component of second heart sound, a pansystolic murmur of tricuspid regurgitation, a diastolic murmur of pulmonary insufficiency, and an RV third sound. Jugular vein distension, hepatomegaly, peripheral oedema, ascites, and cool extremities characterize patients in a more advanced state.<sup>45</sup> Lung sounds are usually normal. The examination may also provide clues as to the cause of PH. Telangiectasia, digital ulceration, and sclerodactyly are seen in scleroderma, while inspiratory crackles may point towards interstitial lung disease. The stigmata of liver disease such as spider naevi, testicular atrophy, and palmar erythema should be considered. If digital clubbing is encountered in 'IPAH', an alternative diagnosis such as CHD or PVOD should be sought.

### 7.1.2 Electrocardiogram

The ECG may provide suggestive or supportive evidence of PH by demonstrating RV hypertrophy and strain, and right atrial dilatation. RV hypertrophy on ECG is present in 87% and right axis deviation in 79% of patients with IPAH.<sup>44</sup> The absence of these findings does not exclude the presence of PH nor does it exclude severe haemodynamic abnormalities. The ECG has insufficient sensitivity (55%) and specificity (70%) to be a screening tool for detecting significant PH. Ventricular arrhythmias are rare. Supraventricular arrhythmias may be present in advanced stages, in particular atrial flutter, but also atrial fibrillation, which almost invariably leads to further clinical deterioration.<sup>46</sup>

### 7.1.3 Chest radiograph

In 90% of patients with IPAH the chest radiograph is abnormal at the time of diagnosis.<sup>44</sup> Findings include central pulmonary arterial dilatation, which contrasts with 'pruning' (loss) of the peripheral blood vessels. Right atrium and RV enlargement may be seen in more advanced cases. The chest radiograph allows associated moderate-to-severe lung diseases (group 3, Table 4) or pulmonary venous hypertension due to left heart disease (group 2, Table 4) to be reasonably excluded. Overall, the degree of PH in any given patient does not correlate with the extent of radiographic abnormalities.


### 7.1.4 Pulmonary function tests and arterial blood gases

Pulmonary function tests and arterial blood gases will identify the contribution of underlying airway or parenchymal lung disease. Patients with PAH usually have decreased lung diffusion capacity for carbon monoxide (typically in the range of 40–80% predicted) and mild to moderate reduction of lung volumes. Peripheral airway obstruction can also be detected. Arterial oxygen tension is normal or only slightly lower than normal at rest and arterial carbon dioxide tension is decreased because of alveolar hyperventilation. COPD as a cause of hypoxic PH is diagnosed on the evidence of irreversible airflow obstruction together with increased residual volumes and reduced diffusion capacity for carbon monoxide and normal or increased carbon dioxide tension. A decrease in lung volume together with a decrease in diffusion capacity for carbon monoxide may indicate a diagnosis of interstitial lung disease. The severity of emphysema and of interstitial lung disease can be diagnosed using high-resolution computed tomography (CT). If clinically suspected, screening overnight oximetry or polysomnography will exclude significant obstructive sleep apnoea/hypopnoea.

### 7.1.5 Echocardiography

Transthoracic echocardiography provides several variables which correlate with right heart haemodynamics including PAP, and should always be performed in the case of suspected PH.

The estimation of PAP is based on the peak velocity of the jet of tricuspid regurgitation. The simplified Bernoulli equation describes the relationship of tricuspid regurgitation velocity and the peak pressure gradient of tricuspid regurgitation =  $4 \times (\text{tricuspid regurgitation velocity})^2$ . This equation allows for estimation of PA systolic pressure taking into account right atrial pressure: PA systolic pressure = tricuspid regurgitation pressure gradient + estimated right atrial pressure. Right atrial pressure can be estimated based on the diameter and respiratory variation of the inferior vena cava although often a fixed value of 5 or 10 mmHg is assumed. When peak tricuspid regurgitation velocity is difficult to measure (trivial/mild tricuspid regurgitation), use of contrast echocardiography (e.g. agitated saline) significantly increases the Doppler signal, allowing proper measurement of peak tricuspid regurgitation velocity. Also, potential systolic gradients between the RV and PA should be considered. Theoretically, calculation of mean PAP from PA systolic pressure is possible (mean PAP =  $0.61 \times \text{PA systolic pressure} + 2 \text{ mmHg}$ ).<sup>47</sup> This could allow the use of Doppler measurements, applying an accepted definition of PH as mean PAP  $\geq 25$  mmHg. Unfortunately, despite the



**Figure 1** Diagnostic algorithm. ALK-1 = activin-receptor-like kinase; ANA = anti-nuclear antibodies; BMPR2 = bone morphogenetic protein receptor 2; CHD = congenital heart disease; CMR = cardiac magnetic resonance; CTD = connective tissue disease; Group = clinical group (Table 4); HHT = hereditary haemorrhagic telangiectasia; HIV = human immunodeficiency virus; HRCT = high-resolution computed tomography; LFT = liver function tests; mPAP = mean pulmonary arterial pressure; PAH = pulmonary arterial hypertension; PCH = pulmonary capillary haemangiomatosis; PFT = pulmonary function test; PH = pulmonary hypertension; PVOD = pulmonary veno-occlusive disease; PWP = pulmonary wedge pressure; RHC = right heart catheterization; TEE = transoesophageal echocardiography; TTE = transthoracic echocardiography; US = ultrasonography; V/Q scan = ventilation/perfusion lung scan. \*Refer also to Table 12.

strong correlation of the tricuspid regurgitation velocity and tricuspid regurgitation pressure gradient, Doppler-derived pressure estimation may be inaccurate in the individual patient. In patients with severe tricuspid regurgitation use of the simplified form of the Bernoulli equation may lead to underestimation of PA systolic pressure. Also overestimations by >10 mmHg for

PA systolic pressure are common.<sup>47</sup> Therefore, PH cannot be reliably defined by a cut-off value of Doppler-derived PA systolic pressure.

Consequently, estimation of PAP based on Doppler transthoracic echocardiography measurements is not suitable for screening for mild, asymptomatic PH.

An alternative approach to echocardiographic diagnosis of PH is based on comparison of tricuspid regurgitation velocity with values reported in a healthy population. Ideally, the influence of age, sex, and body mass should be taken into consideration.<sup>48</sup> This method avoids cumulative error but is less directly linked to the accepted haemodynamic definition of PH as a mean PAP  $\geq$  25 mmHg.

The reliability of several tricuspid regurgitation velocity cut-off values, using RHC as reference, has been assessed in two large screening studies. A trial evaluating the reliability of prospective screening of patients with scleroderma based on tricuspid regurgitation velocity  $>2.5$  m/s in symptomatic patients or  $>3.0$  m/s irrespective of symptoms, found that 45% of cases of echocardiographic diagnoses of PH were falsely positive.<sup>2</sup> In symptomatic (dyspnoea) patients with HIV infection a PH criterion based on tricuspid regurgitation velocity  $>2.5$  and  $2.8$  m/s was found to be a false positive in 72% and 29%, respectively.<sup>49</sup>

Another trial selected a tricuspid regurgitation pressure gradient  $>40$  mmHg (tricuspid regurgitation velocity  $>3.2$  m/s) with an assumed right atrial pressure of 10 mmHg (thus corresponding to a systolic PAP of  $>50$  mmHg) as the cut-off value for diagnosis of PH.<sup>50</sup> Those criteria were recently prospectively applied in systemic sclerosis patients.<sup>51</sup> The Doppler diagnosis was confirmed in all 32 patients who were submitted to RHC. Like previous trials, the number of false-negative cases could not be assessed.

Other echocardiographic variables that might raise or reinforce suspicion of PH independently of tricuspid regurgitation velocity should always be considered. They include an increased velocity of pulmonary valve regurgitation and a short acceleration time of RV ejection into the PA. Increased dimensions of right heart chambers, abnormal shape and function of the interventricular septum, increased RV wall thickness, and dilated main PA are also suggestive of PH, but tend to occur later in the course of the disease. Their sensitivity is questionable.

In Table 9 this Task Force suggests arbitrary criteria for detecting the presence of PH based on tricuspid regurgitation peak velocity and Doppler-calculated PA systolic pressure at rest (assuming a normal right atrial pressure of 5 mmHg) and additional echocardiographic variables suggestive of PH.

Echocardiography can be helpful in detecting the cause of suspected or confirmed PH. Two-dimensional, Doppler and contrast examinations can be used to identify CHD. High pulmonary blood flow found at pulsed wave Doppler in the absence of detectable shunt, or significant dilatation of proximal PA despite only moderate PH, may warrant transoesophageal examination with contrast or cardiac magnetic resonance imaging to exclude sinus venosus-type ASD or anomalous pulmonary venous return. In cases of suspicion of LV diastolic dysfunction, typical Doppler-echocardiographic signs should be assessed even if their reliability is considered low and a RHC may be required in specific circumstances (see section 9.1).

The practical clinical usefulness of exercise Doppler-echocardiography in the identification of cases with PH only on exercise is uncertain because of the lack of prospective confirmatory data.<sup>52</sup>

7.1.6 Ventilation/perfusion lung scan

The ventilation/perfusion lung scan should be performed in patients with PH to look for potentially treatable CTEPH. The ventilation/

**Table 9** Arbitrary criteria for estimating the presence of PH based on tricuspid regurgitation peak velocity and Doppler-calculated PA systolic pressure at rest (assuming a normal right atrial pressure of 5 mmHg) and on additional echocardiographic variables suggestive of PH

	Class <sup>a</sup>	Level <sup>b</sup>
<b>Echocardiographic diagnosis: PH unlikely</b>		
Tricuspid regurgitation velocity $\leq 2.8$ m/s, PA systolic pressure $\leq 36$ mmHg, and no additional echocardiographic variables suggestive of PH	I	B
<b>Echocardiographic diagnosis: PH possible</b>		
Tricuspid regurgitation velocity $\leq 2.8$ m/s, PA systolic pressure $\leq 36$ mmHg, but presence of additional echocardiographic variables suggestive of PH	IIa	C
Tricuspid regurgitation velocity $2.9\text{--}3.4$ m/s, PA systolic pressure $37\text{--}50$ mmHg with/without additional echocardiographic variables suggestive of PH	IIa	C
<b>Echocardiographic diagnosis: PH likely</b>		
Tricuspid regurgitation velocity $>3.4$ m/s, PA systolic pressure $>50$ mmHg, with/without additional echocardiographic variables suggestive of PH	I	B
<b>Exercise Doppler echocardiography is not recommended for screening of PH</b>	III	C

<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.

perfusion scan remains the screening method of choice for CTEPH because of its higher sensitivity than CT.<sup>53</sup> A normal- or low-probability ventilation/perfusion scan effectively excludes CTEPH with a sensitivity of 90–100% and a specificity of 94–100%. While in PAH the ventilation/perfusion lung scan may be normal, it may also show small peripheral unmatched and non-segmental defects in perfusion. Contrast-enhanced CT may be used as a complementary investigation but does not replace the ventilation/perfusion scan or traditional pulmonary angiogram. A caveat is that unmatched perfusion defects are also seen in PVOD.

7.1.7 High-resolution computed tomography, contrast-enhanced computed tomography, and pulmonary angiography

High-resolution CT provides detailed views of the lung parenchyma and facilitates the diagnosis of interstitial lung disease and emphysema. High-resolution CT may be very helpful where there is a clinical suspicion of PVOD. Characteristic changes of interstitial oedema with diffuse central ground-glass opacification and thickening of interlobular septa suggest PVOD; additional findings may include lymphadenopathy and pleural effusion.<sup>54</sup> Pulmonary capillary haemangiomatosis is suggested by diffuse bilateral thickening of the interlobular septa and the presence of small, centrilobular, poorly circumscribed nodular opacities.



Contrast CT angiography of the PA is helpful in determining whether there is evidence of surgically accessible CTEPH. It can delineate the typical angiographic findings in CTEPH such as complete obstruction, bands and webs, and intimal irregularities as accurately and reliably as digital subtraction angiography.<sup>55,56</sup> With this technique, collaterals from bronchial arteries can be identified.

Traditional pulmonary angiography is still required in many centres for the work-up of CTEPH to identify patients who may benefit from PEA.<sup>22</sup> Angiography can be performed safely by experienced staff in patients with severe PH using modern contrast media and selective injections. Angiography may also be useful in the evaluation of possible vasculitis or pulmonary arteriovenous malformations.

### 7.1.8 Cardiac magnetic resonance imaging

Cardiac magnetic resonance imaging provides a direct evaluation of RV size, morphology, and function, and allows non-invasive assessment of blood flow including stroke volume, CO, distensibility of PA, and RV mass.<sup>57</sup> Cardiac magnetic resonance data may be used to evaluate right heart haemodynamics particularly for follow-up purposes. A decreased stroke volume, an increased RV end-diastolic volume, and a decreased LV end-diastolic volume measured at baseline are associated with a poor prognosis. Among the triad of prognostic signs, increased RV end-diastolic volume may be the most appropriate marker of progressive RV failure in the follow-up.<sup>58</sup>

### 7.1.9 Blood tests and immunology

Routine biochemistry, haematology, and thyroid function tests are required in all patients, as well as a number of other essential blood tests. Serological testing is important to detect underlying CTD, HIV, and hepatitis. Up to 40% of patients with IPAH have elevated anti-nuclear antibodies, usually in low titre (1:80).<sup>59</sup> Systemic sclerosis is the most important CTD to exclude because this condition has a high prevalence of PAH. Anti-centromere antibodies are typically positive in limited scleroderma as are other anti-nuclear antibodies including dsDNA, anti-Ro, U3-RNP, B23, Th/To, and U1-RNP. In the diffuse variety of scleroderma, U3-RNP is typically positive. In individuals with systemic lupus erythematosus, anti-cardiolipin antibodies may be found. Thrombophilia screening including anti-phospholipid antibodies, lupus anticoagulant, and anti-cardiolipin antibodies should be performed in CTEPH. HIV testing is mandatory. Up to 2% of individuals with liver disease will manifest PAH and therefore liver function tests and hepatitis serology should be examined if clinical abnormalities are noted. Thyroid disease is commonly seen in PAH and should always be considered, especially if abrupt changes in the clinical course occur.<sup>60</sup>

### 7.1.10 Abdominal ultrasound scan

Liver cirrhosis and/or portal hypertension can be reliably excluded by the use of abdominal ultrasound. The use of contrast agents and the addition of a colour-Doppler examination may improve the accuracy of the diagnosis.<sup>61</sup> Portal hypertension can be confirmed by the detection of an increased gradient between free and occluded (wedge) hepatic vein pressure at the time of RHC.<sup>62</sup>

### 7.1.11 Right heart catheterization and vasoreactivity

RHC is required to confirm the diagnosis of PAH, to assess the severity of the haemodynamic impairment, and to test the vasoreactivity of the pulmonary circulation. When performed at experienced centres, RHC procedures have low morbidity (1.1%) and mortality (0.055%) rates.<sup>63</sup> The following variables must be recorded during RHC: PAP (systolic, diastolic, and mean), right atrial pressure, PWP, and RV pressure. CO must be measured in triplicate preferably by thermodilution or by the Fick method, if oxygen consumption is assessed. The Fick method is mandatory in the presence of a systemic-to-pulmonary shunt. Superior vena cava, PA, and systemic arterial blood oxygen saturations should also be determined. These measurements are needed for the calculation of PVR. Adequate recording of PWP is required for the differential diagnosis of PH due to left heart disease. In rare cases, left heart catheterization may be required for direct assessment of LV end-diastolic pressure. A PWP > 15 mmHg excludes the diagnosis of pre-capillary PAH. One of the most challenging differential diagnoses of PAH is heart failure with normal LV ejection fraction and diastolic dysfunction (see also section 9.1).<sup>64</sup> In this population, PWP may be mildly elevated or at the higher end of the normal range at rest. Exercise haemodynamics or volume challenge can show a disproportionate increase in PWP, although the relevance of this finding remains to be established. Coronary angiography may be required in the case of the presence of risk factors for coronary artery diseases and angina or in case of listing for double lung transplantation or PEA in patients with CTEPH.

In PAH, vasoreactivity testing should be performed at the time of diagnostic RHC to identify patients who may benefit from long-term therapy with calcium channel blockers (CCBs) (see also section 7.3.3).<sup>65,66</sup> Acute vasodilator challenge should only be performed with short-acting, safe, and easy to administer drugs with no or limited systemic effects. Currently the agent most used in acute testing is NO (Table 9);<sup>66</sup> based on previous experience,<sup>65,67,68</sup> intravenous (i.v.) epoprostenol or i.v. adenosine may also be used as an alternative (but with a risk of systemic vasodilator effects) (Table 10).

Inhaled iloprost and oral sildenafil may be associated with significant vasodilator effects. Their role in the prediction of the response to CCB therapy has not yet been demonstrated. Due to the risk of potentially life-threatening complications, the use of CCBs given orally or i.v. as an acute test is discouraged. A positive acute response (positive acute responder) is defined as a reduction of mean PAP  $\geq 10$  mmHg to reach an absolute value of mean PAP  $\leq 40$  mmHg with an increased or unchanged CO.<sup>66</sup> Only  $\sim 10\%$  of patients with IPAH will meet these criteria. Positive acute responders are most likely to show a sustained response to long-term treatment with high doses of CCBs and they are the only patients that can safely be treated with this type of therapy. About half of IPAH-positive acute responders are also positive long-term responders to CCBs<sup>66</sup> and only in these cases is the continuation of a CCB as a single treatment warranted. The usefulness of acute vasoreactivity tests and long-term treatment with CCBs in patients with other PAH types, such as heritable PAH, CTD, and HIV patients is less clear than in IPAH. Nevertheless, experts recommend performing acute vasoreactivity studies in these patients and to look for a long-term response to CCBs in those in which the test is positive. No data are available on the usefulness of long-term CCB therapy in patients with PH associated

**Table 10** Route of administration, half-life, dose ranges, increments, and duration of administration of the most commonly used agents for pulmonary vasoreactivity tests

Drug	Route	Half-life	Dose range <sup>a</sup>	Increments <sup>b</sup>	Duration <sup>c</sup>
Epoprostenol	Intravenous	3 min	2–12 ng/kg/min	2 ng/kg/min	10 min
Adenosine	Intravenous	5–10 s	50–350 µg/kg/min	50 µg/kg/min	2 min
Nitric oxide	Inhaled	15–30 s	10–20 p.p.m	–	5 min <sup>d</sup>

<sup>a</sup>Initial dose and maximal tolerated dose suggested (maximal dose limited by side effects such as hypotension, headache, flushing, etc.).

<sup>b</sup>Increments of dose by each step.

<sup>c</sup>Duration of administration on each step.

<sup>d</sup>For NO, a single step within the dose range is suggested.

with CHD and therefore the value of performing a vasoreactivity test in this setting is controversial. Acute vasoreactivity studies to identify patients with a long-term favourable response to CCBs is not recommended in clinical groups 2, 3, 4, and 5 (Table 4).

Recommendations for RHC and vasoreactivity test are summarized in the Table 11.

### 7.1.12 Diagnostic algorithm

The diagnostic algorithm is shown in Figure 1: the diagnostic process starts with the identification of the more common clinical groups of PH (group 2—left heart disease and group 3—lung diseases), then distinguishes group 4—CTEPH and finally makes the diagnosis and recognizes the different types in group 1—PAH and the rarer conditions in group 5.

PAH should be considered in the differential diagnosis of exertional dyspnoea, syncope, angina, and/or progressive limitation of exercise capacity, particularly in patients without apparent risk factors, symptoms or signs of common cardiovascular and respiratory disorders. Special awareness should be directed towards patients with associated conditions and/or risk factors for development of PAH, such as family history, CTD, CHD, HIV infection, portal hypertension, haemolytic anaemia, or a history of intake of drugs and toxins known to induce PAH (Table 8). In everyday clinical practice such awareness may be low. More often PH is found unexpectedly on transthoracic echocardiography requested for another indication.

If non-invasive assessment is compatible with PH, clinical history, symptoms, signs, ECG, chest radiograph, transthoracic echocardiogram, pulmonary function tests (including nocturnal oximetry, if required), and high-resolution CT of the chest are requested to identify the presence of group 2—left heart disease or group 3—lung diseases. If these are not found or if PH seems 'out of proportion' to their severity, less common causes of PH should be looked for. Ventilation/perfusion lung scan should be considered. If a ventilation/perfusion scan shows multiple segmental perfusion defects, a diagnosis of group 4—CTEPH should be suspected. The final diagnosis of CTEPH (and the assessment of suitability for PEA) will require CT pulmonary angiography, RHC, and selective pulmonary angiography. The CT scan may also show signs suggestive of group 1'—PVOD. If a ventilation/perfusion scan is normal or shows only subsegmental 'patchy' perfusion defects, a tentative diagnosis of group 1—PAH or the rarer conditions of group 5 is made. In Table 12 the further

**Table 11** Recommendations for right heart catheterization (A) and vasoreactivity testing (B)

	Class <sup>a</sup>	Level <sup>b</sup>
<b>A</b>		
RHC is indicated in all patients with PAH to confirm the diagnosis, to evaluate the severity, and when PAH specific drug therapy is considered	I	C
RHC should be performed for confirmation of efficacy of PAH-specific drug therapy	IIa	C
RHC should be performed for confirmation of clinical deterioration and as baseline for the evaluation of the effect of treatment escalation and/or combination therapy	IIa	C
<b>B</b>		
Vasoreactivity testing is indicated in patients with IPAH, heritable PAH, and PAH associated with anorexigen use to detect patients who can be treated with high doses of a CCB	I	C
A positive response to vasoreactivity testing is defined as a reduction of mean PAP $\geq 10$ mmHg to reach an absolute value of mean PAP $\leq 40$ mmHg with an increased or unchanged CO	I	C
Vasoreactivity testing should be performed only in referral centres	IIa	C
Vasoreactivity testing should be performed using nitric oxide as vasodilator	IIa	C
Vasoreactivity testing may be performed in other types of PAH	IIb	C
Vasoreactivity testing may be performed using i.v. epoprostenol or i.v. adenosine	IIb	C
The use of an oral or i.v. CCB in acute vasoreactivity testing is not recommended	III	C
Vasoreactivity testing to detect patients who can be safely treated with high doses of a CCB is not recommended in patients with other PH groups (groups 2, 3, 4, and 5)	III	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

**Table 12** Probability of PAH diagnosis and suggested management according to the echocardiographic diagnosis of PH (Table 9), symptoms, and additional clinical information

Low probability for PAH diagnosis	Class <sup>a</sup>	Level <sup>b</sup>
Echocardiographic diagnosis of 'PH unlikely', no symptoms: no additional work-up is recommended	I	C
Echocardiographic diagnosis of 'PH unlikely', presence of symptoms and of associated conditions or risks factors for group 1—PAH: echocardiographic follow-up is recommended	I	C
Echocardiographic diagnosis of 'PH unlikely', presence of symptoms, and absence of associated conditions or risks factors for group 1—PAH: evaluation of other causes for the symptoms is recommended	I	C
<b>Intermediate probability for PAH</b>		
Echocardiographic diagnosis of 'PH possible', no symptoms, and absence of associated conditions or risks factors for group 1—PAH: echocardiographic follow-up is recommended	I	C
Echocardiographic diagnosis of 'PH possible', presence of symptoms, and of associated conditions or risks factors for group 1—PAH: RHC may be considered	IIb	C
Echocardiographic diagnosis of 'PH possible', presence of symptoms, and absence of associated conditions or risks factors for group 1—PAH: alternative diagnosis and echocardiographic follow-up may be considered. If symptoms at least moderate RHC may be considered	IIb	C
<b>High probability for PAH</b>		
Echocardiographic diagnosis of 'PH likely', with symptoms and presence/absence of associated conditions or risks factors for group 1—PAH: RHC is recommended	I	C
Echocardiographic diagnosis of 'PH likely', without symptoms and presence/absence of associated conditions or risks factors for group 1—PAH: RHC should be considered	IIa	C

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.

management according to the likelihood of PAH is given including indications for RHC. Additional specific diagnostic tests including haematology, biochemistry, immunology, serology, and ultrasonography will allow the final diagnosis to be refined. Open or thoracoscopic lung biopsy entails substantial risk of morbidity and mortality. Because of the low likelihood of altering the diagnosis and treatment, routine biopsy is discouraged in PAH patients.

Recommendations for diagnostic strategy are summarized in the Table 13.

## 7.2 Evaluation of severity

The evaluation of severity of patients with PAH takes place between the diagnostic process and the therapeutic decision

**Table 13** Recommendations for diagnostic strategy

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Ventilation/perfusion lung scan is recommended in patients with unexplained PH to exclude CTEPH	I	C
Contrast CT angiography of the PA is indicated in the work-up of patients with CTEPH	I	C
Routine biochemistry, haematology, immunology, and thyroid function tests are indicated in all patients with PAH, to identify the specific associated condition	I	C
Abdominal ultrasound is indicated for the screening of portal hypertension	I	C
High-resolution CT should be considered in all patients with PH	IIa	C
Conventional pulmonary angiography should be considered in the work-up of patients with CTEPH	IIa	C
Open or thoracoscopic lung biopsy is not recommended in patients with PAH	III	C

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.

making. The clinical assessment of the patient has a pivotal role in the choice of the initial treatment, the evaluation of the response to therapy, and the possible escalation of therapy if needed.

### 7.2.1 Clinical, echocardiographic, and haemodynamic parameters

Both clinical and haemodynamic assessments yield important prognostic information which may guide clinical management. These data have been derived from cohorts of patients and may not accurately reflect the prognosis of individuals. Prognosis is significantly affected by the aetiology of PAH.<sup>69</sup>

Despite large interobserver variation in the measurement, WHO functional class (WHO-FC) (Table 14) remains a powerful predictor of survival. In untreated patients with IPAH or heritable PAH, historical data showed a median survival of 6 months for WHO-FC IV, 2.5 years for WHO-FC III, and 6 years for WHO-FC I and II.<sup>8</sup> Extremes of age (<14 years or >65 years), falling exercise capacity, syncope, haemoptysis, and signs of RV failure also carry a poor prognosis in IPAH.

Echocardiography generates many indices, and those with the best prognostic value identified by multivariate analysis are pericardial effusion,<sup>70,71</sup> indexed right atrium area,<sup>71</sup> LV eccentricity index,<sup>71</sup> and the RV Doppler index.<sup>72,73</sup> Estimated systolic PAP derived from tricuspid regurgitant jet velocity is not prognostic.<sup>71</sup> The tricuspid annular plane systolic excursion (TAPSE) has been reported to be of prognostic value.<sup>74</sup>

Resting haemodynamics measured at RHC predict prognosis.<sup>8</sup> These include PA oxygen saturation, right atrial pressure, CO, PVR, and a marked vasoreactivity response. PAP is also prognostic but less reliable as it may fall towards the end stage of the disease as the RV fails. Some studies suggest that reduced arterial O<sub>2</sub> saturation, low systolic blood pressure, and increased heart rate carry a worse prognosis.<sup>75</sup>

**Table 14 Functional classification of pulmonary hypertension modified after the New York Heart Association functional classification according to the WHO 1998<sup>76</sup>**

<b>Class I</b>	Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea or fatigue, chest pain, or near syncope.
<b>Class II</b>	Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, chest pain, or near syncope.
<b>Class III</b>	Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnoea or fatigue, chest pain, or near syncope.
<b>Class IV</b>	Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Right atrial pressure, CI, and mean PAP have been incorporated in a formula to predict prognosis.<sup>8</sup> It is unclear whether this formula is applicable to current clinical practice.

### 7.2.2 Exercise capacity

For objective assessment of exercise capacity, the 6-minute walking test (6MWT) and cardiopulmonary exercise testing are commonly used in patients with PAH.

The 6MWT is technically simple, inexpensive, reproducible, and well standardized.<sup>77</sup> In addition to distance walked, dyspnoea on exertion (Borg scale) and finger O<sub>2</sub> saturation are recorded. Walking distances <332 m<sup>78</sup> or <250 m<sup>79</sup> and O<sub>2</sub> desaturation >10%<sup>80</sup> indicate impaired prognosis in PAH. With respect to treatment effects, absolute values >380 m following 3 months of i.v. epoprostenol correlated with improved survival in IPAH patients while the increase from baseline did not.<sup>79</sup> The increase in 6MWT distance has remained the primary endpoint in most pivotal PAH RCTs. The test is not sufficiently validated in PAH subgroups and is influenced by (but not corrected for) body weight, gender, height, age, and patient motivation.<sup>77</sup>

With cardiopulmonary exercise testing gas exchange and ventilation are continuously recorded throughout incremental exercise. In PAH, O<sub>2</sub> uptake at the anaerobic threshold and peak exercise are reduced in relation to disease severity, as are peak work rate, peak heart rate, O<sub>2</sub> pulse, and ventilatory efficiency.<sup>81</sup> Following multivariate analysis of clinical, haemodynamic, and exercise parameters peak O<sub>2</sub> uptake (<10.4 ml O<sub>2</sub>/kg/min) and peak systolic arterial pressure during exercise (<120 mmHg) independently predicted a worse prognosis in IPAH patients.<sup>75</sup>

While the results of both methods do correlate in PAH, cardiopulmonary exercise testing failed to confirm improvements observed with 6MWT in RCTs.<sup>82,83</sup> Although lack of standardization and insufficient expertise in performing cardiopulmonary exercise testing were identified as the main reasons explaining

this discrepancy,<sup>81</sup> the 6MWT remains until now the only Food and Drug Administration- and European Agency for the Evaluation of Medicinal Products-accepted exercise endpoint for studies evaluating treatment effects in PAH. Despite detailed recommendations,<sup>84,85</sup> a generally accepted standardization of cardiopulmonary exercise testing with respect to data acquisition and analysis in PAH is lacking.

### 7.2.3 Biochemical markers

Biochemical markers emerged within the last decade as an attractive non-invasive tool for assessment and monitoring of RV dysfunction in patients with PH.

Serum uric acid is a marker of impaired oxidative metabolism of ischaemic peripheral tissue. High uric acid levels were found to relate to poor survival in patients with IPAH.<sup>86</sup> However, allopurinol is often prescribed to patients with PAH, and hyperuricaemia and diuretics influence its plasma levels, impairing the value of clinical monitoring based on uric acid levels.

Atrial natriuretic peptide and brain natriuretic peptide (BNP) share similar physiological properties. Both induce vasodilatation and natriuresis and are released from myocardium in response to wall stress. Interest in the clinical application of natriuretic peptides in monitoring RV failure due to chronic PH has focused on BNP.

The final step of BNP synthesis consists of a high molecular weight precursor, proBNP cleaved into biologically inactive N-terminal segment (NT-proBNP) and the proper low molecular weight BNP. NT-proBNP has a longer half-life and a better stability both in circulating blood and after sampling. RV failure is the main cause of death in PAH, and BNP/NT-proBNP levels reflect the severity of RV dysfunction. Nagaya *et al.*<sup>87</sup> showed that the baseline median value of BNP (150 pg/mL) distinguished patients with a good or bad prognosis. In 49 out of 60 patients, BNP measurement was repeated after 3 months of targeted therapy and again the supramedian level (>180 pg/mL) was related to worse long-term outcome. Plasma BNP significantly decreased in survivors but increased in non-survivors despite treatment. In a trial involving 68 patients with PAH associated with scleroderma, NT-proBNP below a median of 553 pg/mL was related to better 6-month and 1-year survival.<sup>88</sup> Using receiver operating characteristic (ROC) analysis, an NT-proBNP cut-off point at 1400 pg/mL was predictive of a 3-year outcome in 55 patients with severe precapillary PH.<sup>89</sup> Serum NT-proBNP below 1400 pg/mL seemed particularly useful for identification of patients with good prognosis, who would not need escalation of treatment in the immediate future, and this has been independently confirmed.<sup>90</sup> Larger outcome trials are still required to verify the suggested cut-off levels for NT-proBNP.

Increases in NT-proBNP plasma levels on follow-up have been associated with worse prognosis.<sup>88</sup> Several recent trials assessing new drugs in PAH or CTEPH reported a significant decrease in NT-proBNP in the actively treated vs. placebo patients.

Elevated plasma levels of cardiac troponin T and troponin I are established specific markers of myocardial damage and are prognostic indicators in acute coronary syndromes and acute pulmonary embolism. Elevated cardiac troponin T was an independent predictor of fatal outcome during 2-year follow-up in a single trial on 51 patients with PAH and five with CTEPH.<sup>91</sup> In some



patients cardiac troponin T disappeared from plasma either temporarily or permanently after introduction of treatment. The value of monitoring of the cardiac troponin T level in patients with PH still requires confirmation in future studies. Other biomarkers are currently under investigation.<sup>92,93</sup>

In conclusion, several circulating biomarkers convey prognostic information in patients with PAH, but their value in everyday clinical practice is still not established.

BNP/NT-proBNP plasma levels should be recommended for initial risk stratification and may be considered for monitoring the effects of treatment, in view of their prognostic implications. Low and stable or decreasing BNP/NT-proBNP may be a useful marker of successful disease control in PAH.

#### 7.2.4 Comprehensive prognostic evaluation

Regular evaluation of patients with PAH should focus on variables with established prognostic importance as outlined above. Treatment decisions should be based on parameters that reflect symptoms and exercise capacity and that are relevant in terms of predicting outcome. Not all parameters obtained repeatedly in PAH patients are equally well suited to assess disease severity. For example, PAP is measured on a regular basis, either by RHC or by echocardiography. The magnitude of the PAP correlates poorly with symptoms and outcome as it is determined not only by the degree of PVR increase but also by the performance of the RV. Thus, the PAP alone should not be used for therapeutic decision making. *Table 15* lists several parameters of known prognostic importance that are widely used as follow-up tools. Not all parameters need to be assessed at every visit (*Table 16*), but in order to obtain a clear picture it is important to look at a panel of data derived from clinical evaluation, exercise tests, biochemical

markers, and echocardiographic and haemodynamic assessments. It is crucial not to rely just on a single parameter as several assessments may provide divergent results. In addition, no clear-cut thresholds for any single parameters can be identified to separate patients with good prognosis from those with a poor one. In *Table 15*, patients with better or worse prognosis are separated by an intermediate group for which prognostication is more difficult. In these cases, additional factors not included in *Table 15* should be considered such as age, aetiology, and co-morbidities.

#### 7.2.5 Definition of patient status

Based on the clinical, non-invasive and invasive findings the clinical condition of a patient can be defined as stable and satisfactory, stable but not satisfactory, unstable and deteriorating:

*Stable and satisfactory*—Patients in this condition should fulfil the majority of the findings listed in the ‘better prognosis’ column of *Table 15*. In particular, the patient is characterized by absence of clinical signs of RV failure,<sup>79</sup> stable WHO-FC I or II without syncope, a 6 min walk distance >500 m<sup>79,95</sup> depending on the individual patient, a peak  $\text{VO}_2$  >15 mL/min/kg,<sup>75,96</sup> normal or near-normal BNP/NT-proBNP plasma levels,<sup>87,89</sup> no pericardial effusion,<sup>71</sup> TAPSE >2.0 cm,<sup>74</sup> right atrial pressure <8 mmHg, and a CI  $\geq 2.5$  L/min/m<sup>2</sup>.<sup>2,8,79,95,97,98</sup>

*Stable and not satisfactory*—This is a patient who although stable has not achieved the status which patient and treating physician would consider desirable. Some of the limits described above for a stable and satisfactory condition and included in the first column of *Table 15* are not fulfilled. These patients require re-evaluation and consideration for additional or different treatment following full assessment in the referral centre (see specific paragraph for definition).

**Table 15** Parameters with established importance for assessing disease severity, stability and prognosis in PAH (adapted from McLaughlin and McGoon<sup>94</sup>)

Better prognosis	Determinants of prognosis	Worse prognosis
No	Clinical evidence of RV failure	Yes
Slow	Rate of progression of symptoms	Rapid
No	Syncope	Yes
I, II	WHO-FC	IV
Longer (>500 m) <sup>a</sup>	6MWT	Shorter (<300 m)
Peak $\text{O}_2$ consumption >15 mL/min/kg	Cardio-pulmonary exercise testing	Peak $\text{O}_2$ consumption <12 mL/min/kg
Normal or near-normal	BNP/NT-proBNP plasma levels	Very elevated and rising
No pericardial effusion TAPSE <sup>b</sup> >2.0 cm	Echocardiographic findings <sup>b</sup>	Pericardial effusion TAPSE <sup>b</sup> <1.5 cm
RAP <8 mmHg and CI $\geq 2.5$ L/min/m <sup>2</sup>	Haemodynamics	RAP >15 mmHg or CI $\leq 2.0$ L/min/m <sup>2</sup>

<sup>a</sup>Depending on age.

<sup>b</sup>TAPSE and pericardial effusion have been selected because they can be measured in the majority of the patients.

BNP = brain natriuretic peptide; CI = cardiac index; 6MWT = 6-minute walking test; RAP = right atrial pressure; TAPSE = tricuspid annular plane systolic excursion; WHO-FC = WHO functional class.

**Table 16** Suggested assessments and timing for the follow-up of patients with PAH

	At baseline (prior to therapy)	Every 3–6 months <sup>a</sup>	3–4 months after initiation or changes in therapy	In case of clinical worsening
Clinical assessment WHO-FC ECG	✓	✓	✓	✓
6MWT <sup>b</sup>	✓	✓	✓	✓
Cardio-pulmonary exercise testing <sup>b</sup>	✓		✓	✓
BNP/NT-proBNP	✓	✓	✓	✓
Echocardiography	✓		✓	✓
RHC	✓ <sup>c</sup>		✓ <sup>d</sup>	✓ <sup>d</sup>

<sup>a</sup>Intervals should be adjusted to individual patients needs.

<sup>b</sup>Usually one of the two exercise tests is performed.

<sup>c</sup>Is recommended (Table 11A).

<sup>d</sup>Should be performed (Table 11A).

BNP = brain natriuretic peptide; ECG = electrocardiogram; RHC = right heart catheterization; 6MWT = 6-minute walking test; WHO-FC = WHO functional class.

*Unstable and deteriorating*—Patients in this condition fulfil the majority of the findings listed in the ‘worse prognosis’ column of Table 15. In particular the patient is characterized by evidence of progression of RV failure symptoms and signs, worsening WHO-FC, i.e. from II to III or from III to IV, a 6 min walk distance of <300 m,<sup>79,95</sup> a peak  $\text{VO}_2$  <12 mL/min/kg,<sup>75</sup> rising BNP/NT-proBNP plasma levels,<sup>87,89</sup> evidence of pericardial effusion,<sup>71</sup> TAPSE <1.5 cm,<sup>74</sup> right atrial pressure >15 mmHg and rising, or a CI that is  $\leq 2.0$  L/min/m<sup>2</sup> and falling.<sup>8,79,95,97,98</sup> Clinical warning signs are increasing oedema and/or the need to escalate diuretic therapy, new onset or increasing frequency/severity of angina which can be a sign of deteriorating RV function, and the onset or increasing frequency of syncope which is often a grim prognostic sign and requires immediate attention as it heralds low output heart failure. Supraventricular arrhythmias may be seen in this condition and contribute to clinical deterioration.

### 7.2.6 Treatment goals and follow-up strategy (see also section 7.3.7 and Table 22)

Treatment goals for PAH patients which may be considered are those listed in the ‘stable and satisfactory definition’ and in the ‘better prognosis’ column of Table 15.

Target values and treatment goals should be adjusted to the individual patient. For example, a 6MWT >400 m is usually considered acceptable in PAH patients. Younger patients are often capable of walking 500 m or more despite the presence of severe PH and RV dysfunction. In these patients, additional exercise testing with cardiopulmonary exercise test and/or RHC is particularly useful in order to obtain a more reliable assessment of RV function. Peak  $\text{VO}_2$ ,  $\text{O}_2$  pulse, peak systolic blood pressure during exercise, and the minute ventilation/carbon dioxide production slope (ventilator efficacy) provide important information about RV function during exercise.<sup>75,96</sup> Biomarkers, echocardiography,

**Table 17** Recommendations for evaluation of severity and follow-up

Statement	Class <sup>a</sup>	Level <sup>b</sup>
It is recommended to evaluate the severity of PAH patients with a panel of data derived from clinical evaluation, exercise tests, biochemical markers, and echocardiographic and haemodynamic assessments (Table 15)	I	C
It is recommended to perform regular follow-up every 3–6 months (Table 16) also in stable patients with PAH	I	C
A goal-oriented treatment strategy is recommended in patients with PAH	I	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

and RHC are useful additional tools to decide whether or not the patient can be considered stable. Suggested follow-up strategies for patients with PAH are reported in Table 16.

There is no universally accepted consensus about when and how often to perform follow-up RHC. Some, but not all, expert centres perform RHC regularly, for example once a year. Some centres use RHC whenever a change in treatment is considered, while others regularly perform RHC 3–6 months after new treatments have been instituted to ensure that haemodynamics are in the desired range. In terms of prognostic importance, the most relevant haemodynamic variables are cardiac output, RAP and mixed-venous oxygen saturation, i.e. those variables that reflect RV function. Recommendations for the use of RHC in PAH patients are provided in Table 11.

Recommendations for evaluation of severity and follow-up are summarized in Table 17.

### 7.3 Therapy

In the past few years, treatment of PAH has undergone an extraordinary evolution, which has led to the current approval by regulatory agencies of eight drugs with different routes of administration. Additional drugs are expected in the near future. Modern drug therapy leads to a significant improvement in patients' symptomatic status and a slower rate of clinical deterioration. In addition, a meta-analysis performed on 23 RCTs in PAH patients (published prior to October 2008) reports a 43% decrease in mortality and a 61% reduction in hospitalizations in patients treated with specific drug therapies vs. patients randomized to placebo.<sup>99</sup> These results, achieved after an average treatment period of 14.3 weeks, support the efficacy of the currently approved PAH treatments. Despite this finding, PAH remains a chronic disease without a cure. In addition, the medical and interventional treatments for more advanced cases are still invasive and prone to significant side effects.

*The therapy of PAH patients cannot be considered as a mere prescription of drugs but is characterized by a complex strategy which includes the evaluation of severity, supportive and general measures, the assessment of vasoreactivity, the estimation of efficacy, and combination of different drugs plus interventions. In any of these steps, the knowledge and experience of the responsible physician are critical to optimize the available resources.*

#### 7.3.1 General measures

Patients with PAH require sensible advice about general activities of daily living and need to adapt to the uncertainty associated with a serious chronic life-threatening disease. The diagnosis usually confers a degree of social isolation.<sup>100</sup> Encouraging patients and their family members to join patient support groups can have positive effects on coping, confidence, and outlook.

##### *Physical activity and supervised rehabilitation*

Patients should be encouraged to be active within symptom limits. Mild breathlessness is acceptable but patients should avoid exertion that leads to severe breathlessness, exertional dizziness, or chest pain. A recent study has shown the value of a training programme in improving exercise performance.<sup>101</sup> Patients should therefore avoid excessive physical activity that leads to distressing symptoms, but when physically deconditioned may undertake supervised exercise rehabilitation.

One recent study has demonstrated an improvement in exercise capacity in patients with PAH who took part in a training programme.<sup>101</sup> More data are required before appropriate recommendations can be made. There is growing evidence supporting loss of peripheral muscle mass in patients with advanced PAH, and this may be corrected by a defined rehabilitation programme.

##### *Pregnancy, birth control, and post-menopausal hormonal therapy*

There is consistency from the WHO, existing guidelines, and the Expert Consensus Document of the ESC<sup>102</sup> that pregnancy is associated with 30–50% mortality in patients with PAH,<sup>103</sup> and as a consequence PAH is a contra-indication to pregnancy. There is less consensus relating to the most appropriate methods of birth control. Barrier contraceptive methods are safe

for the patient but with an unpredictable effect. Progesterone-only preparations such as medroxyprogesterone acetate and etonogestrel are effective approaches to contraception and avoid potential issues of oestrogens as those included in the old generation mini-pill.<sup>104</sup> It should be remembered that the endothelin receptor antagonist (ERA) bosentan may reduce the efficacy of oral contraceptive agents. The Mirena coil is also effective but rarely leads to a vasovagal reaction when inserted, which may be poorly tolerated in severe PAH.<sup>104</sup> A combination of two methods may also be utilized. The patient who becomes pregnant should be informed of the high risk of pregnancy, and termination of pregnancy discussed. Those patients who choose to continue pregnancy should be treated with disease-targeted therapies, planned elective delivery, and effective close collaboration between obstetricians and the PAH team.<sup>105,106</sup>

It is not clear if the use of hormonal therapy in post-menopausal women with PAH is advisable or not. It may be considered in cases of intolerable menopausal symptoms in conjunction with oral anticoagulation.

##### *Travel*

There are no studies using flight simulation to determine the need for supplemental O<sub>2</sub> during prolonged flights in patients with PAH. The known physiological effects of hypoxia suggest that in-flight O<sub>2</sub> administration should be considered for patients in WHO-FC III and IV and those with arterial blood O<sub>2</sub> pressure consistently <8 kPa (60 mmHg). A flow rate of 2 L/min will raise inspired O<sub>2</sub> pressure to values seen at sea level. Similarly, such patients should avoid going to altitudes above 1500–2000 m without supplemental O<sub>2</sub>. Patients should be advised to travel with written information about their PAH and be advised how to contact local PH clinics in close proximity to where they are travelling.

##### *Psychosocial support*

Many PAH patients develop anxiety and depression leading to impairment in quality of life. Timely referral to a psychiatrist or psychologist should be made when appropriate. Information on the severity of the disease is available from many non-professional sources, and an important role of the PAH multidisciplinary team is to support patients with accurate and up to date information. Patient support groups may also play an important role in this area, and patients should be advised to join such groups.

##### *Infection prevention*

Patients with PAH are susceptible to developing pneumonia, which is the cause of death in 7% of cases.<sup>44</sup> Whilst there are no controlled trials, it is recommended to vaccinate against influenza and pneumococcal pneumonia.

##### *Elective surgery*

Elective surgery is expected to have an increased risk in patients with PAH. It is not clear as to which form of anaesthesia is preferable but epidural is probably better tolerated than general anaesthesia. Patients usually maintained on oral therapy may require temporary conversion to i.v. or nebulized treatment until they are able both to swallow and to absorb drugs taken orally.

**Table 18** Recommendations for general measures

Statement	Class <sup>a</sup>	Level <sup>b</sup>
It is recommended to avoid pregnancy in patients with PAH	I	C
Immunization of PAH patients against influenza and pneumococcal infection is recommended	I	C
Physically deconditioned PAH patients should be considered for supervised exercise rehabilitation	IIa	B
Psychosocial support should be considered in patients with PAH	IIa	C
In-flight O <sub>2</sub> administration should be considered for patients in WHO-FC III and IV and those with arterial blood O <sub>2</sub> pressure consistently less than 8 kPa (60 mmHg)	IIa	C
Epidural anaesthesia instead of general anaesthesia should be utilised, if possible, for elective surgery	IIa	C
Excessive physical activity that leads to distressing symptoms is not recommended in patients with PAH	III	C

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.

Recommendations for general measures are summarized in the Table 18.

### 7.3.2 Supportive therapy

#### Oral anticoagulants

There is a high prevalence of vascular thrombotic lesions at post-mortem in patients with IPAH.<sup>107</sup> Abnormalities in coagulation and fibrinolytic pathways have also been reported.<sup>108–110</sup> This, together with the possible presence of non-specific risk factors for venous thromboembolism, including heart failure and immobility, represents the rationale for oral anticoagulation in PAH. Evidence in favour of oral anticoagulation is confined to patients with IPAH, heritable PAH, and PAH due to anorexigens; it is generally retrospective and based on single centre experience.<sup>65,107</sup> The potential benefits of oral anticoagulation should be weighed against the risks in patients with other forms of PAH especially when there is an increased risk of bleeding such as portopulmonary hypertension with severe oesophageal varices. Further research into the role of oral anticoagulation and PAH is encouraged. Advice regarding the target international normalized ratio (INR) in patients with IPAH varies from 1.5–2.5 in most centres of North America to 2.0–3.0 in European centres. Generally, patients with PAH receiving therapy with long-term i.v. prostaglandins are anticoagulated in the absence of contra-indications due in part to the additional risk of catheter-associated thrombosis.

#### Diuretics

Decompensated right heart failure leads to fluid retention, raised central venous pressure, hepatic congestion, ascites, and peripheral oedema. Although there are no RCTs of diuretics in PAH, clinical experience shows clear symptomatic benefit in fluid-overloaded patients treated with this therapy. The choice and dose of diuretic

**Table 19** Recommendations for supportive therapy

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Diuretic treatment is indicated in PAH patients with signs of RV failure and fluid retention	I	C
Continuous long-term O <sub>2</sub> therapy is indicated in PAH patients when arterial blood O <sub>2</sub> pressure is consistently less than 8 kPa (60 mmHg) <sup>c</sup>	I	C
Oral anticoagulant treatment should be considered in patients with IPAH, heritable PAH, and PAH due to use of anorexigens	IIa	C
Oral anticoagulant treatment may be considered in patients with APAH	IIb	C
Digoxin may be considered in patients with PAH who develop atrial tachyarrhythmias to slow ventricular rate	IIb	C

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.<sup>c</sup>See also recommendations for PAH associated with congenital cardiac shunts (Table 25).

therapy may be left to the PAH physician. The addition of aldosterone antagonists should also be considered. It is important to monitor renal function and blood biochemistry in patients to avoid hypokalaemia and the effects of decreased intravascular volume leading to pre-renal failure.

#### Oxygen

Although O<sub>2</sub> administration has been demonstrated to reduce the PVR in patients with PAH there are no randomized data to suggest that long-term O<sub>2</sub> therapy is beneficial. Most patients with PAH except those with CHD and pulmonary-to-systemic shunts have minor degrees of arterial hypoxaemia at rest unless they have a patent foramen ovale. There are data showing that nocturnal O<sub>2</sub> therapy does not modify the natural history of advanced Eisenmenger's syndrome.<sup>111</sup> Guidance may be based on evidence in patients with COPD; when arterial blood O<sub>2</sub> pressure is consistently less than 8 kPa (60 mmHg) patients are advised to take O<sub>2</sub> to achieve a arterial blood O<sub>2</sub> pressure of >8 kPa for at least 15 h/day.<sup>112</sup> Ambulatory O<sub>2</sub> may be considered when there is evidence of symptomatic benefit and correctable desaturation on exercise.

#### Digoxin

Digoxin has been shown to improve cardiac output acutely in IPAH although its efficacy is unknown when administered chronically.<sup>113</sup> It may be given to slow ventricular rate in patients with PAH who develop atrial tachyarrhythmias.

Recommendations for general measures are summarized in the Table 19.

### 7.3.3 Specific drug therapy

#### Calcium channel blockers

Smooth muscle cell hypertrophy, hyperplasia, and vasoconstriction have long been known to contribute to the pathogenesis of IPAH and this has led to the use of traditional vasodilators since the mid 1980s, principally involving the use of CCBs. It has been



increasingly recognized that only a small number of patients with IPAH who demonstrate a favourable response to acute vasodilator testing at the time of RHC (see also section 7.1.11) do well with CCBs.<sup>65,66</sup>

The CCBs that have been predominantly used in reported studies are nifedipine, diltiazem, and amlodipine, with particular emphasis on the first two.<sup>65,66</sup> The choice of CCB is based upon the patient's heart rate at baseline, with a relative bradycardia favouring nifedipine and amlodipine and a relative tachycardia favouring diltiazem. The daily doses of these drugs that have shown efficacy in IPAH are relatively high, 120–240 mg for nifedipine, 240–720 mg for diltiazem, and up to 20 mg for amlodipine. It is advisable to start with a low dose, e.g. 30 mg of slow release nifedipine twice a day, 60 mg of diltiazem three times a day (t.i.d.), or 2.5 mg of amlodipine once a day and increase cautiously and progressively to the maximum tolerated dose. Limiting factors for dose increase are usually systemic hypotension and lower limb peripheral oedema. Patients with IPAH who meet the criteria for a positive vasodilator response and are treated with a CCB should be followed closely for both safety and efficacy with an initial reassessment after 3–4 months of therapy including RHC.

If the patient does not show an adequate response (Figure 2), defined as being in WHO-FC I or II and with a marked haemodynamic improvement, additional PAH therapy should be instituted. Patients who have not undergone a vasoreactivity study or those with a negative study should not be started on a CCB because of potential severe side effects (e.g. hypotension, syncope, and RV failure).

Vasodilator responsiveness does not appear to predict a favourable long-term response to CCB therapy in patients with PAH in the setting of CTD, and high dose CCBs are often not well tolerated in such patients.<sup>114</sup>

### Prostanoids

Prostacyclin is produced predominantly by endothelial cells and induces potent vasodilatation of all vascular beds. This compound is the most potent endogenous inhibitor of platelet aggregation and it also appears to have both cytoprotective and antiproliferative activities.<sup>115</sup> Dysregulation of the prostacyclin metabolic pathways has been shown in patients with PAH as assessed by reduction of prostacyclin synthase expression in the pulmonary arteries and of prostacyclin urinary metabolites.<sup>116</sup> The clinical use of prostacyclin in patients with PAH has been extended by the synthesis of stable analogues that possess different pharmacokinetic properties but share qualitatively similar pharmacodynamic effects.

**Epoprostenol.** Epoprostenol (synthetic prostacyclin) is available as a stable freeze-dried preparation that needs to be dissolved in alkaline buffer for i.v. infusion. Epoprostenol has a short half-life (3–5 min) and is stable at room temperature for only 8 h. This explains why it needs to be administered continuously by means of an infusion pump and a permanent tunnelled catheter. The efficacy of continuous i.v. administration of epoprostenol has been tested in three unblinded RCTs in patients with IPAH<sup>117,118</sup> and in those with PAH associated with the scleroderma spectrum of diseases.<sup>119</sup> Epoprostenol improves symptoms, exercise capacity, and haemodynamics in both clinical conditions, and is the only treatment shown to improve survival in IPAH in a randomized


study.<sup>118</sup> Long-term persistence of efficacy has also been shown<sup>79,97</sup> in IPAH, as well as in other APAH conditions<sup>120–122</sup> and in non operable CTEPH.<sup>123</sup>

Treatment with epoprostenol is initiated at a dose of 2–4 ng/kg/min, with doses increasing at a rate limited by side effects (flushing, headache, diarrhoea, leg pain). The optimal dose varies between individual patients, ranging in the majority between 20 and 40 ng/kg/min.<sup>79,97</sup>

Serious adverse events related to the delivery system include pump malfunction, local site infection, catheter obstruction, and sepsis. Guidelines for the prevention of central venous catheter bloodstream infections have recently been proposed.<sup>124</sup> Abrupt interruption of the epoprostenol infusion should be avoided as, in some patients, this may lead to a rebound PH with symptomatic deterioration and even death.

**Iloprost.** Iloprost is a chemically stable prostacyclin analogue available for i.v., oral, and aerosol administration. Inhaled therapy for PAH is an attractive concept that has the theoretical advantage of being selective for the pulmonary circulation. Inhaled iloprost has been evaluated in one RCT (AIR) in which daily repetitive iloprost inhalations (6–9 times, 2.5–5 µg/inhalation, median 30 µg daily) were compared with placebo inhalation in patients with PAH and CTEPH.<sup>125</sup> The study showed an increase in exercise capacity and improvement in symptoms, PVR, and clinical events in enrolled patients. A second RCT (STEP) on 60 patients already treated with bosentan has shown increase in exercise capacity ( $P < 0.051$ ) in the subjects randomized to the addition of inhaled iloprost in comparison with placebo.<sup>126</sup> Overall, inhaled iloprost was well tolerated, with flushing and jaw pain being the most frequent side effects. Continuous i.v. administration of iloprost appears to be as effective as epoprostenol in a small series of patients with PAH and CTEPH.<sup>127</sup> The effects of oral iloprost have not been assessed in PAH.

**Treprostinil.** Treprostinil is a tricyclic benzidine analogue of epoprostenol, with sufficient chemical stability to be administered at ambient temperature. These characteristics allow administration of the compound by the i.v. as well as the s.c. route. The s.c. administration of treprostinil can be accomplished by a microinfusion pump and a small subcutaneous catheter. The effects of treprostinil in PAH were studied in the largest worldwide RCT performed in this condition, and showed improvements in exercise capacity, haemodynamics, and symptoms.<sup>128</sup> The greatest exercise improvement was observed in patients who were more compromised at baseline and in subjects who could tolerate the upper quartile dose ( $>13.8$  ng/kg/min). Infusion site pain was the most common adverse effect of treprostinil, leading to discontinuation of the treatment in 8% of cases on active drug and limiting dose increase in an additional proportion of patients.<sup>128</sup> Among the 15% of patients who continued to receive s.c. treprostinil alone, survival appears to be improved.<sup>129</sup> In another long-term, open-label study, a sustained improvement in exercise capacity and symptoms with s.c. treprostinil was reported in patients with IPAH or CTEPH, with a mean follow-up of 26 months.<sup>130</sup> Treatment with s.c. treprostinil is initiated at a dose of 1–2 ng/kg/min, with doses increasing at a rate limited by side effects (local site pain, flushing, headache). The optimal dose varies between individual patients, ranging in the majority between 20 and 80 ng/kg/min. Treprostinil has been recently approved in the USA also for i.v. use in patients with PAH: the effects appear to be comparable with those of epoprostenol but at a dose which is between two and



**Figure 2** Evidence-based treatment algorithm for pulmonary arterial hypertension patients (for group 1 patients only). \*To maintain arterial blood O<sub>2</sub> pressure ≥ 8 kPa (60 mmHg). †Under regulatory review in the European Union. §IIa-C for WHO-FC II. APAH = associated pulmonary arterial hypertension; BAS = balloon atrial septostomy; CCB = calcium channel blocker; ERA = endothelin receptor antagonist; IPAH = idiopathic pulmonary arterial hypertension; PDE5 I = phosphodiesterase type-5 inhibitor; WHO-FC = World Health Organization functional class.

three times higher.<sup>131,132</sup> It is, however, more convenient for the patient because the reservoir can be changed every 48 h as compared with 12 h with epoprostenol. A phase III RCT (TRIUMPH) of inhaled treprostinil in patients on background therapy with either

the ERA bosentan or the phosphodiesterase type-5 inhibitor sildenafil was recently completed, and preliminary data show improvements in exercise capacity.<sup>133</sup> Oral treprostinil is currently being evaluated in RCTs in PAH.

**Beraprost.** Beraprost is the first chemically stable and orally active prostacyclin analogue. The RCT ALPHABET<sup>134</sup> in Europe and a second in the USA<sup>82</sup> with this compound have shown an improvement in exercise capacity that unfortunately persists only up to 3–6 months. There were no haemodynamic benefits. The most frequent adverse events were headache, flushing, jaw pain, and diarrhoea.

#### Endothelin receptor antagonists

Activation of the endothelin system has been demonstrated in both plasma and lung tissue of PAH patients.<sup>135</sup> Although it is not clear if the increases in endothelin-1 plasma levels are a cause or a consequence of PH,<sup>136</sup> these data support a prominent role for the endothelin system in the pathogenesis of PAH.<sup>137</sup> Endothelin-1 exerts vasoconstrictor and mitogenic effects by binding to two distinct receptor isoforms in the pulmonary vascular smooth muscle cells, endothelin-A and endothelin-B receptors. Endothelin-B receptors are also present in endothelial cells, and their activation leads to release of vasodilators and antiproliferative substances such as NO and prostacyclin that may counterbalance the deleterious effects of endothelin-1. Despite potential differences in receptor isoform activity, the efficacy in PAH of the dual endothelin-A and endothelin-B receptor antagonist drugs and of the selective ERA compounds appears to be comparable.

**Bosentan.** Bosentan is an oral active dual endothelin-A and endothelin-B receptor antagonist and the first molecule of its class that was synthesized. Bosentan has been evaluated in PAH (idiopathic, associated with CTD, and Eisenmenger's syndrome) in five RCTs (Pilot, BREATHE-1, BREATHE-2, BREATHE-5, and EARLY) that have shown improvement in exercise capacity, functional class, haemodynamics, echocardiographic and Doppler variables, and time to clinical worsening.<sup>138–142</sup> Two RCTs have enrolled exclusively patients with WHO-FC II<sup>141</sup> or patients with Eisenmenger's syndrome.<sup>142</sup> This has resulted in regulatory authority approval for the use of bosentan in the treatment of PAH patients in WHO-FC II and also in patients with PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Bosentan treatment is started at the dose of 62.5 mg twice daily and uptitrated to 125 mg twice daily after 4 weeks. In paediatric patients doses are reduced according to the body weight. Long-term observational studies have demonstrated the durability of the effect of bosentan in adult IPAH patients over time.<sup>98</sup> Increases in hepatic aminotransferases occurred in ~10% of the subjects but were found to be dose dependent and reversible after dose reduction or discontinuation. For these reasons, liver function test should be performed monthly in patients receiving bosentan. Reductions on haemoglobin levels and impaired spermatogenesis have also been observed.

**Sitaxentan.** Sitaxentan, a selective orally active endothelin-A receptor antagonist, has been assessed in two RCTs (STRIDE 1 and 2) on patients with WHO-FC II and III PAH.<sup>83,143</sup> Aetiology included IPAH and PAH associated with CTDs or CHD. The studies demonstrated improvements in exercise capacity and haemodynamics. A 1-year, open-label observational study has demonstrated the durability of the effects of sitaxentan over time.<sup>144</sup> The incidence of abnormal liver function tests was 3–5% for the approved dose of 100 mg once daily. Monthly checking of liver function tests is required. Sitaxentan interacts with warfarin, and

co-administration requires dose reductions of warfarin to avoid increases of INR (Table 20).

**Ambrisentan.** Ambrisentan is a non-sulfonamide, propanoic acid-class, ERA that is selective for the endothelin-A receptor. Ambrisentan has been evaluated in a pilot study<sup>145</sup> and in two large RCTs (ARIES 1 and 2), which have demonstrated efficacy on symptoms, exercise capacity, haemodynamics, and time to clinical worsening of patients with IPAH and PAH associated with CTD and HIV infection.<sup>146</sup> The open-label continuation study has demonstrated the durability of the effects of ambrisentan for at least 1 year.<sup>146</sup> Ambrisentan has been approved for the treatment of WHO-FC II and III patients. The current approved dose is 5 mg once daily which can be increased to 10 mg once daily when the drug is tolerated at the initial dose.

The incidence of abnormal liver function tests ranges from 0.8 to 3%. In a small group of patients in which treatment with either bosentan or sitaxentan was discontinued due to liver function test abnormalities, ambrisentan at a dose of 5 mg was well tolerated.<sup>147</sup> Nevertheless, patients treated with ambrisentan require monthly liver function test assessment. An increased incidence of peripheral oedema has been reported with ambrisentan use.

#### Phosphodiesterase type-5 inhibitors

Inhibition of the cGMP-degrading enzyme phosphodiesterase type-5 results in vasodilatation through the NO/cGMP pathway at sites expressing this enzyme. Since the pulmonary vasculature contains substantial amounts of phosphodiesterase type-5 the potential clinical benefit of phosphodiesterase type-5 inhibitors has been investigated in PAH. In addition, phosphodiesterase type-5 inhibitors exert antiproliferative effects.<sup>148,149</sup> All three phosphodiesterase type-5 inhibitors approved for the treatment of erectile dysfunction, sildenafil, tadalafil, and vardenafil, cause significant pulmonary vasodilation, with maximum effects observed after 60, 75–90, and 40–45 min, respectively.<sup>150</sup>

**Sildenafil.** Sildenafil is an orally active, potent, and selective inhibitor of phosphodiesterase type-5. A number of uncontrolled studies have reported favourable effects of sildenafil in IPAH, PAH associated with CTD, CHD, and CTEPH.<sup>151–153</sup> An RCT (SUPER-1) on 278 PAH patients treated with sildenafil 20, 40, or 80 mg t.i.d. has confirmed favourable results on exercise capacity, symptoms, and haemodynamics.<sup>154</sup> A *post hoc* analysis of 84 PAH associated with CTD patients receiving sildenafil in the SUPER-1 trial revealed improved exercise capacity, haemodynamic parameters, and functional class at 12 weeks when compared with placebo.<sup>155</sup> The approved dose is 20 mg t.i.d., but the durability of effect up to a year has been demonstrated only with the dose of 80 mg t.i.d. In clinical practice, up-titration beyond 20 mg t.i.d. (mainly 40–80 mg t.i.d.) is needed quite frequently. The PACES trial addressing the effects of adding sildenafil to epoprostenol is discussed in the 'Combination therapy' section.<sup>156</sup> Most side effects of sildenafil were mild to moderate and mainly related to vasodilation (headache, flushing, epistaxis).

**Tadalafil.** Tadalafil is a once-daily dispensed, selective phosphodiesterase type-5 inhibitor, currently approved for the treatment of erectile dysfunction. An RCT (PHIRST) on 406 PAH patients (~50% on background bosentan therapy) treated with tadalafil 5, 10, 20, or 40 mg once daily has shown favourable results on



**Table 20** Potentially significant drug interactions with PAH-targeted therapies

PAH Drug	Mechanism of interaction	Interacting drug	Interaction
<b>Ambrisentan</b>	?	Cyclosporine Ketoconazole	Caution is required in the co-administration of ambrisentan with ketoconazole and cyclosporine.
<b>Bosentan</b>	CYP3A4 inducer	Sildenafil	Sildenafil levels fall 50%; bosentan levels increase 50%. May not require dose adjustments of either drug.
	CYP3A4 substrate	Cyclosporine	Cyclosporine levels fall 50%; bosentan levels increase 4-fold. Combination contraindicated.
	CYP3A4 substrate	Erythromycin	Bosentan levels increase. May not require dose adjustment of bosentan during a short course.
	CYP3A4 substrate	Ketoconazole	Bosentan levels increase 2-fold.
	CYP3A4 substrate + bile salt pump inhibitor	Glibenclamide	Increase incidence of elevated aminotransferases. Potential decrease of hypoglycaemic effect of glibenclamide. Combination contraindicated.
	CYP2C9 and CYP3A4 substrate	Fluconazole, amiodarone	Bosentan levels considerably increase. Combination potentially contraindicated
	CYP2C9 and CYP3A4 inducers	Rifampicin, phenytoin	Bosentan levels decrease by 58%. Need for dose adjustment uncertain.
	CYP2C9 inducer	HMG CoA reductase inhibitors	Simvastatin levels reduce 50%; similar effects likely with atorvastatin. Cholesterol level should be monitored.
	CYP2C9 inducer	Warfarin	Increases warfarin metabolism, may need to adjust warfarin dose. Intensified monitoring of warfarin recommended following initiation but dose adjustment usually unnecessary.
	CYP2C9 and CYP3A4 inducers	Hormonal contraceptives	Hormone levels decrease. Contraception unreliable.
<b>Sitaxentan</b>	CYP2C9 inhibitor	Warfarin	Inhibits warfarin metabolism, warfarin dose needs to be reduced by 80% when initiating sitaxentan and INR monitoring intensified.
	? inhibition of OATP transporter	Cyclosporine	Increases sitaxentan levels; combination contraindicated.
<b>Sildenafil</b>	CYP3A4 substrate	Bosentan	Sildenafil levels fall 50%; bosentan levels increase 50%. May not require dose adjustments of either drug.
	CYP3A4 substrate	HMG CoA reductase inhibitors	May increase simvastatin/atorvastatin levels through competition for metabolism. Sildenafil levels may increase. Possible increased risk of rhabdomyolysis.
	CYP3A4 substrate	HIV protease inhibitors	Ritonavir and saquinovir increase sildenafil levels markedly. Sildenafil dose-adjustments are usually required.
	CYP3A4 inducer	Phenytoin	Sildenafil level may fall.
	CYP3A4 substrate	Erythromycin	Sildenafil levels increase may not require dose adjustment for a short course.
	CYP3A4 substrate	Ketoconazole	Sildenafil levels increase. May not require dose adjustment.
	CYP3A4 substrate	Cimetidine	Sildenafil levels increase. May not require dose adjustment.
	cGMP	Nitrates Nicorandil	Profound systemic hypotension, combination contraindicated.
<b>Tadalafil</b>	CYP3A4 substrate	Bosentan	Tadalafil plasma levels decreases by 42%, no significant changes in bosentan levels. May not require dose adjustment.
	cGMP	Nitrates Nicorandil	Profound systemic hypotension, combination contraindicated.

cGMP = cyclic guanosine monophosphate; OATP = organic anion transporter proteins. The table is adapted from National Pulmonary Hypertension Centres of the UK and Ireland. Consensus Statement on the Management of Pulmonary Hypertension in Clinical Practice in the UK and Ireland. *Heart* 2008;**94**(Suppl 1):11–14. Since the original publication of these Guidelines, the drug **sitaxentan** has been withdrawn from the market due to liver toxicity.



exercise capacity, symptoms, haemodynamics, and time to clinical worsening at the largest dose.<sup>157</sup> The durability of the effect has also been shown. The side effect profile was similar to that of sildenafil.

#### *Experimental compounds and alternative medical strategies*

Despite the progress on the treatment of PAH, the functional limitation and the survival of these patients remain unsatisfactory. For these reasons, additional therapeutic strategies targeted to diverse pathobiological changes are being explored in order to improve symptoms and prognosis further. Phase II and III studies are currently being performed with the following compounds: NO-independent stimulators and activators of cGMP, inhaled vasoactive intestinal peptide, non-prostanoid prostacyclin receptor agonists, tissular dual ERA-, tyrosine kinase inhibitors (platelet-derived growth factor inhibitors), and serotonin antagonists.

The following additional compounds are in an earlier stage of development: rho-kinase inhibitors, vascular endothelial growth factor receptor inhibitors, angiopoietin-1 inhibitors, and elastase inhibitors.

Gene therapy strategies have been tested in animal models. Stem cell therapy has proven to be effective in the monocrotalin rat model and is currently being tested in proof-of-concept and dose-finding studies in PAH patients.

#### *Combination therapy*

The term combination therapy describes the simultaneous use of more than one PAH-specific class of drugs, e.g. ERAs, phosphodiesterase type-5 inhibitors, prostanoids, and novel substances. Combination therapy has become the standard of care in many PAH centres, although long-term safety and efficacy have not yet been amply explored. Numerous case series have suggested that various drug combinations appear to be safe and effective.<sup>140,158–161</sup> In one series, a step-wise use of combination therapy according to predefined treatment goals was associated with an improved outcome compared with a historical control group.<sup>162</sup>

Results of a few RCTs evaluating combination therapy for PAH have been published. The relatively small BREATHE-2 study<sup>140</sup> showed a trend to a better haemodynamic effect of the initial combination epoprostenol-bosentan as compared to epoprostenol alone. The STEP-1 study<sup>163</sup> addressed the safety and efficacy of 12 weeks therapy with inhaled iloprost in addition to bosentan and found a marginal increase in the post-inhalation 6 min walk distance by +26 m ( $P=0.051$ ). When measured at pre-inhalation, the placebo-corrected improvement in 6 min walk distance was +19 m ( $P=0.14$ ). There was no improvement in pre-inhalation haemodynamics in the iloprost group after 12 weeks of treatment, but time to clinical worsening was significantly prolonged in the iloprost group (0 events vs. 5 events in the placebo group;  $P=0.02$ ). In contrast, another RCT, COMBI, which also studied the effects of inhaled iloprost added to bosentan, was stopped prematurely after a planned futility analysis did not show an effect on 6 min walking distance or time to clinical worsening.<sup>164</sup>

Two other RCTs on combination therapy have been concluded: TRIUMPH<sup>133</sup> and PACES.<sup>156</sup> TRIUMPH studied the effects of inhaled treprostinil in patients already treated with bosentan or

sildenafil. The primary endpoint, change in 6MWT at peak exposure, improved by 20 m compared with placebo ( $P<0.0006$ ). At trough exposure, i.e. after >4 h post-inhalation, the difference was 14 m in favour of the treprostinil group ( $P<0.01$ ). There were no significant differences in Borg dyspnoea index, functional class, and time to clinical worsening.

The PACES trial addressed the effects of adding sildenafil to epoprostenol in 267 PAH patients. The most pertinent findings of this study were significant improvements after 12 weeks in 6MWT and time to clinical worsening. Of note, seven deaths occurred in this trial, all in the placebo group.

Additional data from RCTs are available for the combination of ERAs and phosphodiesterase type-5 inhibitors. In the subgroup of patients enrolled in the EARLY study<sup>141</sup> (bosentan in WHO-FC II PAH patients) who were already on treatment with sildenafil, the haemodynamic effect of the addition of bosentan was comparable with that achieved in patients without background sildenafil treatment. A pharmacokinetic interaction has been described between bosentan and sildenafil, which act as inducers or inhibitors of cytochrome P450 CYP3A4, respectively. The co-administration of both substances results in a decline of sildenafil plasma levels and in an increase in bosentan plasma levels.<sup>165</sup> So far there is no indication that these interactions are associated with reduced safety,<sup>166</sup> but the issue of whether the clinical efficacy of sildenafil is significantly reduced is still under debate. No pharmacokinetic interactions have been reported between sildenafil and the two other available ERAs, **sitaxentan** and ambrisentan.

In the PHIRST study<sup>157</sup> the combination of tadalafil and bosentan resulted in an improvement of exercise capacity of borderline statistical significance (subgroup analysis). For these two compounds a pharmacokinetic interaction has also been shown (Table 20).

There are many open questions regarding combination therapy, including the choice of combination agents, the optimal timing [initial combination (in naive patients) or sequential combination (according to the response to the first drug)], when to switch, and when to combine. When combination therapy is considered, patients should be treated within clinical trials or registries whenever possible. Combination therapy of established PAH drugs is recommended for patients not responding adequately to monotherapy, but combination therapy should be instituted by expert centres only. Whether the response to monotherapy is sufficient or not can only be decided on an individual basis. This is judged in an individual patient who, despite monotherapy and optimized background treatment, has an inadequate clinical response (Figure 2 and Table 22).

The safety and efficacy of tyrosine kinase inhibitors in PAH must be further evaluated and, at present, the use of these drugs should be restricted to RCTs.

#### *Drug interactions*

Significant drug interactions involving the disease-specific therapies for PAH are shown in Table 20. This table highlights known important interactions but does not include theoretical untested interactions, which may still be clinically important.

Bosentan is an inducer of cytochrome P450 isoenzymes CYP3A4 and CYP2C9. Plasma concentrations of drugs

metabolized by these isoenzymes will be reduced when co-administered with bosentan. Bosentan is also metabolised by these enzymes so that their inhibition may increase the plasma concentration of bosentan. In addition to interactions shown in Table 20, a combination of a potent CYP3A4 inhibitor (ketoconazole or ritonavir) and/or a CYP2C9 inhibitor (e.g. amiodarone or fluconazole) with bosentan may cause a potentially contraindicated significant increase in plasma bosentan levels and it is contraindicated. Interactions may theoretically occur with itraconazole, tacrolimus, sirolimus, carbamazepine, phenytoin, phenobarbitone, dapsone, and St John's Wort.

**Sitaxentan** is an inhibitor of cytochrome P450 isoenzyme CYP2C9 and a weak inhibitor of CYP3A4/5, CYP2C19, and CYP2C8. It is metabolized by CYP2C9 and CYP3A4/5. **Sitaxentan** may also be a substrate for organic anion transporter proteins, and plasma **sitaxentan** levels may be elevated by drugs that interact with organic anion transporter proteins such as cyclosporine, some statins, and drugs for tuberculosis. When administered with oral contraceptive agents, **sitaxentan** increases oestrogen exposure, which may result in a theoretically greater risk of thromboembolism.

Sildenafil is metabolized by cytochrome P450 isoenzymes CYP3A4 (major route) and CYP2C9 (minor route). There is an increase in sildenafil bioavailability and reduced clearance with CYP3A4 substrates, and CYP3A4 substrates plus beta-adrenoceptor blockers. CYP3A4 inducers such as carbamazepine, phenytoin, phenobarbital, rifampicin and St John's Wort may significantly lower sildenafil levels. Sildenafil levels are modestly increased by fresh grapefruit juice, a weak inhibitor of CYP3A4.

Finally, care is needed when PAH-specific medications are co-administered with antihypertensive drugs such as  $\beta$ -adrenoceptor blockers, angiotensin-converting enzyme inhibitors, etc., to avoid excessive systemic hypotension.

### 7.3.4 Treatment of arrhythmias

Arrhythmias are an increasing clinical problem in PAH patients. In contrast to patients with left heart disease, malignant ventricular arrhythmias such as ventricular tachycardia, ventricular flutter, and ventricular fibrillation are rare in PAH patients. In a series of 132 witnessed cardiac arrests in patients with PAH, ventricular fibrillation was observed in only 8% of the cases.<sup>168</sup> Another series of 231 patients with PAH or CTEPH followed over a 6-year period did not report any case of malignant ventricular arrhythmia.<sup>46</sup> In that series, supraventricular tachyarrhythmias occurred with an annual incidence of 2.8%. Atrial flutter and atrial fibrillation were equally common and both arrhythmias invariably led to clinical deterioration with signs of right heart failure. Treatment of atrial flutter proved to be more successful than treatment of atrial fibrillation. Restoration of a stable sinus rhythm was associated with a favourable long-term survival while persistent atrial fibrillation was associated with a 2-year mortality of >80%.<sup>46</sup> Although prospective and controlled data are lacking, these findings suggest that maintenance of a stable sinus rhythm should be considered an important treatment goal in patients with PAH. In order to achieve a stable sinus rhythm, prophylaxis with antiarrhythmic drugs without negative inotropic effects such as amiodarone (see interactions in Table 20) should also be considered even if specific data regarding its efficacy are lacking.

### 7.3.5 Balloon atrial septostomy

Patients with Eisenmenger's syndrome and patients with IPAH with a patent foramen ovale have a survival advantage over those without a patent foramen ovale,<sup>169</sup> supporting the concept of atrial septostomy as a treatment for IPAH. The creation of an inter-atrial right-to-left shunt can decompress the right heart chambers, and increase LV preload and CO.<sup>170,171</sup> In addition, this improves systemic O<sub>2</sub> transport despite arterial O<sub>2</sub> desaturation<sup>170</sup> and decreases sympathetic hyperactivity. The recommended technique is graded balloon dilation atrial septostomy, which produces equivalent improvements in haemodynamics and symptoms but reduced risk compared with the original blade technique. Other techniques are considered to be experimental.<sup>172</sup>

A careful pre-procedure risk assessment ensures reduced mortality. Balloon atrial septostomy (BAS) should be avoided in end-stage patients presenting with a baseline mean RAP of >20 mmHg and O<sub>2</sub> saturation at rest of <80% on room air. Patients should be on optimal medical therapy, which may include pre-conditioning with i.v. inotropic drugs, prior to considering BAS. Evidence suggests a benefit in patients who are in WHO-FC IV with right heart failure refractory to medical therapy or with severe syncopal symptoms.<sup>170,171</sup> It may also be considered in patients awaiting transplantation or when medical therapy is not available. Severe IPAH has been the main indication for BAS in adults, although other indications include PAH associated with surgically corrected CHD, CTD, distal CTEPH, PVOD, and pulmonary capillary haemangiomatosis.

Evidence shows improvements in CI, decreases in right atrial pressure with improvement in 6MWT.<sup>170,171</sup>

The impact of BAS on long-term survival has not been established in RCTs.<sup>170,171</sup> BAS should be regarded as a palliative or bridging procedure to be performed only by centres with experience in the method.<sup>42</sup>

### 7.3.6 Transplantation

The advent of disease-specific therapy for severe PAH has reduced patient referral for lung transplant programmes.<sup>42</sup> The long-term outcomes of medically treated patients remains uncertain and transplantation should remain an important option for those who fail on such therapy. Studies indicate that up to 25% of patients with IPAH may fail to improve on disease-specific therapy and the prognosis of patients who remain in WHO-FC III or IV is poor.<sup>79,97</sup> International guidelines to aid referral and listing have been published by the International Society for Heart and Lung Transplantation.<sup>173</sup>

The prognosis of PAH varies according to the aetiology, and PAH associated with CTD has a worse prognosis than IPAH even when treated with prostanoids, while patients with PAH associated with CHD have a better survival. The worst prognosis is seen in patients with PVOD and pulmonary capillary haemangiomatosis because of the lack of effective medical treatments, and those patients should be listed for transplantation at diagnosis.

In any case, patients with features identifying a worse prognosis profile (Table 15) despite maximal medical therapy should be referred for transplant listing.

Both heart–lung and double-lung transplantation have been performed for PAH, although the threshold of unrecoverable RV

systolic dysfunction and/or LV diastolic dysfunction is unknown. As a consequence, each centre has developed its own strategy for the choice of the type of transplantation in the individual patient. However, due to the shortage of donor organs, most patients are considered for double-lung transplantation. While RV afterload is immediately reduced after double-lung transplantation, RV systolic and LV diastolic functions do not improve immediately and haemodynamic instability is a common problem in the early post-operative period. Both single and bilateral procedures have been performed, apparently with similar survival. However, any complication occurring in the allograft following single lung transplantation is associated with severe hypoxaemia. Currently the vast majority of patients worldwide receive bilateral lungs, as evidenced by the International Society for Heart and Lung Transplantation Registry figures.<sup>174</sup>

Although patients with Eisenmenger's syndrome due to simple shunts have been treated by isolated lung transplantation and repair of the cardiac defect,<sup>174</sup> patients with ventricular septal defects may have a better outcome with heart–lung transplantation.<sup>175</sup>

The overall 5-year survival following transplantation for PAH is 45–50%, with evidence of continued good quality of life.<sup>174</sup>

### 7.3.7 Treatment algorithm

- A treatment algorithm for PAH patients<sup>176</sup> is shown in *Figure 2*. The grades of recommendation and levels of evidence for the PAH treatments<sup>177</sup> are shown also in *Table 21*. The definition of clinical response to treatments is reported in *Table 22*. Country-specific regulatory approval and labelling for PAH

medical treatments are shown in *Table 23*. Potential drug interactions are shown in *Table 20*.

- Drug classes are listed in alphabetical order (ERAs, phosphodiesterase type-5 inhibitors, prostanoids) and single compounds are listed in alphabetical order within each class in *Figure 2* and *Tables 21* and *23*.
- The treatment algorithm does not apply to patients in other clinical groups, and in particular not to patients with PH associated with group 2—left heart disease or with group 3—lung diseases. In addition, the different treatments have been evaluated by RCTs mainly in IPAH, heritable PAH, PAH due to anorexigen drugs, and in PAH associated with CTD or with CHD (surgically corrected or not). The grades of recommendation and levels of evidence for the other PAH subgroups are lower (see the section on specific PAH subsets).
- The suggested initial approach after the diagnosis of PAH, is the adoption of the general measures, the initiation of the supportive therapy, and referral to an expert centre.
- Acute vasoreactivity testing should be performed in all patients with group 1—PAH, although patients with IPAH, heritable PAH, and PAH associated with anorexigen use are the most likely to exhibit an acute positive response and to benefit from high-dose CCB therapy. Vasoreactive patients, as defined above, should be treated with optimally tolerated doses of CCBs (see section 7.3.3); adequate response should be confirmed after 3–4 months of treatment.
- Non-responders to acute vasoreactivity testing who are in WHO-FC II should be treated with an ERA or a phosphodiesterase type-5 inhibitor.

**Table 21** Recommendations for efficacy of specific drug therapy, balloon atrial septostomy, and lung transplantation for pulmonary arterial hypertension (group 1) according to WHO functional class (WHO-FC)

Measure/treatment		Classes of recommendation–level of evidence		
		WHO-FC II	WHO-FC III	WHO-FC IV
Calcium channel blockers		I–C <sup>a</sup>	I–C <sup>a</sup>	–
Endothelin receptor antagonists	Ambrisentan	I–A	I–A	IIa–C
	Bosentan	I–A	I–A	IIa–C
	Sitaxentan	IIa–C	I–A	IIa–C
Phosphodiesterase type-5 inhibitors	Sildenafil	I–A	I–A	IIa–C
	Tadalafil <sup>b</sup>	I–B	I–B	IIa–C
Prostanoids	Beraprost	–	IIb–B	–
	Epoprostenol (intravenous)	–	I–A	I–A
	Iloprost (inhaled)	–	I–A	IIa–C
	Iloprost (intravenous)	–	IIa–C	IIa–C
	Treprostinil (subcutaneous)	–	I–B	IIa–C
	Treprostinil (intravenous)	–	IIa–C	IIa–C
	Treprostinil (inhaled) <sup>b</sup>	–	I–B	IIa–C
Initial drugs combination therapy		–	–	IIa–C
Sequential drugs combination therapy		IIa–C	IIa–B	IIa–B
Balloon atrial septostomy		–	I–C	I–C
Lung transplantation		–	I–C	I–C

<sup>a</sup>Only in responders to acute vasoreactivity tests, I for idiopathic PAH, heritable PAH, and PAH due to anorexigens; IIa for APAH conditions.

<sup>b</sup>Under regulatory review in the European Union.

**Table 22** Definition of inadequate response to PAH treatments (see also section 7.2.5 and 7.2.6)

Inadequate clinical response for patients who were initially in WHO-FC II or III:

- (1) Resulting clinical status defined as stable and not satisfactory
- (2) Resulting clinical status defined as unstable and deteriorating

Inadequate clinical response for patients who were initially in WHO-FC IV:

- (1) No rapid improvement to WHO-FC III or better
- (2) Resulting clinical status defined as stable and not satisfactory

- Non-responders to acute vasoreactivity testing, or responders who remain in (or progress to) WHO-FC III should be considered candidates for treatment with either an ERA or a phosphodiesterase type-5 inhibitor, or a prostanoid.
- As head-to-head comparisons among different compounds are not available, no evidence-based first-line treatment can be proposed. In this case the choice of the drug is dependent on a variety of factors including the approval status, the route of administration, the side effect profile, patients' preferences, and physicians' experience. Some experts still use first-line i.v. epoprostenol in WHO-FC III patients because of its survival benefits.
- Continuous i.v. epoprostenol is recommended as first-line therapy for WHO-FC IV PAH patients because of the survival benefit in this subset. S.c. and i.v. treprostinil have been also approved for the treatment of WHO-FC IV patients in the USA. Although no RCTs have been performed with the i.v. delivery of iloprost, this prostacyclin analogue has been approved in New Zealand.
- Although ambrisentan, bosentan, and sildenafil are approved in WHO-FC IV patients in the USA, only a small number of these patients were included in the RCTs of these agents. Accordingly, most experts consider these treatments as a second line in severely ill patients.
- In WHO-FC IV patients, initial combination therapy should also be considered.
- In the case of inadequate clinical response (Table 22, Figure 2), sequential combination therapy should be considered. Combination therapy can include either an ERA plus a phosphodiesterase type-5 inhibitor, or a prostanoid plus an ERA, or a prostanoid plus a phosphodiesterase type-5 inhibitor. Appropriate protocols for timing and dosing to limit possible side effects of the combination have still to be defined. In expert centres also triple combination therapy is considered.
- BAS and/or lung transplantation are indicated for PAH with inadequate clinical response (Table 22) despite optimal medical therapy or where medical treatments are unavailable. These procedures should be performed only in experienced centres.

### 7.3.8 End of life care and ethical issues

The clinical course of PH is one of progressive deterioration interspersed with episodes of acute decompensation. It is difficult to predict when patients will die because death may come either suddenly or slowly because of progressive heart failure. It has been

**Table 23** Country-specific regulatory approval and labelling for PAH-specific drug therapy

Treatment	Country	Labelling	
		Aetiology	WHO-FC
Calcium channel blockers	–	–	–
Ambrisentan	USA, Canada	PAH	II–III–IV
	European Union	PAH	II–III
Bosentan <sup>a</sup>	European Union	PAH	II–III
	USA, Canada	PAH	II–III–IV
Sitaxentan	European Union	PAH	III
	USA, Canada	PAH	II–III–IV
Sildenafil	European Union	PAH	II–III
	USA, Canada	PAH	II–III–IV
Tadalafil <sup>b</sup>	USA	PAH	II–III–IV
Beraprost	Japan, Korea	PAH	II–III–IV
Epoprostenol (intravenous)	Europe <sup>c</sup>	PAH	III–IV
	USA, Canada	IPAH and PAH–CTD	III–IV
Iloprost (inhaled)	European Union	IPAH	III
	USA	PAH	III–IV
Iloprost (intravenous)	New Zealand	IPAH, PAH–CTD, and CTEPH	III–IV
	USA	PAH	II–III–IV
Treprostinil (subcutaneous)	Canada	PAH	III–IV
	European Union <sup>d</sup>	IPAH	III
Treprostinil (intravenous)	USA <sup>e</sup>	PAH	II–III–IV
	Canada	PAH	III–IV
Treprostinil (inhaled) <sup>b</sup>	USA	PAH	III

<sup>a</sup>Specifically approved also for PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.

<sup>b</sup>Under regulatory review in the European Union.

<sup>c</sup>Epoprostenol in Europe has not been registered through the centralized procedure of the EMEA but it is approved in different European countries on a national basis.

<sup>d</sup>Treprostinil in Europe has not been registered through the centralized procedure of the EMEA but it is approved in France and in other countries through the mutual recognition process on a national basis.

<sup>e</sup>In the case of intolerance of the subcutaneous form.

CTD = connective tissue disease; CTEPH = chronic thromboembolic pulmonary hypertension; EMEA = European Medicines Agency; IPAH = idiopathic pulmonary arterial hypertension; PAH = pulmonary arterial hypertension; WHO-FC = World Health Organization functional class.

shown that physicians caring for patients tend to be overoptimistic in their prognostication and frequently misunderstand their patients' wishes.

Open and sensitive communication with patients allows advanced planning and discussion about their fears, concerns, and wishes, which is essential to good care. Opportunities to



discuss prognosis should be created at the time of initial diagnosis. Recognition that cardiopulmonary resuscitation in severe PH has poor outcomes may enable a 'do not resuscitate' order. This may increase the chance of patients being in their preferred place of care at the end of life.

Patients approaching the end of life require frequent assessment of their full needs by a multidisciplinary team. Attention should be given to controlling the distressing symptoms and prescribing appropriate drugs while withdrawing unnecessary medication. Well-informed psychological, social, and spiritual support is also vital. Specialist palliative care should be consulted about patients whose needs are beyond the expertise of the PH team.

## 7.4 Specific pulmonary arterial hypertension subsets

Some conditions included in the group 1—PAH, although presenting similarities with IPAH, bear sufficient differences to require specific comments. These conditions comprise paediatric PAH and APAH forms (Table 4) such as CHD, CTD, portal hypertension, and HIV infection. Recognition of these differences is critical because they may influence not only the diagnostic approach but also the global management of PAH.

### 7.4.1 Paediatric pulmonary arterial hypertension

Paediatric PH is similar to adult disease even if the lungs are still developing in a growing child. The worse prognosis in children with a median survival estimated at 10 months compared with 2.8 years in the adult<sup>8</sup> has not been confirmed. The exact incidence and prevalence of PH in children is not known. All forms of PH included in the clinical classification (Table 4) have been described in children, but the majority of patients present with PH associated with CHD or idiopathic/heritable forms. In contrast, the prevalence of PH associated with CTD, portal hypertension, HIV infection, and drugs and toxins is lower. Patients with chronic lung disease of prematurity are a growing population. Persistent PH of the neonate is also classified under PAH. Its natural history, treatment, and outcome are sufficiently different to justify its exclusion from this discussion.<sup>178</sup>

No clear differences have been identified among the mechanisms involved in the development of PAH in children and adults.

#### Diagnosis

Based on old studies it was thought that 40% of children with IPAH were vasoreactive, but it seems that new figures are closer to those of the adult patient population, with a range of 10–15% of acute responders or even less.<sup>179,180</sup>

Children often present sicker than adults. Dyspnoea, fatigue, and failure to thrive are common symptoms. Syncope is more frequent in the child, but overt RV failure is a late event and the child may die suddenly before the appearance of RV failure. A similar diagnostic work-up to that in the adult is suggested. Even if some associations are rare they should be excluded before a definite diagnosis. A thorough family and personal history with pregnancy, delivery, and postnatal details is essential. 6MWT and cardiopulmonary exercise testing can be performed but require expertise and should be adapted to age. Diagnosis requires RHC and vasoreactivity testing which are performed as in adults. In children these

procedures may require general anaesthesia, which increases the risks.

#### Therapy

The response to therapy is difficult to predict, with some patients having a dramatic response and some requiring rapid escalation of therapy. The therapeutic algorithm used for children is similar to the one used in adults even if specific RCTs are lacking. Several expert centres have suggested specific, but indeed very similar, treatment algorithms.<sup>179</sup> Only a few studies have been performed to confirm the exact dose of new therapies to be applied in children.

Therapy should include close follow-up. Rapid treatment of any upper or lower airway infection is essential because of the danger of a rapid deterioration. The use of anticoagulation is controversial as no studies are available in children. The risk–benefit profile is a problem in small children. The use of aspirin instead of coumadin is also controversial. The consensus is to anticoagulate patients with overt right heart failure.

CCBs are used in responders, but close follow-up is mandatory as patients may fail long-term therapy.

Data are available with bosentan, the pharmacokinetics of which have been assessed in one study.<sup>181</sup> Several uncontrolled studies in children have shown positive results similar to adults, with survival rates of 80–90% at 1 year.<sup>182</sup> A new paediatric formulation has been recently approved by the European Medicines Agency. Data about selective endothelin-A receptor antagonists are not available so far.

Sildenafil has shown some efficacy,<sup>183</sup> and an RCT is underway to define dose and efficacy.

Indications for epoprostenol are similar to those in adults. The usual starting dose is 2 ng/kg/min with a rapid increase. Optimal doses vary considerably between patients and thus individual titration is required.<sup>184,185</sup> Administration of i.v. iloprost and trepostinil has been reported as in adults. Oral beraprost is only used in some countries, but lack of proof of efficacy is a problem. S.c. trepostinil may be an option, but local pain is a serious problem in children. Inhaled iloprost is also difficult, but a recent report has shown some efficacy.<sup>186</sup>

An increasing number of paediatric patients are on combination therapy even though evidence is still lacking.<sup>187</sup> Atrial septostomy as well as a Pott's shunt<sup>188</sup> are possible in children, with good results. As in adults, cure of PAH is only obtained with lung transplantation, but lack of suitable donors is a major problem.

Recommendations for pediatric PAH are summarized in the Table 24.

**Table 24 Recommendations for paediatric PAH**

Statement	Class <sup>a</sup>	Level <sup>b</sup>
The PH diagnostic work-up proposed for adults should also be considered in children	Ila	C
The PAH therapeutic algorithm proposed for adults should also be considered in children	Ila	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

### 7.4.2 Pulmonary arterial hypertension associated with congenital cardiac shunts

PAH associated with CHD is included in group 1 of the PH clinical classification (Table 4). A specific clinical classification (Table 6) and an anatomical–pathophysiological classification (Table 7) are useful to better define each individual patient with PAH associated with CHD.<sup>1,16</sup>

Epidemiological data remain scarce as no studies were designed to assess the prevalence of PAH in adult CHD, although 5–10% was suggested in a recent study.<sup>189</sup> The persistent exposure of the pulmonary vasculature to increased blood flow due to systemic-to-pulmonary shunts as well as increased pressure may result in a typical pulmonary obstructive arteriopathy (identical to other PAH forms) that leads to the increase of PVR. If PVR approaches or exceeds systemic vascular resistance, the shunt is reversed (Eisenmenger's syndrome).<sup>190</sup>

#### Diagnosis

The signs and symptoms of Eisenmenger's syndrome result from PH, low arterial O<sub>2</sub> saturation, and secondary erythrocytosis. They include dyspnoea, fatigue, and syncope. In patients with PAH associated with CHD without reversal of the shunt, the degree of cyanosis and erythrocytosis may be mild to moderate. Eisenmenger's syndrome patients also suffer from haemoptysis, cerebrovascular accidents, brain abscesses, coagulation abnormalities, and sudden death. Subjects with Eisenmenger's syndrome have reduced life expectancy, although many survive into their third or fourth decade, with some even surviving into their seventh decade.<sup>191</sup> In patients listed for lung or heart–lung transplantation when no medical treatment was available, Eisenmenger's syndrome had better survival compared with IPAH, with a 3-year survival rate of 77% compared with 35% for untreated IPAH.<sup>192</sup> Of all patients with CHD, those with Eisenmenger's syndrome are the most severely compromised in terms of exercise intolerance.<sup>193</sup>

Improved survival may result possibly from preservation of RV function as the RV does not undergo remodelling at birth and remains hypertrophied.<sup>194</sup> The RV is also relieved by the right-to-left shunt, sustaining systemic CO, at the expense of hypoxaemia and cyanosis.

Patients with CHD (in particular those without shunts) may also develop PH due to left heart disease (group 2, Table 4) or to concomitant lung diseases (group 3, Table 4). In these cases a comprehensive diagnostic work-up, as reported in section 7.1.12, is recommended.

#### Therapy

The treatment strategy for patients with PAH associated with CHD and in particular for subjects with Eisenmenger's syndrome is mainly based on the clinical experience of experts rather than formally evidence based.<sup>190</sup> A specific treatment algorithm similar to that in Figure 2 has been recently proposed.<sup>16</sup>

Eisenmenger's syndrome patients should be managed in specialized centres. Patient education, behavioural modifications, and awareness of potential medical risk factors are important aspects of management.

Patients with Eisenmenger's syndrome may present with clinical deterioration in different circumstances, including non-cardiac surgery with general anaesthesia, dehydration, lung infections,

and high altitude. It is recommended to avoid strenuous exercise but mild activities seem to be beneficial. Pregnancy is associated with high risk to both mother and fetus. Pregnancy should be discouraged, and contraception is indicated.

Long-term home O<sub>2</sub> therapy may improve symptoms, but has not been shown to modify survival, at least when given only at night.<sup>111</sup> The use of supplemental O<sub>2</sub> therapy is recommended in cases in which it produces a consistent increase in arterial oxygen saturation and reduces symptoms.

The use of oral anticoagulant treatment in Eisenmenger's syndrome is controversial: a high incidence of PA thrombosis and stroke is reported but there is also an increased risk of haemorrhage and haemoptysis.<sup>195</sup> No data exist on this issue and definite recommendations cannot therefore be made. Oral anticoagulant treatment may be considered in patients with PA thrombosis, signs of heart failure, and absent or only mild haemoptysis.<sup>195</sup>

Secondary erythrocytosis is beneficial for adequate O<sub>2</sub> transport and delivery, and routine phlebotomy should be avoided. If symptoms of hyperviscosity are present, phlebotomy with isovolumic replacement should be performed, usually when the haematocrit is >65%. Iron deficiency should be corrected. No clear data support the use of CCBs in patients with Eisenmenger's syndrome, and the empirical use of CCBs is dangerous and should be avoided.

One RCT is available with specific drug therapy: bosentan has been shown to improve 6MWT and decrease PVR after 16 weeks of treatment in WHO-FC III patients.<sup>142</sup> The long-term follow-up (40 weeks) showed sustained improvement.<sup>196</sup> Bosentan is currently approved in Europe for WHO-FC III Eisenmenger's syndrome patients. No studies are available with the use of other ERAs in this setting.

Anecdotal experiences with the phosphodiesterase type-5 inhibitors sildenafil<sup>197</sup> and tadalafil<sup>198</sup> show favourable functional and haemodynamic results in patients with PAH associated with CHD and Eisenmenger's syndrome.

The use of i.v. epoprostenol has been reported in Eisenmenger's syndrome patients, with favourable effects on haemodynamics and exercise capacity, although central lines expose the patients to the risk of paradoxical embolism and sepsis.<sup>120</sup> No data are available with the use of other prostanoids.

There are no published data on combination therapy, but the rationale is the same as in IPAH. Since the introduction of targeted therapies in Eisenmenger's syndrome, there is growing interest in pre-Eisenmenger's syndrome patients considered inoperable on the basis of haemodynamic changes (PVR too high) in order to remodel the pulmonary vascular bed and perform interventional or surgical correction. No recommendation can be given in this setting as only anecdotal cases have been reported.

Heart–lung or lung transplantation with heart surgery is an option in special cases not responsive to medical treatment, but is limited by organ availability. Short- and long-term survival rates following heart–lung transplantation are similar to other forms of PAH. The prolonged estimated survival of patients with Eisenmenger's syndrome makes the decision if and when patients should be listed difficult.<sup>16</sup>

Recommendations for pulmonary arterial hypertension associated with congenital cardiac shunts are summarized in the Table 25.

**Table 25** Recommendations for PAH associated with congenital cardiac shunts

Statement	Class <sup>a</sup>	Level <sup>b</sup>
The ERA bosentan is indicated in WHO-FC III patients with Eisenmenger's syndrome	I	B
Other ERAs, phosphodiesterase type-5 inhibitors, and prostanoids should be considered in patients with Eisenmenger's syndrome	IIa	C
In the absence of significant haemoptysis, oral anticoagulant treatment should be considered in patients with PA thrombosis or signs of heart failure	IIa	C
The use of supplemental O <sub>2</sub> therapy should be considered in cases in which it produces a consistent increase in arterial oxygen saturation and reduces symptoms	IIa	C
If symptoms of hyperviscosity are present, phlebotomy with isovolumic replacement should be considered usually when the haematocrit is > 65%	IIa	C
Combination therapy may be considered in patients with Eisenmenger's syndrome	IIb	C
The use of CCBs is not recommended in patients with Eisenmenger's syndrome	III	C

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.

### 7.4.3 Pulmonary arterial hypertension associated with connective tissue disease

PAH is a well-known complication of CTDs such as systemic sclerosis,<sup>114</sup> systemic lupus erythematosus, mixed CTD, and, to a lesser extent, rheumatoid arthritis, dermatomyositis, and Sjögren's syndrome. PAH associated with CTD is the second most prevalent type of PAH after IPAH in registries.<sup>3,4</sup>

Systemic sclerosis, particularly in its limited variant (CREST syndrome), represents the main CTD associated with PAH. The prevalence of haemodynamically proven PAH in large cohorts of patients with systemic sclerosis is between 7 and 12%.<sup>2,114</sup> In these patients, PAH may occur in association with interstitial fibrosis or as a result of an isolated pulmonary arteriopathy. In addition, pulmonary venous hypertension from left heart disease may be present. It is imperative to determine which mechanism is operative since this dictates treatment.

Histopathological changes in PAH associated with CTD are generally indistinguishable from those of classical IPAH, although there is more frequent involvement of the pulmonary veins.<sup>199</sup> The pathophysiological mechanisms leading to PAH in patients with CTD remain unknown. The presence of antinuclear antibody, rheumatoid factor, immunoglobulin G, and complement fraction deposits in the pulmonary vessels wall suggest a role for an immunological mechanism.

#### Diagnosis

Compared with IPAH, patients with CTD and PAH are mainly women (women/men ratio 4:1), are older (mean age at diagnosis, 66 years), may present concomitant disorders (pulmonary fibrosis, left heart disease), and have shorter survival.<sup>114</sup> The unadjusted risk of death for systemic sclerosis-associated PAH compared with

IPAH is 2.9<sup>200</sup> and the predictors of outcome are the same as for IPAH (RAP, PAP, and CI). Symptoms and clinical presentation are very similar to those of IPAH and occasional patients thought to have IPAH can be identified as having an associated CTD by immunological screening tests. High-resolution CT is helpful for evaluating the presence of associated interstitial lung disease. An isolated reduction of diffusion capacity of carbon monoxide is a frequent abnormality in systemic sclerosis associated with PAH.

Echocardiographic screening for the detection of PH has been recommended annually in asymptomatic patients with the scleroderma spectrum of diseases but only in the presence of symptoms in other CTDs. The cost-effectiveness of this strategy has not been clarified as compared with symptom-based screening (see also section 7.1.5). As in other forms of PAH, RHC is recommended in all cases of suspected PAH associated with CTD to confirm the diagnosis, determine severity, and rule out left-sided heart disease. RHC is mandatory if targeted treatments are considered. The proportion of responders in the acute vasodilator test is lower than in IPAH.<sup>66</sup>

#### Therapy

Treatment of patients with PAH associated with CTD appears more complex than that of patients with IPAH. Immunosuppressive therapy combining glucocorticosteroids and cyclophosphamide may result in clinical improvement in patients with PAH associated with systemic lupus erythematosus or mixed CTD.<sup>201</sup>

Long-term favourable response to CCB treatment in vasoreactive patients is seen less often than in IPAH. The risk-to-benefit ratio of oral anticoagulation is not well understood.

Treatment of patients with CTD and PAH should follow the same treatment algorithm as in IPAH (Figure 2). This recommendation is based on the fact that patients with CTD have been included in most of the major RCTs for regulatory approval of PAH therapy, including those with combination therapy.

Subgroup analyses of patients with scleroderma enrolled in the RCTs performed with bosentan,<sup>139</sup> **sitaxentan**,<sup>202</sup> sildenafil,<sup>155</sup> and s.c. treprostinil<sup>203</sup> have shown favourable effects. In some of these trials the magnitude of the response in the PAH subgroup associated with CTD was lower than in IPAH.

Continuous i.v. epoprostenol therapy has been shown to improve exercise capacity, symptoms, and haemodynamics in a 3-month RCT of patients with the scleroderma spectrum of the diseases.<sup>119</sup> Retrospective analysis shows, however, that the effect of i.v. epoprostenol on survival of IPAH patients seems to be better than that of scleroderma patients. The presence of a CTD is not a contra-indication for lung transplantation *per se* if medical treatments fail.

Recommendations for pulmonary arterial hypertension associated with CTD are summarized in the Table 26.

### 7.4.4 Pulmonary arterial hypertension associated with portal hypertension

PAH is a well-recognized complication of chronic liver diseases.<sup>204,205</sup> Portal hypertension rather than the hepatic disorder itself seems to be the main determining risk factor for developing PAH.<sup>204</sup>

The condition is not uncommon since PAH associated with portal hypertension (also named as portopulmonary hypertension)

**Table 26** Recommendations for PAH associated with connective tissue disease

Statement	Class <sup>a</sup>	Level <sup>b</sup>
In patients with PAH associated with CTD the same treatment algorithm as in patients with IPAH is recommended	I	A
Echocardiographic screening for the detection of PH is recommended in symptomatic patients with scleroderma spectrum of diseases	I	B
Echocardiographic screening for the detection of PH is recommended in symptomatic patients with all other CTDs	I	C
RHC is indicated in all cases of suspected PAH associated with CTD, in particular if specific drug therapy is considered	I	C
Oral anticoagulation should be considered on an individual basis	IIa	C
Echocardiographic screening for the detection of PH may be considered in asymptomatic patients with the scleroderma spectrum of disease	IIb	C

<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.

represents ~10% of the PAH population.<sup>3</sup> It is believed that 1–2% of patients with liver disease and portal hypertension develop PAH, but the prevalence of PAH may reach 5% among patients with advanced liver disease evaluated for liver transplantation.<sup>206</sup> The pathogenesis is unclear and may be related to toxic substances derived from the gastrointestinal tract, which are not eliminated by the liver due to portosystemic shunts, thus causing damage to the lung endothelium. Another possibility is that the high CO state is inducing PAH.

*Diagnosis*

The clinical picture of patients with portopulmonary hypertension may be indistinguishable from that of those with IPAH or may include a combination of symptoms and signs of the underlying liver disease.<sup>204</sup>

Echocardiographic screening for the detection of PH in patients with liver diseases is appropriate in symptomatic patients and/or in candidates for liver transplantation. An RHC should be performed in all cases with increased systolic PAP in order to clarify the underlying haemodynamic changes and define prognostic and therapeutic implications. Patients with portopulmonary hypertension have a significantly higher CO and significantly lower systemic vascular resistance and PVR, compared with patients with IPAH. In a retrospective study,<sup>204</sup> patients with portopulmonary hypertension had a better rate of survival than patients with IPAH, although this is debated.

*Therapy*

Portopulmonary hypertension is part of the PAH spectrum of disease and in general these patients should be treated similarly to those with other forms of PAH, while taking into consideration the presence of liver disease and its consequences for their

**Table 27** Recommendations for PAH associated with portal hypertension

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Echocardiographic screening for the detection of PH is recommended in symptomatic patients with liver diseases and/or in candidates for liver transplantation	I	B
In patients with PAH associated with portal hypertension the same treatment algorithm as in patients with IPAH should be considered, taking into consideration comorbidities	IIa	C
Anticoagulation is not recommended in patients with increased risk of bleeding	III	C
Significant PAH is a contraindication to liver transplantation if mean PAP is $\geq 35$ mmHg and/or PVR is $\geq 250$ dynes.s.cm <sup>-5</sup>	III	C

<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.

management. The treatment algorithm (Figure 2) can also be applied in this setting with adaptations.

Anticoagulant therapy should be avoided in patients at increased risk of bleeding.  $\beta$ -Adrenoceptor blockers, often used in patients with portal hypertension to reduce the risk of variceal bleeding, worsen haemodynamics and exercise capacity in portopulmonary PAH patients.<sup>207</sup>

Patients with portopulmonary hypertension have been excluded from almost all RCTs in PAH. Case series suggest that epoprostenol, bosentan, and sildenafil may exert beneficial haemodynamic and clinical effects in selected patients.<sup>208–210</sup> In a retrospective study treatment with bosentan appeared to be better than inhaled iloprost.<sup>211</sup> Careful monitoring should be performed if ERA treatment is initiated because of the hepatotoxicity of these compounds.

PAH can substantially increase the risk associated with liver transplantation and usually PAH is a contraindication if mean PAP is  $\geq 35$  mmHg and/or PVR is  $\geq 250$  dynes.s.cm<sup>-5</sup>.<sup>206,212</sup> It has been suggested that PAH-specific drug therapy should be used to improve haemodynamics prior to liver transplantation, but the effects on the outcome of liver transplantation have not been evaluated sufficiently.

Selected patients with end-stage liver disease and severe PH may be considered for combined liver–lung or liver–heart–lung transplantation. The largest series of combined liver–lung transplantation so far has reported a 3-year survival of 62%. This treatment option is offered by only a few centres worldwide.<sup>213</sup>

Recommendations for pulmonary arterial hypertension associated with portal hypertension are summarized in the Table 27.

**7.4.5 Pulmonary arterial hypertension associated with human immunodeficiency virus infection**

The use of highly active antiretroviral therapy and aggressive management of opportunistic infections has contributed to increased life expectancy in HIV-infected patients. Consequently, the spectrum of complications has shifted towards other long-term conditions, including cardiovascular diseases such as dilated cardiomyopathy, pericardial disorders, non-infectious thrombotic



endocarditis, accelerated atherosclerosis, and PAH. The initial prevalence of PAH was found to be 0.1–0.5% with an estimated incidence of 0.1% per year.<sup>214</sup> It was suggested that the use of highly active antiretroviral therapy could decrease the rate of PAH associated with HIV infection, but a population study recently conducted in France contradicts this hypothesis because the calculated minimal prevalence of HIV-related PAH was 0.46%, very similar to before the highly active antiretroviral therapy era.<sup>49</sup>

The pathogenesis of HIV-related PAH remains unclear. The absence of viral particles in the complex plexiform lesions found from these patients suggests that an indirect action of viral infection on inflammation and growth factors may act as a trigger on a predisposed patient.<sup>49</sup>

### Diagnosis

HIV-related PAH shares a similar clinical presentation with IPAH. At the time of diagnosis, 71–81% of patients are in an advanced WHO-FC.<sup>49,122</sup> Patients may present with other risk factors for PAH such as liver disease (chronic hepatitis B or C), exposure to drugs and toxins, or pulmonary embolism due to i.v. drug abuse. Patients with HIV-related PAH are more likely to be male and i.v. drug abusers.<sup>49</sup> More than 80% are well controlled on highly active antiretroviral therapy, and CD4 count does not appear to be a risk factor for PAH.<sup>49,122</sup>

Asymptomatic HIV-infected patients should not be screened for PAH. Echocardiography must be performed in patients with unexplained dyspnoea to detect HIV-related cardiovascular complications such as myocarditis, cardiomyopathy, or PAH. An RHC confirmation is mandatory to establish the diagnosis of HIV-related PAH and the absence of left heart disease.

PAH is an independent risk factor for death in HIV-infected patients, with a 3-year survival rate as low as 21% in the most advanced cases (WHO-FC III/IV), compared with 84% in mildly symptomatic patients.<sup>122</sup> In a single-centre study, a better outcome was associated with CD4 count >212 cells/ $\mu$ L, highly active antiretroviral therapy, and epoprostenol therapy.<sup>122</sup>

### Therapy

Treatment of HIV-related PAH is less well established in comparison with other forms of PAH. Only three RCTs, one with the orally active prostanoid beraprost<sup>134</sup> and two with the selective endothelin receptors antagonist ambrisentan,<sup>146</sup> allowed inclusion of patients with HIV-related PAH who represented <5% of the total population.

Anticoagulation is not routinely recommended because of an increased risk of bleeding, anticipated compliance issues, and drug interactions. Patients with HIV-related PAH appear to be non-responders to vasoreactivity tests<sup>66</sup> and thus should not receive CCBs.

Several uncontrolled studies suggest that i.v. epoprostenol,<sup>122</sup> s.c. treprostinil,<sup>215</sup> and inhaled iloprost<sup>216</sup> may improve exercise tolerance, haemodynamics and symptoms in HIV-related PAH.

Two open-label studies reported the effects of bosentan in patients with HIV-related PAH,<sup>217,218</sup> showing an improvement in all efficacy measures, including 6MWT, WHO-FC, Doppler-derived haemodynamic variables, and invasive haemodynamics. Hepatic tolerability was similar to previously reported

**Table 28** Recommendations for PAH associated with HIV infection

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Echocardiography is indicated in patients with unexplained dyspnoea to detect HIV-related cardiovascular complications	I	C
In patients with PAH associated with HIV infection, the same treatment algorithm as in patients with IPAH should be considered, taking into consideration co-morbidities and drug–drug interactions	IIa	C
Anticoagulation is not recommended in patients with increased risk of bleeding	III	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

observations in other forms of PAH. The interpretation of these studies is limited by the small sample size and the open-label nature.

In the case of use of sildenafil, the dose should be adjusted if ritonavir and saquinovir are co-administered due to drug–drug interactions (Table 20).

HIV infection is generally considered an exclusion criterion for lung transplantation even if in some centres a specific programme has been implemented.

Recommendations for pulmonary arterial hypertension associated with HIV infection are summarized in the Table 28.

## 8. Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis (group 1')

Both PVOD and pulmonary capillary haemangiomatosis are uncommon conditions, but are increasingly recognized as causes of PAH.<sup>219</sup> They have been classified in a specific subgroup of the clinical classification (Table 4, group 1') for the pathological, clinical, and therapeutic differences with the other forms of PAH included in group 1. Fewer than 200 cases of PVOD and pulmonary capillary haemangiomatosis have been reported in the literature. PVOD and pulmonary capillary haemangiomatosis are similar in some respects particularly in relation to the changes in the pulmonary parenchyma which have been described above.<sup>20</sup> Familial occurrence of PVOD has been reported, and a bone morphogenetic protein receptor-2 mutation has been found in a patient with this disease.<sup>220</sup> These findings suggest that PAH and PVOD may represent different phenotypic manifestations of a spectrum of a single disease. In contrast to IPAH, there is a male predominance in PVOD<sup>221</sup> and the prognosis appears to be worse.

### 8.1 Pulmonary veno-occlusive disease

#### 8.1.1 Diagnosis

The diagnosis of PVOD can be established with a high probability by the combination of clinical suspicion, physical examination,

bronchoscopy, and radiological findings.<sup>221</sup> This non-invasive approach may avoid lung biopsy (the gold standard to confirm a diagnosis of PVOD) in most of the cases. Most patients complain of dyspnoea on exertion and fatigue, a clinical presentation that is indistinguishable from IPAH. Physical examination may reveal digital clubbing and bi-basal crackles on lung auscultation, these being unusual in other forms of PAH. Case series suggest that patients with PVOD are more severely hypoxaemic and have a much lower diffusion capacity of carbon monoxide than in other forms of PAH.<sup>54,221,222</sup> This can be explained by the presence of chronic interstitial pulmonary oedema typical of PVOD and/or a low CO state and/or the presence of a patent foramen ovale.

Chest radiograph may reveal Kerley B lines and peripheral interstitial infiltrate in addition to other typical signs of PH.

High-resolution CT scanning is the investigation of choice. Typical findings suggestive of PVOD are the presence of subpleural thickened septal lines, centrilobular ground-glass opacities (contrasting with a panlobular distribution found in IPAH), and mediastinal lymphadenopathy.<sup>54</sup> The association of these three findings was found to be 100% specific for PVOD in cases of PAH, with a 66% sensitivity.<sup>54</sup> In addition, their presence appears to correlate closely with the risk of pulmonary oedema with epoprostenol therapy.<sup>223,224</sup>

Because PVOD may be associated with occult alveolar haemorrhage, bronchoscopy with bronchoalveolar lavage may be a useful tool in the diagnostic strategy. In a retrospective study, the results of bronchoalveolar lavage performed in 19 patients with suspicion of IPAH were analysed.<sup>222</sup> Compared with IPAH, the eight cases of PVOD presented with a significantly elevated cell count, a higher percentage of haemosiderin-laden macrophages, and a markedly elevated Golde score. The percentage of macrophages, lymphocytes, and neutrophils was similar.

Haemodynamic presentation of PVOD is similar to IPAH. Importantly, PWP is almost invariably normal because the pathological changes occur in small venules and do not affect the larger pulmonary veins. Vasoreactivity testing may be complicated by acute pulmonary oedema.

### 8.2.2 Therapy

There is no established medical therapy for PVOD. Most importantly, vasodilators and especially prostanoids must be used with great caution because of the high risk of pulmonary oedema.<sup>223,224</sup> However, there are reports of sustained clinical improvement in individual patients treated with these medications. There are no data regarding the use of newer medical therapies such as ERAs or phosphodiesterase type-5 inhibitors in the treatment of PVOD and pulmonary capillary haemangiomatosis. Therefore, therapy for PVOD should be undertaken only at centres with extensive experience in the management of PH, and patients should be fully informed about the risks. Atrial septostomy may be considered but is usually limited by hypoxaemia. The only curative therapy for PVOD and pulmonary capillary haemangiomatosis is lung transplantation, and similarly to IPAH there are no reports of recurrence of disease following transplantation. Patients with PVOD should be referred to a transplant centre for evaluation as soon as the diagnosis is established.

Recommendations for PVOD are summarized in the Table 29.

**Table 29 Recommendations for pulmonary veno-occlusive disease**

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Referral of patients with PVOD to a transplant centre for evaluation is indicated as soon as the diagnosis is established	I	C
Patients with PVOD should be managed only in centres with extensive experience in PAH due to the risk of lung oedema after the initiation of PAH-specific drug therapy	Ila	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 8.2 Pulmonary capillary haemangiomatosis

This very rare condition may be difficult to differentiate from PVOD, and the diagnostic and therapeutic aspects are very similar. Often, only pathological examination is able to distinguish the two conditions.<sup>20</sup>

## 9. Pulmonary hypertension due to left heart disease (group 2)

Most of the advances in the treatment of PH have been made in PAH. At the same time, virtually no progress has been made for the much more common forms of PH as encountered in patients with left heart diseases, lung diseases, or CTEPH. Despite the lack of data, drugs with proven efficacy in PAH are increasingly being used for other forms of PH. This may be clinically justified in some carefully selected patients but may turn out to be useless or even harmful in many others. This development is of concern, and the use of PAH drugs for other forms of PH outside expert centres is discouraged.

The pathology, pathophysiology, and epidemiology of PH due to left heart disease have been discussed previously.

PH carries a poor prognosis for patients with chronic heart failure.<sup>225</sup> In one study the mortality rate after 28 months of follow-up was 57% in patients with moderate PH compared with 17% in patients without PH. In addition, patients who have a PVR exceeding 6–8 Wood units (480–640 dynes.s.cm<sup>-5</sup>) have an increased risk of post-operative RV failure following heart transplantation.

### 9.1 Diagnosis

The diagnostic approach to PH due to left heart disease is similar to that for PAH, Doppler echocardiography being the best tool for screening purposes. LV diastolic dysfunction should be suspected in the presence of a dilated left atrium, atrial fibrillation, characteristic changes in mitral flow profile, pulmonary venous flow profile, and mitral annulus tissue Doppler signals and LV hypertrophy.<sup>64,226</sup> Data on tissue Doppler assessment show that the ratio E/E' of early mitral valve flow velocity (E) divided by the early diastolic (E') lengthening velocities correlates closely with LV filling pressures:

**Table 30** Factors favouring diagnosis of left ventricular diastolic dysfunction in the presence of pulmonary hypertension as assessed by Doppler echocardiography

**Clinical features**

Age >65  
Elevated systolic blood pressure  
Elevated pulse pressure  
Obesity, metabolic syndrome  
Hypertension  
Coronary artery disease  
Diabetes mellitus  
Atrial fibrillation

**Echocardiography**

Left atrial enlargement  
Concentric remodelling of the LV (relative wall thickness >0.45)  
LV hypertrophy  
Presence of echocardiographic indicators of elevated LV filling pressure<sup>64,226</sup>

**Interim evaluation (after echocardiography)**

Symptomatic response to diuretics  
Exaggerated increase in systolic blood pressure with exercise  
Re-evaluation of chest radiograph consistent with heart failure<sup>226</sup>

Modified from Hoeper et al.<sup>227</sup>  
LV = left ventricle.

when the ratio  $E/E'$  exceeds 15, LV filling pressures are elevated and when the ratio is lower than 8, LV filling pressures are low; if  $15 > E/E' > 8$ , additional non-invasive investigations are required.<sup>64</sup> Characteristic clinical and echocardiographic features of PH associated with LV diastolic dysfunction are listed in Table 30.<sup>227</sup>

Although increased left-sided filling pressures can be estimated by Doppler echocardiography,<sup>64,228</sup> invasive measurements of PWP or LV end-diastolic pressure may be necessary to confirm the diagnosis of PH due to left heart disease (see also section 7.1.11).<sup>64</sup> PWP and LV end-diastolic pressure can be 'pseudo-normal', especially when patients have been treated with diuretics. In this setting, exercise haemodynamics volume challenge has been proposed to identify LV dysfunction, but these diagnostic tools require further standardization. An elevated transpulmonary gradient (mean PAP minus mean PWP) >12 mmHg is suggestive of intrinsic changes in the pulmonary circulation over-riding the passive increase in PWP. In some patients, it may be difficult to distinguish PAH from PH associated with LV dysfunction especially in patients with borderline values of PWP (15–18 mmHg).

The usefulness of BNP plasma levels for the diagnosis of left heart disease in the presence of PH is not well established because BNP elevations can be observed in both pathophysiological conditions. The value of performing a haemodynamic evaluation with exercise or fluid challenge is also not well established.

The role, significance, and setting of pharmacological testing remain unclear in PH due to left heart disease, although it is recommended in heart transplant candidates to identify patients at higher risk of acute post-operative RV failure.<sup>229</sup> In heart transplant

candidates, a persistent increase in PVR >2.5 Wood units and/or TPG >15 mmHg are associated with up to a 3-fold increase in risk of RV failure and early post-transplant mortality.<sup>230</sup> When the PVR can be lowered pharmacologically (e.g. with i.v. nitroprusside) this risk may be reduced.<sup>231</sup> The absence of consensus on a standardized protocol leads to the use of various agents for testing the responsiveness of the pulmonary circulation, including inotropic agents, vasodilators, prostanoids, NO, and phosphodiesterase type-5 inhibitors. Acute post-operative RV failure may also be observed in patients with normal baseline pulmonary haemodynamics, suggesting that other mechanisms may be involved.

## 9.2 Therapy

Currently, there is no specific therapy for PH due to left heart disease. A number of drugs (including diuretics, nitrates, hydralazine, ACE inhibitors,  $\beta$ -adrenoceptor blockers, nesiritide, and inotropic agents) or interventions (LV assist device implantation, valvular surgery, resynchronization therapy, and heart transplantation) may lower PAP more or less rapidly through a drop in left-sided filling pressures.<sup>12</sup> Therefore, management of PH due to left heart disease should be aimed at the optimal treatment of the underlying disease. No heart failure drugs are contraindicated because of PH.<sup>226</sup> Few studies have examined the role of drugs currently recommended in PAH. RCTs evaluating the effects of chronic use of epoprostenol<sup>232</sup> and bosentan<sup>233,234</sup> in advanced heart failure have been terminated early due to an increased rate of events in the investigational drug-treated group compared with conventional therapy. A small sized study recently suggested that sildenafil may improve exercise capacity and quality of life in patients with PH due to left heart disease.<sup>235</sup> The history of medical therapy for heart failure is full of examples where drugs had positive effects on surrogate endpoints but eventually turned

**Table 31** Recommendations for PH due to left heart disease

Statement	Class <sup>a</sup>	Level <sup>b</sup>
The optimal treatment of the underlying left heart disease is recommended in patients with PH due to left heart disease	I	C
Patients with 'out of proportion' PH due to left heart disease (Table 3) should be enrolled in RCTs targeting PH specific drugs	IIa	C
Increased left-sided filling pressures may be estimated by Doppler echocardiography	IIb	C
Invasive measurements of PWP or LV end-diastolic pressure may be required to confirm the diagnosis of PH due to left heart disease	IIb	C
RHC may be considered in patients with echocardiographic signs suggesting severe PH in patients with left heart disease	IIb	C
The use of PAH specific drug therapy is not recommended in patients with PH due to left heart disease	III	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

out to be detrimental, such as the phosphodiesterase type-3 inhibitors. Thus, the use of PAH-specific drugs is not recommended until robust data from long-term studies are available, in particular in ‘out of proportion’ PH associated with left heart disease (Table 3). A sustained reduction of PH is expected in weeks to months in most patients successfully operated for mitral valve disease even if PH represents a risk factor for surgery.<sup>33,236</sup>

Recommendations for PH due to left heart disease are summarized in the Table 31.

## 10. Pulmonary hypertension due to lung diseases and/or hypoxia (group 3)

The pathology, pathophysiology, and epidemiology of these conditions have been discussed previously. In COPD, the presence of PH is associated with shorter survival<sup>237</sup> and frequent episodes of exacerbation.<sup>238</sup> PH is a poor prognostic factor in interstitial lung diseases and PAP is the most important predictor of mortality.<sup>37</sup>

### 10.1 Diagnosis

Clinical symptoms and physical signs of PH may be difficult to identify in patients with respiratory disorders. In addition, in COPD, peripheral oedema may not be a sign of RV failure, because it may result from the effects of hypoxaemia and hypercapnia on the renin–angiotensin–aldosterone system. Furthermore, concomitant left heart disease, which is commonly associated with chronic respiratory diseases, may also contribute to raise PAP.

As in other forms of PH, echocardiography is the best screening tool for the assessment of PH. Nevertheless, its diagnostic value in advanced respiratory diseases is lower than in PAH. Reliable assessment of systolic PAP is only feasible in a limited number of cases; estimation of systolic PAP may be inaccurate. The specificity of systolic PAP in detecting PH is low, although the negative predictive value is acceptable.<sup>239,240</sup> Indications for echocardiography for the screening of PH in COPD and interstitial lung diseases include: (i) exclusion of significant PH; (ii) evaluation of concomitant left heart disease; and (iii) selection of patients for RHC.

A definite diagnosis of PH relies on measurements obtained at RHC. The indication for RHC in advanced lung disease are: (i) proper diagnosis of PH in candidates for surgical treatments (transplantation, lung volume reduction); (ii) suspected ‘out of proportion’ PH potentially amenable to be enrolled in an RCT with specific PAH drug therapy; (iii) frequent episodes of RV failure; and (iv) inconclusive echocardiographic study in cases with a high level of suspicion.

### 10.2 Therapy

Currently there is no specific therapy for PH associated with COPD or interstitial lung diseases. Long-term O<sub>2</sub> administration has been shown partially to reduce the progression of PH in COPD. Nevertheless, with this treatment PAP rarely returns to normal values and the structural abnormalities of pulmonary vessels remain unaltered.<sup>112</sup> In interstitial lung diseases, the role

**Table 32** Recommendations for PH due to lung diseases

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Echocardiography is recommended as a screening tool for the assessment of PH due to lung diseases	I	C
RHC is recommended for a definite diagnosis of PH due to lung diseases	I	C
The optimal treatment of the underlying lung disease including long-term O <sub>2</sub> therapy in patients with chronic hypoxaemia is recommended in patients with PH due to lung diseases	I	C
Patients with ‘out of proportion’ PH due to lung diseases should be enrolled in RCTs targeting PAH-specific drugs	IIa	C
The use of PAH-specific drug therapy is not recommended in patients with PH due to lung diseases	III	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

of long-term O<sub>2</sub> therapy in PH progression is less clear. Treatment with conventional vasodilators is not recommended because they may impair gas exchange due to the inhibition of hypoxic pulmonary vasoconstriction<sup>241,242</sup> and their lack of efficacy after long-term use.<sup>243,244</sup> Published experience with specific PAH drug therapy is scarce and consists of the assessment of acute effects<sup>245,246</sup> and uncontrolled studies in small series.<sup>247–251</sup>

The treatment of choice for patients with COPD or interstitial lung diseases and associated PH who are hypoxaemic is long-term O<sub>2</sub> therapy. Patients with ‘out of proportion’ PH due to lung diseases (characterized by dyspnoea insufficiently explained by lung mechanical disturbances and mean PAP ≥40–45 mmHg at rest) should be referred to expert centres and enrolled in clinical trials targeting PAH-specific drug therapy. The use of targeted PAH therapy in patients with COPD or interstitial lung diseases and mean PAP <40 mmHg is currently discouraged because there are no systematic data regarding its safety or efficacy.

Recommendations for PH due to lung diseases are summarized in the Table 32.

## 11. Chronic thromboembolic pulmonary hypertension (group 4)

The pathology, pathophysiology, and epidemiology of this condition have been discussed above. CTEPH is one of the most prevalent forms of PH. Nevertheless, it is almost impossible to determine the overall prevalence of CTEPH since not all of these patients have a history of acute pulmonary embolism. While acute pulmonary embolism may be clinically silent,<sup>252</sup> there is accumulating evidence that CTEPH may also develop in the absence of previous pulmonary embolism.<sup>40</sup> In these cases, the disease is probably initiated by thrombotic or inflammatory lesions in the pulmonary vasculature. Once vessel obliteration is



sufficient to cause increases in the PAP, a process of pulmonary vascular remodelling is started which self-perpetuates the progression of PH, even in the absence of further thromboembolic events.<sup>253</sup> Certain conditions are associated with an increased risk of CTEPH, including previous splenectomy, the presence of a ventriculo-atrial shunt for the treatment of hydrocephalus, myeloproliferative disorders, and chronic inflammatory bowel diseases. The mechanisms linking these conditions to CTEPH have not been fully explored, but chronic inflammation or chronic bloodstream infection may play a critical role.<sup>254</sup>

## 11.1 Diagnosis

Any patient with unexplained PH should be evaluated for the presence of CTEPH. Suspicion should be high when the patient presents with a history of previous venous thromboembolism. Survivors of acute pulmonary embolism should be followed after the acute episode to detect signs or symptoms of CTEPH. Patients with acute pulmonary embolism showing signs of PH or RV dysfunction at any time during their hospital stay should receive a follow-up echocardiography after discharge (usually after 3–6 months) to determine whether or not PH has resolved.

In patients with unexplained PH, a ventilation/perfusion lung scan is recommended to exclude CTEPH. A normal ventilation/perfusion scan rules out CTEPH. Multirow CT angiography is indicated when the ventilation/perfusion lung scan is indeterminate or reveals perfusions defects. Even in the era of modern multirow CT scanners, there is not yet enough evidence to suggest that a normal CT angiography excludes the presence of operable CTEPH. Once ventilation/perfusion scanning and/or CT angiogram show signs compatible with CTEPH, the patient should be referred to a centre with expertise in the medical and surgical management of these patients. To determine the appropriate therapeutic strategy, invasive tools including RHC and traditional pulmonary angiography are usually required. Coronary angiography is indicated in candidates for PEA and risk factors for coronary artery disease. In order to minimize risks and repeated procedures these investigations should be performed at the expert centre rather than at the referring hospitals.<sup>63</sup> The final diagnosis of CTEPH is based on the presence of pre-capillary PH (mean PAP  $\geq 25$  mmHg, PWP  $\leq 15$  mmHg, PVR  $> 2$  Wood units) in patients with multiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries (main, lobar, segmental, subsegmental).

## 11.2 Therapy

Patients with CTEPH should receive life-long anticoagulation, usually with vitamin K antagonists adjusted to a target INR between 2.0 and 3.0.

The decision on how to treat patients with CTEPH should be made at an experienced centre based upon interdisciplinary discussion among internists, radiologists, and expert surgeons. PEA is the treatment of choice for patients with CTEPH as it is a potentially curative option. As a rule, a patient should not be considered inoperable as long as the case has not been reviewed by an experienced surgeon. Detailed pre-operative patient evaluation and selection, surgical technique and experience, and meticulous post-operative management are essential prerequisites for success after this intervention.<sup>55</sup> The selection of patients for surgery depends

on the extent and location of the organized thrombi in relation to the degree of PH and taking into consideration age and co-morbidities. Proximal organized thrombi represent the ideal indication, while more distal obstructions may prevent a successful procedure. After an effective intervention, a dramatic drop of PVR can be expected with a near normalization of pulmonary haemodynamics. A centre can be considered to have sufficient expertise in this field if it performs at least 20 PEA operations per year with a mortality rate  $< 10\%$ .

Specific PAH drug therapy may play a role in selected CTEPH patients, mainly for three different scenarios: (i) if patients are not considered candidates for surgery; (ii) if pre-operative treatment is deemed appropriate to improve haemodynamics; and (iii) if patients present with symptomatic residual/recurrent PH after pulmonary endarterectomy surgery. Several uncontrolled clinical studies suggest that prostanoids, ERAs, and phosphodiesterase type-5 inhibitors may exert haemodynamic and clinical benefits in patients with CTEPH, regardless of whether these patients were considered operable or inoperable.<sup>255–260</sup> The only randomized, placebo-controlled clinical trial that has so far addressed the safety and efficacy of medical treatment was the BENEFIT study, which investigated the effects of bosentan in patients with inoperable CTEPH for a 16-week period.<sup>261</sup> This study revealed a significant drop in PVR in the bosentan group but no change in 6MWT, functional class, or time to clinical worsening.

**Table 33 Recommendations for chronic thromboembolic pulmonary hypertension**

Statement	Class <sup>a</sup>	Level <sup>b</sup>
The diagnosis of CTEPH is based on the presence of pre-capillary PH (mean PAP $\geq 25$ mmHg, PWP $\leq 15$ mmHg, PVR $> 2$ Wood units) in patients with multiple chronic/organized occlusive thrombi/emboli in the elastic pulmonary arteries (main, lobar, segmental, subsegmental)	I	C
In patients with CTEPH lifelong anticoagulation is indicated	I	C
Surgical pulmonary endarterectomy is the recommended treatment for patients with CTEPH	I	C
Once perfusion scanning and/or CT angiography show signs compatible with CTEPH, the patient should be referred to a centre with expertise in surgical pulmonary endarterectomy	IIa	C
The selection of patients for surgery should be based on the extent and location of the organized thrombi, on the degree of PH, and on the presence of co-morbidities	IIa	C
PAH-specific drug therapy may be indicated in selected CTEPH patients such as patients not candidates for surgery or patients with residual PH after pulmonary endarterectomy	IIb	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

Given these limited data, further studies are necessary to obtain reliable long-term data on the effects of medical therapies in patients with CTEPH, and these patients should be treated within clinical trials whenever possible. For the present time, no medical therapy has been approved in Europe or the USA for CTEPH. Bilateral lung transplantation is an option for advanced cases that are not suited for PEA.

Recommendations for PH due to CTEPH are summarized in the Table 33.

## 12. Definition of a pulmonary arterial hypertension referral centre

The purpose of a referral centre is to undertake assessment and investigation of all causes of PH, routinely manage appropriate patients with PAH-specific drug therapy, work with other health-care providers to obtain best outcomes for patients, and undertake audit, research, and education. Since, in general, centres with a high volume of patients tend to obtain best outcomes, referral centres will need to have sufficient patients on chronic therapy and new referrals to warrant this status. A referral centre should follow at least 50 patients with PAH or CTEPH and should receive at least two new referrals per month with documented PAH or CTEPH. These figures can be adapted according to specific country characteristics (population distribution, geographical constraints, etc.).

Facilities and skills in a referral centre:<sup>180</sup>

- (1) Referral centres will provide care by a multiprofessional team, which should as a minimum comprise:
  - Two consultant physicians (normally from either or both of cardiology and respiratory medicine) with a special interest in PH
  - Clinical nurse specialist
  - Radiologist with expertise in PH imaging
  - Cardiologist with expertise in echocardiography
  - Access to psychological and social work support
  - Appropriate on-call cover and expertise.
- (2) Referral centres will have the following facilities:
  - A ward where staff have special expertise in PH
  - An intensive therapy unit with relevant expertise
  - A specialist outpatient service
  - Emergency care
  - Diagnostic investigations including echocardiography, CT scanning, nuclear scanning, magnetic resonance imaging, ultrasound, exercise testing, lung function testing, and catheterization laboratory (with expertise in performing vasoreactivity test)

**Table 34 Recommendations for a pulmonary hypertension referral centre**

Statement	Class <sup>a</sup>	Level <sup>b</sup>
Referral centres are required to provide care by a multiprofessional team (cardiology and respiratory medicine physicians, clinical nurse specialist, radiologists, psychological and social work support, appropriate on-call expertise)	I	C
Referral centres are required to have direct links and quick referral patterns to other services (such as CTD service, family planning service, PEA service, lung transplantation service, adult congenital heart disease service)	I	C
A referral centre should follow at least 50 patients with PAH or CTEPH and should receive at least two new referrals per month with documented PAH or CTEPH	IIa	C
Referral centres should perform at least 20 vasoreactivity tests in PAH patients per year	IIa	C
Referral centres should participate in collaborative clinical research in PAH, which includes phase II and phase III clinical trials	IIa	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

- Access to the full range of specific PAH drug therapy in their country.
- (3) There will be established links (e.g. referral criteria, patient pathway, and clinical management protocols) to other services, which may not necessarily be on the same site:
    - Genetics service (for research purposes)
    - CTD service
    - Family planning service
    - PEA service
    - Lung transplantation services
    - Adult congenital heart disease service.
  - (4) Referral centres are required to undertake a programme of clinical audit of outcomes, which will include survival analysis.
  - (5) Referral centres will participate in collaborative clinical research in PAH, which includes phase II and phase III clinical trials.
  - (6) Referral centres will provide regular education about all clinical aspects of PH to appropriate healthcare professionals.
  - (7) Referral centres will have a link to their national and/or European pulmonary hypertension patients association.

Recommendations for a PH referral centre are summarized in the Table 34.



The CME Text 'Guidelines for the diagnosis and treatment of pulmonary hypertension' is accredited by the European Board for Accreditation in Cardiology (EBAC). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/EACCME guidelines, all authors participating in this programme have disclosed potential conflicts of interest that might cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the CME activities.

CME questions for this article are available at: *European Heart Journal* [http://cme.oxfordjournals.org/cgi/hierarchy/oup\\_cme\\_node;ehj](http://cme.oxfordjournals.org/cgi/hierarchy/oup_cme_node;ehj) and European Society of Cardiology <http://www.escardio.org/guidelines>.

## References

- Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine S, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2009;**54**:S43–S54.
- Hachulla E, Gressin V, Guillemin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Frances C, Launay D, Mouthon L, Allanore Y, Kiet PT, Clerson P, de Groote P, Humbert M. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. *Arthritis Rheum* 2005;**52**:3792–3800.
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. *Am J Respir Crit Care Med* 2006;**173**:1023–1030.
- Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. *Eur Respir J* 2007;**30**:104–109.
- Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ, van der Velde ET, Bresser P, Mulder BJM. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. *Int J Cardiol* 2007;**120**:198–204.
- Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SSL, Armstrong IJ, Torpy C, Craddock R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension patients. *Am J Respir Crit Care Med* 2008;**177**:1122–1127.
- Hatano S, Strasser T. World Health Organization 1975. *Primary pulmonary hypertension*. Geneva: WHO; 1975.
- D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;**115**:343–349.
- Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. *Eur Respir J* 2009;doi: 10.1183/09031936.00145608.
- Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz R, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**54**:S55–S56.
- Naeije R, Melot C, Niset G, Delcroix M, Wagner PD. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. *J Appl Physiol* 1993;**74**:1666–1671.
- Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. *Clin Chest Med* 2007;**28**:233–241.
- Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004;**43**:S5–S12.
- Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, Glissmeyer E, Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szweczyk G, Parma J, Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N, Morisaki T, Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, Trembath RC. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Hum Mutat* 2006;**27**:121–132.
- Machado R, Eickelberg O, Elliott CG, Geraci M, Hanoaka M, Loyd J, Newman J, Phillips JA, Soubrier F, Trembath R, Chung WK. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**54**:S32–S42.
- Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Dotti A, Branzi A, Picchio FM. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. *Drugs* 2008;**68**:1049–1066.
- Lapa MS, Ferreira EV, Jardim C, Martins BC, Arakaki JS, Souza R. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. *Rev Assoc Med Bras* 2006;**52**:139–143.
- Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *N Engl J Med* 2004;**350**:886–895.
- Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO III, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. *Nat Med* 2002;**8**:1383–1389.
- Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tudor RM. Pathologic assessment of vasculopathies in pulmonary hypertension. *J Am Coll Cardiol* 2004;**43**:S25–S32.
- Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth S. Pulmonary circulation: development and pathology. *J Am Coll Cardiol* 2009;**54**:S3–S9.
- Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. *N Engl J Med* 2001;**345**:1465–1472.
- Galie N, Kim NHS. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. *Proc Am Thorac Soc* 2006;**3**:S71–S76.
- Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004;**43**:S13–S24.
- Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Lloyd-Jones P, Maitland ML, Michelakis E, Morrell N, Newman B, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel N, Yuan JX, Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. *J Am Coll Cardiol* 2009;**54**:S10–S19.
- Morrell N, Adnot S, Archer S, Dupuis J, Jones P, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**54**:S20–S31.
- Delgado JF, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez MA, Escribano P, Sotelo T, Gomez de la Camara A, Cortina J, de la Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. *Eur J Heart Fail* 2005;**7**:1011–1016.
- Lang IM. Chronic thromboembolic pulmonary hypertension—not so rare after all. *N Engl J Med* 2004;**350**:2236–2238.
- Gabbay E, Yeow W, Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. *Am J Respir Crit Care Med* 2007;**175**:A713.
- Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. *Am J Respir Crit Care Med* 2008;**177**:1377–1383.
- Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughan J, Pauculo M, Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. *N Engl J Med* 2001;**345**:325–334.
- Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Cardiol* 2001;**37**:183–188.
- Vahanian A, Baumgartner H, Bax J, Bruchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Jung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 2007;**28**:230–268.
- Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Darteville P, Housset B, Hamon M, Weitzenblum E, Adnot S. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. *Circulation* 2003;**108**:1839–1844.
- Thabut G, Dauriat G, Stern JB, Logeart D, Lévy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. *Chest* 2005;**127**:1531–1536.
- Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**172**:189–194.
- Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest* 2006;**129**:746–752.
- Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune, Valeyre D, Cordier JF. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *Eur Respir J* 2005;**26**:586–593.
- Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Illiceto S, Prandoni P. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 2004;**350**:2257–2264.
- Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. *Circulation* 2006;**113**:2011–2020.
- Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV. Beta-adrenergic neuroeffector

- abnormalities in the failing human heart are produced by local rather than systemic mechanisms. *J Clin Invest* 1992;**89**:803–815.
42. Keogh A, Benza RL, Corris P, Darteville P, Frost A, Kim NH, Lang IM, Pepke-Zaba J, Sandoval J, Mayer E. Interventional and surgical modalities of treatment in pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**54**:S67–S77.
  43. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, Bristow MR, Perryman MB, Voelkel NF. Importance of angiotensin-converting enzyme in pulmonary hypertension. *Cardiology* 1995;**10**(Suppl. 1): 9–15.
  44. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK. Primary pulmonary hypertension. A national prospective study. *Ann Intern Med* 1987;**107**:216–223.
  45. Gaine SP, Rubin LJ. Primary pulmonary hypertension [published erratum appears in *Lancet* 1999;**353**:74]. *Lancet* 1998;**352**:719–725.
  46. Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. *Am Heart J* 2007;**153**:127–132.
  47. Fisher MR, Forfia PR, Chamera E, Houston-Harris T, Champion HC, Girgis RE, Corretti MC, Hassoun MB. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Resp Crit Care Med* 2009;**179**:615–621.
  48. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. *Circulation* 2001;**104**:2797–2802.
  49. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De ZD, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *Am J Respir Crit Care Med* 2008;**177**:108–113.
  50. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, Black CM, Coghlan JG. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology* 2004;**43**: 461–466.
  51. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, Matran R, Lambert M, Queyrel V, Morell-Dubois S, Guillemin L, Hatron PY. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. *J Rheumatol* 2007;**34**:1005–1011.
  52. Grunig E, Weissmann S, Ehken N, Fijalkowska A, Fischer C, Fourme T, Galie N, Ghofrani A, Harrison RE, Huez S, Humbert M, Janssen B, Kober J, Koehler R, Machado RD, Mereles D, Naeije R, Olschewski H, Provencher S, Reichenberger F, Retailleau K, Rocchi G, Simonneau G, Torbicki A, Trembath R, Seeger W. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. *Circulation* 2009;**119**:1747–1757.
  53. Tunariu N, Gibbs SJR, Win Z, Gin-Sing W, Graham A, Gishen P, Al-Nahhas A. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. *J Nucl Med* 2007;**48**:680–684.
  54. Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, Simonneau G, Musset D. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. *Am J Roentgenol* 2004;**183**:65–70.
  55. Darteville P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G. Chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2004;**23**:637–648.
  56. Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital subtraction angiography. *Eur J Radiol* 2009;**71**:49–54.
  57. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Götte MJW, Vonk-Noordegraaf A. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. *J Am Coll Cardiol* 2008;**51**: 750–757.
  58. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. *Eur Heart J* 2007;**28**:1187–1189.
  59. Rich S, Kieras K, Groves B, Stobo JD, Brundage B. Antinuclear antibodies in primary pulmonary hypertension. *J Am Coll Cardiol* 1986;**8**:1307–1311.
  60. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. *Chest* 2002;**122**:1668–1673.
  61. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. *Lancet* 1999;**353**:1579–1583.
  62. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. *Swiss Med Wkly* 2003;**133**:163–169.
  63. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol* 2006;**48**:2546–2552.
  64. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007;**28**:2539–2550.
  65. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992;**327**: 76–81.
  66. Sitbon O, Humbert M, Jais X, Ios V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* 2005;**111**: 3105–3111.
  67. Galie N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. *Am J Cardiol* 1995;**75**:55A–62A.
  68. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostanol) therapy in primary pulmonary hypertension. *N Engl J Med* 1998;**338**:273–277.
  69. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn GS. Prognosis of pulmonary arterial hypertension ACCP evidence-based clinical practice guidelines. *Chest* 2004;**126**:785–925.
  70. Eysmann SB, Palevsky HI, Reichel N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. *Circulation* 1989;**80**:353–360.
  71. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, Schwartz T, Koch G, Clayton LM, Jobsis MM, Crow JW, Long W. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. *J Am Coll Cardiol* 2002;**39**:1214–1219.
  72. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB. Doppler echocardiographic index for assessment of global right ventricular function. *J Am Soc Echocardiogr* 1996;**9**:838–847.
  73. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. *Am J Cardiol* 1998;**81**: 1157–1161.
  74. Forfia PR, Fisher MR, Mathai SC, Houston-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM. Tricuspid annular displacement predicts survival in pulmonary hypertension. *Am J Respir Crit Care Med* 2006;**174**:1034–1041.
  75. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. *Circulation* 2002;**106**:319–324.
  76. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004;**43**:S40–S47.
  77. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;**166**:111–117.
  78. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2000;**161**:487–492.
  79. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol* 2002;**40**: 780–788.
  80. Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. *Eur Respir J* 2001;**17**:647–652.
  81. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. *Am J Cardiol* 2006;**97**:123–126.
  82. Barst RJ, McGoon M, McLaughlin VV, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins I, Channick R, Badesch BD, Rayburn BK, Flinchbaugh R, Sigman J, Arneson K, Jeffs R, for the Beraprost Study Group.



- Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2003;**41**: 2125.
83. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2004;**169**:441–447.
  84. Ross RM. ATS/ACCP statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003;**167**:1451.
  85. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007;**29**: 185–209.
  86. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuricemia in severe pulmonary hypertension. *Chest* 2000;**117**:19–24.
  87. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* 2000;**102**:865–870.
  88. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smees J, Nair D, Denton CP, Black CM, Coghlan JG. Role of N-terminal brain natriuretic peptide (N-TroBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J* 2006;**27**:1485–1494.
  89. Fijalkowska A, Kurzya M, Torbicki A, Szwedczyk G, Florkczyk M, Pruszczyk P, Szturmowicz M. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest* 2006;**129**:1313–1321.
  90. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. *Am J Cardiol* 2006;**98**:525–529.
  91. Torbicki A, Kurzya M, Kuca P, Fijalkowska A, Sikora J, Florkczyk M, Pruszczyk P, Burakowski J, Wawrzynska L. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation* 2003;**108**:844–848.
  92. Lankeit M, Dellas C, Panzenbock A, Skoro-Sajer N, Bonderman D, Olschewski M, Schafer K, Puls M, Konstantinides S, Lang IM. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2008;**31**:1024–1029.
  93. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2008;**178**:534–541.
  94. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. *Circulation* 2006;**114**:1417–1431.
  95. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. *Thorax* 2005;**60**:1025–1030.
  96. Sun XG, Hansen JE, Oudiz R, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 2001;**104**:429–435.
  97. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation* 2002;**106**:1477–1482.
  98. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J* 2005;**25**:244–249.
  99. Galie N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. *Eur Heart J* 2009;**30**:394–403.
  100. Loewe B, Graefe K, Ufer C, Kroenke K, Grünig E, Herzog W, Borst MM. Anxiety and depression in patients with pulmonary hypertension. *Psychosom Med* 2004;**66**: 831–836.
  101. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzappel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. *Circulation* 2006;**114**:1482–1489.
  102. The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. *Eur Heart J* 2003;**24**: 761–781.
  103. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? *Eur Heart J* 2009;**30**:256–265.
  104. Thorne S, Nelson-Piercy C, MacGregor A, Gibbs S, Crowhurst J, Panay N, Rosenthal E, Walker F, Williams D, de Swiet M, Guillebaud J. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. *J Fam Plann Reprod Health Care* 2006;**32**:75–81.
  105. Bendayan D, Hod M, Oron G, Sagie A, Eidelman L, Shitrit D, Kramer MR. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. *Obstet Gynecol* 2005;**106**:1206–1210.
  106. Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jais X, Humbert M, Audibert F, Frydman R, Simonneau G, Benhamou D. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. *Anesthesiology* 2005;**102**:1133–1137.
  107. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation* 1984;**70**:580–587.
  108. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. *Clin Chest Med* 2001;**22**:451–458.
  109. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. *Eur Respir J* 1998;**12**:1446–1449.
  110. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. *Am J Respir Crit Care Med* 1994;**150**:929–933.
  111. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, Rosas M, Bautista E. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. *Am J Respir Crit Care Med* 2001;**164**:1682–1687.
  112. Weitzenblum E, Sautegau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1985;**131**:493–498.
  113. Rich S, Seidltz M, Dodin E, Osimani D, Judd D, Genthner D, McLaughlin V, Francis G. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. *Chest* 1998;**114**:787–792.
  114. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. *Ann Rheum Dis* 2003;**62**: 1088–1093.
  115. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. *Mol Pharmacol* 1995;**48**: 890–896.
  116. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. *Am J Respir Med* 2003;**2**:123–137.
  117. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med* 1990;**112**:485–491.
  118. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med* 1996;**334**:296–302.
  119. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med* 2000;**132**: 425–434.
  120. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. *Circulation* 1999;**99**: 1858–1865.
  121. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. *Hepatology* 1999;**30**:641–648.
  122. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, Barst RJ, Simonneau G. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2003;**167**:1433–1439.
  123. Cabrol S, Souza R, Jais X, Fadel E, Ali RHS, Humbert M, Dartevelle P, Simonneau G, Sitbon O. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant* 2007;**26**:357–362.
  124. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. *Int J Clin Pract Suppl* 2008;**160**: 5–9.

125. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Sitbon O, Speich R, Hoepfer M, Behr J, Winkler J, Seeger W, for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. *N Engl J Med* 2002;**347**:322–329.
126. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2006;**174**:1257–1263.
127. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. *Heart* 1998;**80**:151–155.
128. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 2002;**165**:800–804.
129. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. *Eur Respir J* 2006;**28**:1195–1203.
130. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escibano P, Skoro-Sajer N, Vachiery JL. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. *Chest* 2006;**129**:1636–1643.
131. Tapson VF, Gombert-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-Week trial. *Chest* 2006;**129**:683–688.
132. Sitbon O, Manes A, Jais X, Palladini M, Humbert M, Presotto L, Paillette L, Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie N. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. *J Cardiovasc Pharmacol* 2007;**49**:1–5.
133. McLaughlin V, Rubin L, Benza RL, Channick R, Vosswinkel R, Tapson V, Robbins I, Olschewski H, Seeger W. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2009;**177**:A965.
134. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoepfer M, Chaouat A, Morand S, Besse B, Simonneau G. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. *J Am Coll Cardiol* 2002;**39**:1496–1502.
135. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1993;**328**:1732–1739.
136. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? *Ann Intern Med* 1991;**114**:464–469.
137. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. *Cardiovasc Res* 2004;**61**:227–237.
138. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 2001;**358**:1119–1123.
139. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002;**346**:896–903.
140. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J* 2004;**24**:353–359.
141. Galie N, Rubin LJ, Hoepfer M, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet* 2008;**371**:2093–2100.
142. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. *Circulation* 2006;**114**:48–54.
143. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. *J Am Coll Cardiol* 2006;**47**:2049–2056.
144. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a one year, prospective, open label, observation of outcome and survival. *Chest* 2008;**134**:775–782.
145. Galie N, Badesch BD, Oudiz R, Simonneau G, McGoon M, Keogh A, Frost A, Zwicke D, Naeije R, Shapiro RS, Olschewski H, Rubin L. Ambrisentan therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2005;**46**:529–535.
146. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation* 2008;**117**:3010–3019.
147. McGoon M, Frost A, Oudiz R, Badesch BD, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. *Chest* 2009;**135**:122–129.
148. Wharton J, Strange JW, Moller GMO, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *Am J Respir Crit Care Med* 2005;**172**:105–113.
149. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri G, Zannoli R, Branzi A, Galie N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. *Basic Res Cardiol* 2005;**100**:131–138.
150. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *J Am Coll Cardiol* 2004;**44**:1488–1496.
151. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. *Mayo Clin Proc* 2003;**78**:1207–1213.
152. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* 2003;**108**:2066–2069.
153. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med* 2003;**167**:1139–1141.
154. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. *New Engl J Med* 2005;**353**:2148–2157.
155. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *J Rheumatol* 2007;**34**:2417–2422.
156. Simonneau G, Rubin L, Galie N, Barst RJ, Fleming T, Frost A, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch BD, for the Pulmonary Arterial Hypertension combination Study of Epoprostenol and Sildenafil (PACES) Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. *Ann Intern Med* 2008;**149**:521–530.
157. Galie N, Brundage B, Ghofrani A, Oudiz R, Simonneau G, Safdar Z, Shapiro RS, White J, Chan M, Beardsworth A, Frumkin LR, Barst R. Tadalafil therapy for pulmonary arterial hypertension. *Circulation* 2009;**119**:2894–2903.
158. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol* 2003;**42**:158–164.
159. Hoepfer MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2004;**24**:1007–1010.
160. Hoepfer M, Taha N, Bekjarova A, Spiekeroetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostanoids. *Eur Respir J* 2003;**22**:330–334.
161. Mathai SC, Girgis RE, Fisher MR, Champion HC, Houston-Harris T, Zaiman A, Hassoun PM. Addition of sildenafil to bosentan monotherapy in pulmonary hypertension. *Eur Respir J* 2007;**29**:469–475.
162. Hoepfer MM, Markevych I, Spiekeroetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. *Eur Respir J* 2005;**26**:858–863.
163. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2006;**174**:1257–1263.

164. Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J* 2006;**4**:691–694.
165. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *Br J Clin Pharmacol* 2005;**60**:107–112.
166. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. *Eur Respir J* 2007;**30**:338–344.
167. Wrishko RE, Dingemans J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. *J Clin Pharmacol* 2008;**48**:610–618.
168. Hoeper MM, Galie N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachieri JL, Torbicki A, Behr J, Barst RJ. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2002;**165**:341–344.
169. Rozkovec A, Montes A, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. *Br Heart J* 1986;**55**:449–458.
170. Sandoval J, Gaspar J, Pulido T, Bautista E, Martínez Guerra ML, Zeballos M, Palomar A, Gómez A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. *J Am Coll Cardiol* 1998;**32**:297–304.
171. Kurzyrna M, Dabrowski M, Bielecki D, Fijałkowska A, Pruszczyk P, Opolski G, Burakowski J, Florkczyk M, Tomkowski WZ, Wawrzynska L, Szturmowicz M, Torbicki A. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. *Chest* 2007;**131**:977–983.
172. Althoff TF, Knebel F, Panda A, McArdle J, Glied V, Franke I, Witt C, Baumann G, Borges AC. Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. *Chest* 2008;**133**:283–285.
173. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachieri JL, Glanville AR; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2006;**25**:745–755.
174. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI; International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty third official adult lung and heart lung transplantation report—2006. *J Heart Lung Transplant* 2006;**25**:880–892.
175. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart–lung or lung transplantation for Eisenmenger syndrome. *J Heart Lung Transplant* 2002;**21**:731–737.
176. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**54**:S78–S84.
177. Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Recommendations for Task Force Creation and Report Production. A document for Task Force members and expert panels responsible for the creation and production of Guidelines and Expert Consensus Documents Committee for Practice Guidelines (CPG) of the European Society of Cardiology. European Society of Cardiology Website. <http://www.escardio.org/scinfo/Recommendations.pdf>
178. Konduri GG. New approaches for persistent pulmonary hypertension of newborn. *Clin Perinatol* 2004;**31**:591–611.
179. Rosenzweig EB, Widlitz A, Barst R. Pulmonary arterial hypertension in children. *Pediatr Pulmon* 2004;**38**:2–22.
180. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. *Heart* 2008;**94**:i1–i41.
181. Barst R, Ivy D, Widlitz AC, Moore K, Doran A, Nguyen N, Gaitonde M. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. *Clin Pharmacol Ther* 2003;**73**:372–382.
182. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. *J Am Coll Cardiol* 2005;**46**:697–704.
183. Humpl T, Reyes JT, Holtby H, Stephens D, Adata I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. *Circulation* 2005;**111**:3274–3280.
184. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. *Circulation* 1999;**99**:1197–1208.
185. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. *Heart* 2007;**93**:739–743.
186. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. *J Am Coll Cardiol* 2008;**51**:161–169.
187. Micheletti A, Hislop AA, Lammers A, Bonhoeffer P, Derrick G, Rees P, Haworth SG. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. *Heart* 2006;**92**:969–972.
188. Blanc J, Vouhe P, Bonnet D. Potts shunt in patients with pulmonary hypertension. *N Engl J Med* 2004;**350**:623.
189. Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E, Gatzoulis MA, Mulder BJM. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. *Heart* 2007;**93**:682–687.
190. Beghetti M, Galie N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;**53**:733–740.
191. Daliotto L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. *Eur Heart J* 1998;**19**:1845–1855.
192. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. *J Heart Lung Transplant* 1996;**15**:100–105.
193. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. *Circulation* 2007;**115**:1039–1050.
194. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. *Coron Artery Dis* 2005;**16**:19–25.
195. Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, Davidson SJ, Bouzas B, Gibbs JS, Burman J, Gatzoulis MA. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. *J Am Coll Cardiol* 2007;**50**:634–642.
196. Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. *Int J Cardiol* 2007;**127**:27–32.
197. Palazzini M, Manes A, Romanazzi S, Gambetti S, Leci E, Grossi M, Negro L, Ionico T, Branzi A, Galie N. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts. *Eur Heart J* 2007;**28**:308.
198. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. *Circulation* 2006;**114**:1807–1810.
199. Dorfmueller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, Capron F. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. *Hum Pathol* 2007;**38**:893–902.
200. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. *Chest* 2003;**123**:344–350.
201. Jais X, Launay D, Yaici A, Le PJ, Tchekian C, Sitbon O, Simonneau G, Humbert M. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. *Arthritis Rheum* 2008;**58**:521–531.
202. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. *Ann Rheum Dis* 2007;**66**:1467–1472.
203. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, Simonneau G. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. *Chest* 2004;**126**:420–427.
204. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. *Eur Respir J* 1998;**11**:1153–1166.
205. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. *Lancet* 2004;**363**:1461–1468.
206. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. *Hepatology* 2006;**44**:1502–1510.
207. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. *Gastroenterology* 2006;**130**:120–126.



208. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J. Bosentan therapy for portopulmonary hypertension. *Eur Respir J* 2005;**25**:502–508.
209. Reichenberger F, Voswinkel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, Seeger W, Ghofrani HA. Sildenafil treatment for portopulmonary hypertension. *Eur Respir J* 2006;**28**:563–567.
210. Kuop PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. *Transplantation* 1997;**63**:604–606.
211. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. *Eur Respir J* 2007;**30**:1096–1102.
212. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. *Liver Transpl* 2000;**6**:443–450.
213. Grannas G, Neipp M, Hoeper MM, Gottlieb J, Luck R, Becker T, Simon A, Strassburg CP, Manns MP, Welte T, Haverich A, Klempnauer J, Nashan B, Strueber M. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. *Transplantation* 2008;**85**:524–531.
214. Opravil M, Pechère M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Lüthy R. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. *Am J Respir Crit Care Med* 1997;**155**:990–995.
215. Cea-Calvo L, Escibano Subias P, Tello de Meneses R, Lazaro Salvador M, Gomez Sanchez MA, Delgado Jimenez JF, Pindado Rodriguez C, Ruiz Cano MJ, Saenz de la Calzada C. Treatment of HIV-associated pulmonary hypertension with treprostinil. *Rev Esp Cardiol* 2003;**56**:421–425.
216. Ghofrani HA, Friesse G, Discher T, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F, Lohmeyer J. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. *Eur Respir J* 2004;**23**:321–326.
217. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2004;**170**:1212–1217.
218. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. *Heart* 2006;**92**:1164–1166.
219. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. *Chest* 2000;**118**:1671–1679.
220. Runo JR, Vnencak-Jones CL, Prince M, Loyd JE, Wheeler L, Robbins IM, Lane KB, Newman JH, Johnson J, Nichols WC, Phillips JA. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. *Am J Respir Crit Care Med* 2003;**167**:889–894.
221. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. *Am J Respir Crit Care Med* 2000;**162**:1964–1973.
222. Rabiller A, Jais X, Hamid A, Resten A, Parent F, Haque R, Capron F, Sitbon O, Simonneau G, Humbert M. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. *Eur Respir J* 2006;**27**:108–113.
223. Montani D, Price LC, Dorfmueller P, Achouh L, Jais X, Yaici A, Sitbon O, Musset D, Simonneau G, Humbert M. Pulmonary veno-occlusive disease. *Eur Respir J* 2009;**33**:189–200.
224. Humbert M, Maître S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. *Am J Respir Crit Care Med* 1998;**157**:1681–1685.
225. Grigioni F, Potena L, Galie N, Fallani F, Bigliardi M, Cocco F, Magnani G, Manes A, Barbieri A, Fucili A, Magelli C, Branzi A. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. *J Heart Lung Transplant* 2006;**25**:1241–1246.
226. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J* 2008;**29**:2388–2442.
227. Hoeper M, Barbera JA, Channick R, Hassoun PM, Lang I, Manes A, Martinez F, Naeije R, Olschewski H, Pepke-Zaba J, Redfield M, Robbins I, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-PAH pulmonary hypertension. *J Am Coll Cardiol* 2009;**54**:S85–S96.
228. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. *N Engl J Med* 2004;**351**:1097–1105.
229. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. *Circulation* 1995;**92**:3593–3612.
230. Chang PP, Longenecker JC, Wang NY, Baughman KL, Conte JV, Hare JM, Kasper EK. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. *J Heart Lung Transplant* 2005;**24**:998–1007.
231. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *Am Heart J* 1997;**134**:44–54.
232. Packer M, McMurray J, Massie BM, Caspi A, Charlton V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. *J Card Fail* 2005;**11**:12–20.
233. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? *Int J Cardiol* 2002;**85**:195–197.
234. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. *Circulation* 2007;**116**:1555–1562.
235. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg* 1999;**15**:816–822.
236. Oswald-Mammoser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. *Chest* 1995;**107**:1193–1198.
237. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**159**:158–164.
238. Arcasoy SM, Christie JD, Ferrari VA, St John SM, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med* 2003;**167**:735–740.
239. Fisher MR, Criner GJ, Fishman AP, Hassoun PM, Minai OA, Scharf SM, Fessler AH. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. *Eur Respir J* 2007;**30**:914–921.
240. Agusti AG, Barbera JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. *Chest* 1990;**97**:268–275.
241. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. *Lancet* 1996;**347**:436–440.
242. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, Beddoes RJ. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. *Respir Res* 2005;**6**:88–95.
243. Saadjan AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by nifedipine: an 18-month haemodynamic study. *Eur Respir J* 1988;**1**:716–720.
244. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walrmath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. *Lancet* 2002;**360**:895–900.
245. Olschewski H, Ghofrani HA, Walrmath D, Schermuly R, Temmesfeld-Wollbrück B, Grimminger F, Seeger W. Inhaled prostacyclin and



- iloprost in severe pulmonary hypertension secondary to lung fibrosis. *Am J Respir Crit Care Med* 1999;**160**:600–607.
247. Alp S, Skrygan M, Schmidt WE, Bastian A. Sildenafil improves hemodynamic parameters in COPD—an investigation of six patients. *Pulm Pharmacol Ther* 2006;**19**:386–390.
  248. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. *Chest* 2007;**131**:897–899.
  249. Gunther A, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stahler G, Seeger W, Grimminger F, Leconte I, Roux S, Ghofrani HA. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. *Eur Respir J* 2007;**29**:713–719.
  250. Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. *Vascul Pharmacol* 2006;**44**:372–376.
  251. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. *Eur Respir J* 2008;**31**:759–764.
  252. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJB, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Document Review, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez Isla L, Schwehr U, Torracca L, Vachiery JL. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J* 2008;**29**:2276–2315.
  253. Rubin LJ, Hoeper MM, Klepetko W, Galie N, Lang IM, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. *Proc Am Thorac Soc* 2006;**3**:601–607.
  254. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, Simkova I, Martischknig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2009;**33**:325–331.
  255. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2004;**23**:595–600.
  256. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, Nakanishi N. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. *Chest* 2003;**123**:338–343.
  257. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, Mayer E. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. *Chest* 2005;**128**:2363–2367.
  258. Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, Pepke-Zaba J. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. *Thorax* 2005;**60**:707.
  259. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. *Chest* 2005;**128**:2599–2603.
  260. Reichenberger F, Voswinckel R, Enke B, Rutsch M, Fechtali EE, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2007;**30**:922–927.
  261. Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. *J Am Coll Cardiol* 2008;**52**:2127–2134.